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Abstract 
The	  kinesins	  form	  a	  superfamily	  of	  molecular	  motors	  that	  use	  energy	  from	  ATP	  turnover	  
to	   generate	   force.	   They	   carry	  out	   a	  diverse	   set	  of	   cellular	   functions	  by	   transducing	   this	  
force	  to	  transport	  cargos	  along	  microtubule	  (MTs)	  tracks.	  Kinesins	  are	  distributed	  among	  
14	  families	  with	  different	  structural	  organisations	  all	  sharing	  a	  conserved	  motor	  domain	  
that	   is	   comprised	   of	   a	   catalytic	   site	   for	   ATP	   hydrolysis	   and	   a	  MT	   binding	   site.	   Kinesins	  
perform	  different	  functions	  with	  numerous	  key	  roles	  in	  mitosis.	  	  
The	  kinesin-­‐5	  family	  member,	  Eg5,	  has	  been	  shown	  to	  play	  a	  key	  role	  in	  cross-­‐linking	  and	  
separating	   anti-­‐parallel	   MTs.	   Inhibition	   of	   Eg5	   leads	   to	   the	   formation	   of	   characteristic	  
monoastral	  spindles,	  cell	  cycle	  arrest	  and	  may	  also	  lead	  to	  apoptotic	  cell	  death.	  This	  has	  
led	   to	   Eg5	   being	   identified	   as	   a	   potential	   target	   for	   drug	   development	   in	   cancer	  
chemotherapy.	   To	   understand	   the	   mode	   of	   interaction	   between	   the	   protein	   and	   the	  
potent	   drug	   candidate	   ispinesib,	   an	   extensive	   study	   using	   biochemical	   and	   biophysical	  
techniques	  together	  with	  crystallography	  is	  presented	  in	  this	  thesis.	  	  
Sustained	   chemotherapy	   imposes	   selection	   pressure	   on	   cancer	   cells,	   and	   can	   generate	  
resistant	  mutants	  against	  chemotherapeutic	  agents.	  We	  have	  employed	  crystallographic,	  
biochemical	   and	   biophysical	   approaches	   to	   understand	   the	   underlying	   molecular	  
mechanism	   of	   resistance	   to	   Eg5	   inhibition.	   These	   approaches	   establish	   that	   the	   point	  
mutations	   in	   the	   inhibitor-­‐binding	   pocket	   decrease	   the	   potency	   of	   SB743921,	   a	   potent	  
Eg5	   inhibitor	   binding	   at	   a	   site	   near	   loop	   L5,	   by	   more	   than	   1000-­‐fold.	   By	   determining	  
crystal	   structures	   of	   the	   mutant	   Eg5	   motor	   domains	   in	   the	   presence	   and	   absence	   of	  
SB743921	  and	   combining	   the	   results	  with	   calorimetric	   and	  molecular	  dynamics	   studies,	  
we	  show	  that	  the	  development	  of	  resistance	  is	  due	  to	  changes	  in	  the	  global	  flexibility	  of	  
the	  protein.	  
In	  a	  second	  approach	  to	  address	  drug	  resistance	  towards	  allosteric	   inhibitors	  binding	  at	  
the	   loop	   L5	   site,	   we	   have	   also	   characterised	   inhibitor	   binding	   to	   a	   novel	   and	   distinct	  
allosteric	   pocket	   in	   Eg5.	   This	   is	   the	   first	   experimental	   characterisation	  of	   protein-­‐ligand	  
interactions	   in	   this	   new	   site.	   These	   studies	   also	   revealed	   an	   unexpected	   second	   site.	  
Extensive	  biophysical	  characterisation	  was	  used	  to	  determine	  the	  importance	  of	  each	  site	  
to	  the	  observed	  biochemical	  activity.	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Finally,	   I	   have	   investigated	   kinesin-­‐6	   members	   as	   new	   targets	   for	   therapeutic	  
intervention.	   Among	   kinesins	   involved	   in	   the	   mitotic	   phase,	   the	   members	   of	   kinesin-­‐6	  
family	  are	  of	  particular	  interest	  as	  potential	  drug	  targets	  because	  of	  their	  important	  roles	  
during	   the	   anaphase	   to	   telophase	   transition	   until	   completion	   of	   cell	   division	   by	  
cytokinesis.	  This	  family	  consists	  of	  three	  members	  in	  humans;	  MKLP-­‐1,	  MKLP-­‐2	  and	  MPP1	  
with	  a	  unique	  structural	  feature	  of	  a	  long	  insertion	  of	  around	  100	  amino	  acids	  in	  the	  loop	  
L6	  region.	  This	  unique	  feature	  makes	  them	  interesting	  not	  only	  as	  a	  drug	  target	  but	  also	  
to	   understand	   their	   role	   in	   protein	   function.	   The	  motor	   domain	   of	   the	   kinesin-­‐6	   family	  
members,	   MKLP-­‐2	   and	   MPP1	   were	   cloned,	   expressed	   and	   purified	   and	   crystallisation	  
trials	   were	   carried	   out.	   Moderately	   potent	   inhibitors	   were	   identified	   by	   biochemical	  
screening	   of	   freely	   available	   compound	   collections.	   Selectivity	   analysis	  was	   also	   carried	  
out	  against	  other	  kinesin	  members	  to	  provide	  specificity	  data	  about	  the	  inhibitor.	  
In	   collaboration	  with	   Christophe	   Labiere	   from	  Dr.	   Catherine	   Guillou's	   laboratory	   at	   the	  
CNRS,	  Gif-­‐sur	  Yvette,	  France,	  a	  SAR	  investigation	  of	  the	  MKLP-­‐2	  inhibitor	  paprotrain	  was	  
carried	  out	  using	  135	  analogues.	   	  This	   required	  extensive	  biochemical	   screening	  against	  
MKLP-­‐2	  to	  identify	  more	  potent	  analogues	  of	  paprotrain.	  	  
The	  first	  objective	  of	  this	  research	  is	  to	  investigate	  the	  mechanism	  by	  which	  existing	  Eg5	  
inhibitors	   block	   catalytic	   activity	   and	   the	   mechanism	   through	   which	   Eg5	   develops	  
resistance	   to	   these	   inhibitors.	   A	   second	   objective	  was	   to	   lay	   foundations	   for	   structural	  
and	  biochemical	  characterisation	  of	  kinesin-­‐6	   family	  members.	  The	  results	  of	   this	   thesis	  
provide	   a	   detailed	   understanding	   of	   Eg5	   inhibition	   by	   ispinesib	   and	   describe	   an	  
unexpected	   resistance	   mechanism	   towards	   allosteric	   Eg5	   inhibitors	   dependent	   on	  
unfavourable	  entropic	  effects	  in	  the	  mutant.	  The	  experimental	  characterisation	  of	  a	  new	  
allosteric	   inhibitor	  binding	  site	  presented	  here,	  together	  with	  the	  crystal	  structure	  of	  an	  
inhibitor	   binding	   at	   this	   site,	   provides	   a	   foundation	   for	   structure	   based	   design	  
approaches.	   The	  work	   also	   provides	   an	   extensive	   study	   on	  MPP1	   and	  MKLP-­‐2	   cloning,	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Definitions / Abbreviations 
Å	   	   Ångström	  	  
aa	   	   amino	  acid	  
A600	   	   Absorbance	  at	  600	  nm	   	  
ADP	   	   Adenosine	  diphosphate	  	  
AMP-­‐PNP	   Adenylyl-­‐imidodiphosphate	  	  
ATP	   	   Adenosine	  triphosphate	  
AU	   	   Asymmetric	  unit	  	  
Cdk1	   	   Cyclin	  dependent	  kinase	  1	  	  
cDNA	   	   Complementary	  deoxyribonucleic	  acid	  	  
CENP-­‐E	  	   Centromere-­‐associated	  protein	  E	  	  
CIPD	   	   Chronic	  Inflammatory	  Demyelinating	  Polyneuropathy	  
cm	   	   Centimetre	  	  
CPC	   	   Chromosomal	  Passenger	  Complex	  protein	  
cryo-­‐EM	   Cryo-­‐electron	  microscopy	  	  
Da	   	   Dalton	  	  
DM	   	   Double	  mutant	  
ΔH	   	   Enthalpy	  change	  	  
ΔS	   	   Entropy	  change	  	  
DMSO	   	   Dimethyl	  sulfoxide	  	  
DTT	   	   Dithiothreitol	  	  
EC50	   	   Half	  maximal	  effective	  concentration	  	  
EDTA	   	   Ethylenediaminetetraacetic	  acid	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Na-­‐EGTA	   Ethylene	  glycol	  tetraacetic	  acid	  	  
ESRF	   	   European	  Synchrotron	  Radiation	  Facility	  	  
HCC	  	   	   Hepatocellular	  carcinoma	  
HEPES	   	   4-­‐(2-­‐hydroxyethyl)-­‐1-­‐piperazineethanesulfonic	  acid	  	  
HPV	   	   Human	  papillomavirus  
hr	   	   hour	  
HT	   	   High-­‐throughput 
IC50	  	   	   half	  maximal	  inhibitory	  concentration	  
IPTG	  	   	   Isopropyl	  β-­‐D-­‐1-­‐thiogalactopyranoside	  
ITC	  	   	   Isothermal	  titration	  calorimetry	  
KAP	   	   kinesin	  accessory	  protein	  
K2HPO4	  	   Dipotassium	  phosphate	  
Ka	  	   	   acid	  dissociation	  constant	  
kcal/mol	  	   kilocalorie	  per	  mole	  
KCl	  	   	   potassium	  chloride	  
Kd	  	   	   dissociation	  constant 	  
kDa   Kilodalton	  
KHC	  	   	   Kinesin	  Heavy	  Chain	  
KIF	   	   Kinesin	  Family	  Member	  
Kiapp	  	   	   apparent	  inhibition	  constant	  
KLC	  	   	   Kinesin	  Light	  Chain	  
MCAK	  	  	   Mitotic	  centromere-­‐associated	  kinesin	  
MD	   	   motor	  domain	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MDR	  	   	   multiple	  drug	  resistant	  
MES	  	   	   2-­‐(N-­‐morpholino)ethanesulfonic	  acid	  
mg	  	   	   milligrams	  
Mg2+ADP	  	   Magnesium	  (II)	  Adenosine-­‐5'-­‐triphosphate 
Mg2+ATP	   Magnesium	  (II)	  Adenosine	  diphosphate	  
MgCl2	  	   	   Magnesium	  chloride	  	  
MIA	   	   Maximum	  inhibition	  attained	  
mins	  	   	   minutes	  
MKLP-­‐1	   Mitotic	  kinesin	  like	  protein	  1	  
MKLP-­‐2	   Mitotic	  kinesin	  like	  protein	  2	  
ml	  	   	   millilitre	  
mm	  	   	   millimetre	  
mM	  	   	   milli	  molar	  
MPP1	   	   M-­‐phase	  phosphoprotein	  1	  
mRNA	  	  	   messenger	  Ribonucleic	  acid 
MT	  	   	   microtubules	  
N	  	   	   Stoichiometry	  
NaCl	  	   	   Sodium	  chloride	  
Ncd	  	   	   Non-­‐claret	  disjunctional	  
NCI	   	   National	  Cancer	  Institute	  
NEB	  	   	   New	  England	  Biolabs	  
Ni2+NTA	  	   Ni(II)-­‐nitrilotriacetic	  acid	  
nm	   	   Nanometre	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Nm	   	   Nanomolar	  	  
NMR	   	   Nuclear	  magnetic	  resonance	  
NTA	   	   Nitriloacetic	  acid	  
PAGE	   	   Polyacrylamide	  gel	  electrophoresis	  
PCR	  	   	   Polymerase	  chain	  reaction	  	  
PEG	  	   	   Polyethylene	  glycol	  	  
PGP	   	   P-­‐glycoprotein	  	  
PIPES	  	   	   Piperazine-­‐N,N′-­‐bis(2-­‐ethanesulfonic	  acid)	  	  
PMSF	  	   	   Phenylmethane	  sulfonylfluoride	  
PtK	   	   Protein	  tyrosine	  kinase	   
rmsd	  	   	   Root-­‐mean-­‐square	  deviation	  	  
RT	  	   	   Room	  temperature	  	  
SAR	  	   	   Structure-­‐activity	  relationship	  	  
SAXS	   	   Small-­‐angle	  X-­‐ray	  scattering	  
SDS	  	   	   Sodium	  dodecyl	  sulfate	  	  
sec	  	   	   seconds	  	  
siRNA	  	   	   Small	  interfering	  ribonucleic	  acid	  
SPR	   	   surface	  plasmon	  resonance	  	  	  
STLC	  	   	   S-­‐trityl-­‐L-­‐cysteine	  	  
TB	  	   	   Terrific	  broth	  	  
TPX2	  	   	   Targeting	  Protein	  for	  Xklp2 
Tris	  	   	   Tris(hydroxymethyl)aminomethane	  
uv	   	   Ultra	  violet	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Xklp2	  	   	   Xenopus	  plus-­‐end-­‐directed	  kinesin-­‐like	  protein	  2	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1 Introduction 
Cell	  cycle	  progression	  is	  fundamentally	  dependent	  on	  the	  highly	  organised	  movement	  of	  
genetic	   material	   to	   the	   poles	   of	   the	   mitotic	   spindle	   and	   into	   daughter	   cells.	   Spindle	  
formation,	   chromosome	   separation	   and	   chromosome	   motility	   all	   require	   a	   force-­‐
generating	  sub-­‐cellular	  machinery	  to	  drive	  proteins	  and	  chromosomes	   in	  a	  spatially	  and	  
temporally	  controlled	  manner	  to	  segregate	  chromatids	  correctly.	  
Three	   major	   families	   of	   cytoskeletal	   molecular	   motors	   have	   been	   identified	   which	   are	  
able	   to	  generate	   force	   in	  cells,	   in	  each	  case	  converting	  the	  chemical	  energy	  of	  ATP	   into	  
mechanical	   force	   (Figure	  1-­‐1).	   The	   first	  of	   these	   families	   to	  be	   identified	  was	  myosin	   in	  
1939.1	  	  Myosin	  slides	  over	  actin	  filaments	  and	  is,	  for	  example,	  the	  major	  force	  generator	  
in	  muscle	   tissue.	   Subsequently,	   dynein	   was	   discovered	   in	   19632	   and	   was	   shown	   to	   be	  
important	   in	   transporting	   vesicles	   and	   positioning	   the	   Golgi	   complex.	   In	   contrast	   to	  
myosin,	  dynein	  moves	  along	  microtubule	  (MT)	  tracks.	  Then	  in	  19853,4,	  the	  first	  member	  of	  
the	   kinesin	   family	   (named	   conventional	   kinesin;	   kinesin-­‐1)	  was	  discovered.	   Like	  dynein,	  
kinesins	  move	  along	  MT	  tracks	  and	  the	  family	  is	  now	  known	  to	  consist	  of	  more	  than	  650	  
proteins,	   with	   important	   functions	   in	   a	   range	   of	   cellular	   processes	   including	   mitosis,	  
meiosis	  and	  axonal	   transport.5	  Members	  of	   the	  kinesin	   family	  have	  now	  been	  shown	  to	  
play	  critical	  roles	  in	  the	  formation	  of	  the	  mitotic	  spindle,	  MT	  sliding	  during	  metaphase	  and	  
in	   the	   depolymerisation	   of	   MTs	   during	   different	   stages	   of	   mitosis.	   Their	   important	  
biological	   roles	   in	   the	   cell	   cycle6	   and	   the	   mechanism	   by	   which	   the	   kinesins	   convert	  
chemical	  energy	  into	  force	  has	  raised	  a	  number	  of	  questions	  about	  the	  structure	  of	  these	  
proteins,	  and	  the	  key	  features	  of	  the	  proteins	  required	  to	  create	  and	  transmit	  this	  force.	  
Clinical	  interest	  in	  certain	  kinesins	  is	  also	  high	  with	  anti-­‐proliferative	  inhibitors	  currently	  in	  
Phase	   II	   clinical	   trials.7-­‐10	   The	  work	  presented	   in	   this	   thesis	   focuses	  on	   investigating	   the	  
molecular	   mechanism	   of	   allosteric	   inhibition	   of	   the	   kinesin-­‐5	   family	   member	   Eg5	   by	   a	  
number	  of	  different	  series	  of	  compounds	  in	  order	  to	  understand	  the	  key	  interactions	  and	  
the	   implications	   for	   kinesins	   as	   a	   therapeutic	   target.	   In	   addition,	   progress	   in	   the	  
expression,	  purification	  and	  crystallisation	  of	  two	  members	  of	  the	  kinesin-­‐6	  family,	  MPP1	  
and	  MKLP-­‐2,	   is	  described	  together	  with	   initial	  progress	  towards	  developing	   inhibitors	  of	  
these	  proteins.	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Figure	  1-­‐1:	  Structural	  representation	  of	  motor	  proteins.	  	  
Domain	   organisation	   of	   a)	   conventional	   kinesin,	   b)	   myosin	   V,	   and	   c)	   cytoplasmic	   dynein.	   The	  
motor	  domains	  are	  represented	  in	  shades	  of	  blue,	  followed	  by	  the	  stalk	  domain	   in	  grey	  and	  the	  
tail	   domains	   in	   purple.	   The	   light	   chains	   bound	   to	   or	   bound	   close	   to	   the	   tail	   domain,	   are	  
represented	   in	   green.	   The	   figure	   depicts	   the	   overall	   similarity	   in	   the	   structure	   of	   all	   three	  
superfamilies	   of	   proteins,	  which	  may	   have	   diversified	   from	   a	   common	   ancestor.	   Adapted	   from	  
Kolomeisky	  et	  al.,	  2007.11	  
 
1.1 Kinesin, a perspective 
The	  kinesins	   (KIF)	  were	   first	   identified	   in	   the	  mid-­‐1980s	   in	   squid	  and	  mammalian	  brain,	  
using	   in	   vitro	   motility	   assays.4,12-­‐14,15	   The	   kinesin	   superfamily	   consists	   of	   at	   least	   650	  
distinct	  motor	  proteins.	  The	  first	  major	  members	  of	  the	  kinesin	  superfamily	  were	  initially	  
identified	   based	   on	   observations	   made	   using	   electron	   microscopy	   on	   mouse	   brain.1,3	  
Recent	  analysis	  has	   identified	  many	  different	   families	  with	   the	   total	  number	  of	   families	  
identified	   to	   be	   fourteen.16,4,12,3	   In	  mammals,	   45	   KIF	   genes	   that	   are	   related	   to	   kinesins	  
have	   been	   identified	   to	   belong	   to	   these	   families,	   but	   there	   could	   be	   many	   more	   KIF	  
proteins	  as	  multiple	   isoforms	  are	  generated	  by	  alternative	  mRNA	  splicing	   (Figure	  1-­‐2).17	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Figure	  1-­‐2:	  Phylogenetic	  tree	  of	  kinesins.	  	  
Current	   phylogenetic	   tree	   based	   on	   sequence	   homology	   analysis	   categorises	   kinesins	   into	   14	  
distinct	  families,	  with	  each	  member	  of	  a	  family	  sharing	  sequence	  homology,	  domain	  organisation,	  
motility	  characteristics	  and	  similar	  functions	  (Red:	  chromosome	  and	  spindle	  organisation;	  green:	  
vesicular	   and	   organelle	   transport).	   The	   individual	   families	   are	   represented	   in	   brown.	   Adapted	  
from	  Hirokawa	  et	  al.,	  2009	  and	  Dagenbach	  et	  al.,	  2004.16,18	  
 
1.1.1 Structure and organisation of kinesins 
Typically,	  kinesins	  consist	  of	  three	  main	  domains;	  (1)	  the	  motor	  domain	  (MD),	  responsible	  
for	  ATP	  hydrolysis	  and	  MT-­‐binding.	   It	  also	  supports	  force	  generation	  with	  the	  aid	  of	  the	  
small	  neck	   linker	  region	  that	  follows	  the	  motor	  domain,	   (2)	  the	  tail	  domain	  which	  binds	  
Introduction 
   
  Sandeep K Talapatra 
24 
diverse	  cargos	  or	  adaptor	  proteins	  and	  (3)	  the	  stalk	  or	  coiled	  coil	  domain	  which	  links	  the	  
motor	   and	   tail	   domains	   and	   mediates	   oligomerisation	   of	   a	   number	   of	   different	  
kinesins.19,20	  
Based	   on	   the	   arrangement	   of	   these	   three	   domains,	   the	   kinesins	   are	   divided	   into	   three	  
categories:	  N-­‐terminal,	   Internal	  or	  C-­‐terminal.	  N-­‐type	  kinesins	  (e.g.	  conventional	  kinesin,	  
kinesin-­‐1)	  have	  the	  MD	  situated	  at	  the	  N-­‐terminus	  and	  move	  towards	  the	  plus-­‐end	  of	  MTs	  
(the	  dynamically	   growing	  end)	  with	   the	  exception	  of	   KIF14	  where	   the	  motor	  domain	   is	  
located	   internally	   but	   have	   consensus	   N-­‐type	   motor	   sequence	   as	   other	   N-­‐terminal	  
kinesins.21,22	   C-­‐type	   kinesins	   (e.g.	   kinesin-­‐14	   family	   members)	   have	   their	  MD	   at	   the	   C-­‐
terminus	  and	  travel	   to	  the	  MT	  minus	  end.	  M-­‐type	  kinesins	  have	  the	  MD	  situated	   in	  the	  
middle	  of	  the	  amino	  acid	  sequence	  and	  diffuse	  one-­‐dimensionally	  along	  MTs	  in	  the	  proto-­‐
filament	  promoting	  depolymerisation	  of	  the	  terminal	  MT	  dimer	  (Figure	  1-­‐3).23	   
	  
Figure	  1-­‐3:	  Classification	  of	  kinesins	  based	  on	  the	  position	  of	  the	  motor	  domain.	  	  
Bar	  diagram	  representing,	  Kin-­‐N	  (N-­‐terminal	  motor	  domain),	  Kin-­‐C	  (C-­‐terminal	  motor	  domain)	  and	  
Kin-­‐I	  (internal	  motor	  domain).	  Taxonomy	  of	  the	  kinesin	  superfamily	  illustrated	  here	  by	  amino	  acid	  
sequence	  conservation.	  The	   red	  colour	   indicates	   the	  approximate	  position	  of	   the	  catalytic	   core;	  
the	  blue	  colour	  indicates	  the	  position	  of	  the	  coiled	  coil	  region	  and	  the	  green	  colour	  represents	  the	  
tail	  domain	  with	  all	  domains	  corresponding	  to	  the	  sequences	  alignment	  of	  different	  kinesins.	  The	  
orphan	   kinesin	   motors	   also	   have	   their	   catalytic	   cores	   positioned	   at	   the	   N-­‐terminus	   of	   the	  
polypeptide	  chain.	  Adapted	  from	  Vale	  et	  al,	  1997.12	  
 
The	  105	  crystal	  structures	  of	  kinesins	  deposited	  in	  the	  PDB	  show	  the	  conserved	  nature	  of	  
the	   motor	   domain	   irrespective	   of	   the	   position	   of	   the	   motor	   domain.24-­‐26	   The	   overall	  
structure	  of	  the	  motor	  domain	  of	  conventional	  kinesin	  demonstrates	  an	  eight-­‐stranded	  β-­‐
sheet,	   surrounded	   by	   three	   major	   α-­‐helices	   on	   each	   side	   (Figure	   1-­‐4a).	   The	   force	  
generating	   function	   of	   kinesins	   uses	   chemical	   energy	   from	  ATP	   hydrolysis.	   For	   this	   the	  
motor	  domain	  contains	  the	  catalytic	  site	  for	  ATP	  binding.	  There	  is	  considerable	  structural	  
detail	  in	  the	  PDB	  revealing	  the	  interactions	  between	  kinesins	  and	  ADP.27,28	  This	  active	  site,	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includes	   a	   highly	   conserved	   loop,	   the	   P-­‐loop	   (GxxxxGKS/T)	   or	   Walker	   motif,	   which	   is	  
conserved	  in	  kinesins,	  G	  proteins	  and	  myosins	  and	  interacts	  with	  the	  α-­‐	  and	  β-­‐phosphates	  
of	  ADP.	  The	  ADP	  binding	  to	  this	  exposed	  surface	  cleft	  is	  co-­‐ordinated	  with	  a	  magnesium	  
ion.29	   	   The	   P-­‐loop	   motif	   also	   shares	   similarity	   with	   a	   diverse	   set	   of	   proteins	   such	   as	  
adenylate	   kinase,	   transducin,	   Ras	   and	   RecA	   though	   there	   is	   no	   other	   structural	   or	  
sequence	  similarity	  (Figure	  1-­‐4b).30,31	  Interactions	  with	  the	  γ-­‐phosphate	  are	  also	  mediated	  
by	  conserved	  residues.	  In	  human	  conventional	  kinesin,	  amino	  acids	  201–203	  contain	  the	  
universally	  conserved	  Ser-­‐Ser-­‐Arg	  motif,	  which	  is	  similar	  to	  that	  of	  myosin.32	  For	  example	  
in	  the	  structures	  of	  human	  Eg5	  and	  mouse	  Kif1a	  both	  in	  complex	  with	  AMPPNP	  (a	  slowly	  
hydrolysable	  form	  of	  ATP)	  there	  is	  an	  interaction	  between	  γ-­‐phosphate	  of	  AMPPNP	  with	  
Ser223	   of	   Eg5	   and	   Ser215	   of	   Kif1a.33	   In	   the	   structure	   of	   Dictyostelium	   myosin	   with	  
Mg2+ADP–AlF4	   (a	  Mg2+-­‐ADP-­‐Pi	  analogue)	  bound,	  Ser243	  of	   this	  motif	  performs	  a	  similar	  
function.	  This	  provides	  evidence	  about	  the	  conserved	  nature	  of	  ATP	  binding	  sites	  where	  
interactions	   with	   ATP	   and	   ADP	   form	   the	   basis	   of	   the	   whole	   cycle	   of	   motility	   in	   these	  
proteins.	  Another	  highly	  conserved	  motif	  in	  kinesins,	  switch	  I	  (SSRSH)	  (Figure	  1-­‐4c)	  act	  as	  
a	   γ-­‐phosphate	   sensor	   and	   translates	   local	   changes	   to	   larger	   conformational	   changes	   in	  
the	  third	  conserved	  motif,	  switch	  II	  (DLAGSE)	  cluster	  (Figure	  1-­‐4d)	  that	  is	  responsible	  for	  
motility.24	  	  
In	   kinesins,	   loop	   L11,	   helix	   4,	   loop	   L12	   and	   helix	   5	   (L11-­‐α4-­‐L12	   and	   α5)	   form	   the	  MT-­‐
binding	   site	   that	   consists	   of	   primarily	   positive	   charged	   residues	   that	   communicate	   via	  
electrostatic	   interactions	  with	  negative	  charged	  residues	  of	  MTs.	  Experimental	  evidence	  
illustrates	  that	  loops	  L7	  and	  L8	  are	  also	  involved	  in	  MT-­‐binding.	  The	  nucleotide	  hydrolysis	  
cycle	  as	  mentioned	  above	  is	  responsible	  for	  conformational	  changes	  that	  affect	  binding	  of	  
kinesin	  to	  MTs.33-­‐35	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Figure	  1-­‐4:	  Overall	  structure	  and	  important	  binding	  sites	  of	  kinesins.	  	  
a)	  The	  dimeric	  structure	  of	  Drosophila	  conventional	  kinesin	  reveals	  the	  conserved	  core	  structure	  
of	  kinesins	  with	  eight	  β-­‐strands	  surrounded	  by	  six	  major	  α-­‐helices	  represented	  in	  gray,	  the	  neck	  
linker	  (magenta)	  and	  the	  portion	  of	  the	  stalk	  domain	  that	  promotes	  dimerisation	  (yellow).36	  It	  also	  
shows	  Mg2+ADP	  bound	  to	  the	  P-­‐loop.	  b)	  P-­‐loop	  motif	  is	  conserved	  in	  kinesins	  as	  in	  various	  other	  
ATPase	  proteins	   like	  closely	  related,	  myosin	  and	  also	  divergent	  ATPase	  protein,	  ATP	  synthase.	  c)	  
Overall	   structure	  of	   the	  kinesin	  motor	  domain	  where	   the	  Mg2+ADP	   is	  bound	   to	   the	  P-­‐loop	   (red)	  
and	   the	   switch	   I	   (blue)	   which	   undergoes	   conformational	   changes	   during	   the	   ATPase	   hydrolysis	  
cycle	  and	  d)	  the	  switch	  II	  cluster	  (green)	  and	  neck	  linker	  (magenta)	  which	  on	  response	  to	  changes	  
in	   switch	   I	   undergoes	   larger	   conformational	   changes	   to	   either	   bind	   to	   or	   release	   from	  MTs.	   e)	  
Major	   secondary	   structural	   elements	   of	   kinesin	   motor	   domain	   showing	   the	   P-­‐loop,	   Switch	   I,	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Linking	  the	  motor	  domain	  to	  the	  stalk	  domain	  is	  a	  short	  polypeptide	  of	  ~15	  residues.	  	  This	  
region	  is	  termed	  the	  neck	  linker	  and	  is	  a	  vital	  component	  in	  transmitting	  force	  from	  the	  
motor	   domain.	   The	  motor	   classification	   is	   also	   related	   to	   the	   conserved	   nature	   of	   the	  
neck	   linker	   sequence.	   The	   characteristic	  motif	   L*E/DLKGN	   preceding	   the	   ﬁrst	   strand	   of	  
the	  catalytic	  core	  is	  present	  in	  C-­‐types	  kinesins	  (Kin-­‐C).	  Similarly,	  the	  N-­‐type	  kinesin	  (Kin-­‐
N)	  motor	  domain	  contains	   the	  consensus	  sequence	  K/R*I*N***V/IN	  at	   the	  beginning	  of	  
the	   neck	   linker	   region.	   N-­‐type	   kinesins	   contain	   some	   highly	   conserved	   hydrophobic	  
residues	  in	  the	  neck	  linker	  C-­‐terminal	  to	  this	  conserved	  sequence.12,22	  
The	  movement	   in	   and	   around	   the	   neck	   linker	   is	   controlled	   by	   the	   ATPase	   cycle	   of	   the	  
kinesin	  motor	  (Figure	  1-­‐5a)	  as	  seen	  in	  myosin	  (Figure	  1-­‐5b).	  When	  kinesin	  is	  not	  bound	  to	  
MTs,	  the	  neck	  linker	  fluctuates	  between	  a	  “docked”	  state	  and	  an	  “undocked”	  state.28	  On	  
binding	  to	  MTs,	  the	  neck	  linker	  is	  in	  an	  “undocked”	  state.	  ADP	  is	  released	  from	  the	  kinesin	  
prompting	  ATP	  binding.	  This	  does	  not	  change	  this	  state	  but	  when	  ATP	  is	  hydrolysed	  and	  
inorganic	  phosphate	  is	  released,	  the	  neck	  linker	  shifts	  downwards	  toward	  the	  C-­‐terminal	  
of	   helix	   α4,	   adopting	   a	   “docked”	   state,	   where	   the	   movement	   of	   helix	   α4	   creates	   the	  
necessary	  space	  to	  accommodate	  the	  neck	  linker.	  This	  is	  brought	  about	  by	  movement	  of	  
switch	   I	   (Figure	   1-­‐5c)	   that	   initiate	   the	   switch	   II	   (α4	   -­‐	   L12	   -­‐	   α5)	   conformational	   changes	  
which	  in	  turn	  allows	  the	  neck	  linker	  to	  move	  down	  to	  the	  “docked”	  position	  (Figure	  1-­‐5d).	  
Thus,	  this	  conformational	  change	  in	  the	  neck	  linker	  is	  believed	  to	  be	  crucial	  in	  producing	  
force	   for	   the	   movement	   of	   the	   motor	   along	   MTs	   and	   also	   for	   giving	   the	   motor	  
directionality.33	  	  
In	   contrast	   to	   this	   model	   of	   ATP	   hydrolysis	   and	   neck	   linker	   movement,	   studies	   on	  
conventional	   kinesin-­‐ADP	   and	   AMPPNP	   crystal	   structures	   reveal	   that	   in	   the	   absence	   of	  
MTs,	  the	  neck	  linker	  can	  adopt	  both	  docked	  and	  undocked	  states.37,38	  The	  common	  belief	  
is	   that	  the	  movement	  between	  two	  states	   is	   related	  to	  the	  nucleotide	  activation,	  which	  
only	  occurs	  on	  MTs	  binding	   linking	   the	  nucleotide	  hydrolysis	   to	   the	  motility	   of	   kinesins	  
along	  MT	  tracks.	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Figure	  1-­‐5:	  Key	   structural	   features	  driving	   conformational	   changes	  during	   the	  ATPase	   cycle	  of	  
conventional	  kinesin.	  
The	  catalytic	  domains	  of	  a)	  conventional	  kinesin	  (PDB	  code	  1BG2)	  and	  b)	  myosin	  (PDB	  code	  2YCU)	  
are	  grey	  with	  the	  force	  generating	  region	  (neck	  linker	  in	  kinesin	  and	  converter	  in	  myosin)	  coloured	  
in	   magenta	   and	   the	   amplifier	   regions	   (neck	   coiled	   coil	   in	   kinesin	   and	   lever	   arm	   in	   myosin)	   in	  
yellow.	  This	  represents	  the	  functionally	  similar	  regions	  of	  conventional	  kinesins	  and	  myosin.	  The	  
conformational	  change	  from	  the	  ATP	  (blue)	  to	  the	  ADP	  (gray)	  state	  for	  c)	  switch	  I	  and	  d)	  switch	  II	  
and	  neck	  linker	  region.	  Adapted	  from	  Sablin	  et	  al,	  2001.39	  
 
Homodimerisation	   is	  necessary	   for	   the	   function40	  of	   certain	  kinesins,	  which	   is	  mediated	  
by	  the	  stalk	  domain	  that	  follows	  the	  neck	  linker	  region.	  The	  stalk	  domain	  can	  also	  induce	  
oligomerisation	  into	  higher	  oligomers	  as	  is	  observed	  in	  kinesin-­‐5	  to	  form	  homotetramers.	  
The	   stalk	   domain	  has	   a	   number	  of	   further	   functions	   beyond	  homo-­‐oligomerisation	   and	  
has	   also	   been	   shown	   to	   regulate	   the	   activity	   of	   the	   motor	   domain.38,41	   In	   addition,	   in	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some	   kinesins,	   e.g.	   kinesin-­‐2	   (Kif3A/Kif3B),	   the	   stalk	   domain	  mediates	   interactions	  with	  
either	  a	  different	  kinesin	  or	  with	  non-­‐motor	  proteins.42	  The	  structure	  of	  the	  entire	  stalk	  
domain	   of	   conventional	   kinesin	   is	   hypothesised	   to	   form	   an	   interrupted	   coiled	   coil	  
structure	  where	   the	  presence	  of	  heptad	   repeats	   in	   its	   sequence	   facilitates	   formation	  of	  
the	   coiled	   coil.43	   The	   flexible	   regions	   called	   hinges	   in	   the	   stalk	   domain	   may	   help	   in	  
facilitating	   interaction	  between	  the	  motor	  domain	  and	  the	   tail	  domain,	  which	  has	  been	  
shown	  to	  be	  important	  in	  regulating	  activity	  of	  the	  motor	  domain.44	  	  
The	   stalk	   domain	   of	   conventional	   kinesin	   links	   the	  MD	   to	   the	   tail	   domain,	  which	   plays	  
both	   an	   important	   regulatory	   role	   and	   a	   functional	   role	   in	   binding	   cargos	   or	   adapter	  
proteins.	  Studies	  have	  shown	  that	  conventional	  kinesin	  folds	  into	  a	  closed	  conformation	  
on	  interaction	  between	  the	  motor	  and	  the	  tail	  domain,	   inhibiting	  motor	  domain	  activity	  
and	  processivity.45	  This	  restricts	  the	  unwanted	  use	  of	  ATP	  when	  kinesin	  is	  not	  performing	  
its	   functions.	   The	   other	   significant	   role	   of	   the	   tail	   domain	   is	   to	   selectively	   binding	  
cargo/adapter	   proteins.	   The	   tail	   domains	   of	   different	   kinesins	   show	   very	   low,	   or	   no,	  
sequence	   similarity,	   which	   may	   explain	   the	   cargo	   specificity	   of	   different	   kinesin	  
subfamilies,	  allowing	  each	  one	  to	  bind	  different	  cargos.	  There	  is	  a	  wide	  range	  of	  different	  
possible	  cargos	  including	  vesicles,	  proteins	  and	  organelles.	  Some	  kinesin	  tail	  domains	  bind	  
MTs, in	   an	   ATP-­‐independent	   manner.	   In	   conjunction	   with	   MT-­‐binding	   by	   the	   motor	  
domain,	   this	  may	   induce	   the	   formation	  of	   large	  protofilament	   sheets,	   suggesting	  a	   tail-­‐
induced	  MT	  bundling	  property.46,47	  
1.1.2 Mechanism of Kinesin motility 
Conventional	   kinesins	   depend	   upon	   their	   processive	   movement	   along	   MT	   tracks	   to	  
perform	  their	  different	  roles	  in	  cellular	  transport.	  Kinesin	  motility	  forms	  an	  integral	  part	  in	  
kinesin	   function.	   For	   example,	   conventional	   kinesin	   takes	   around	  hundred	   steps	  before	  
dissociating	  from	  the	  MT,	  where	  each	  8	  nm	  step	  uses	  the	  chemical	  energy	  from	  one	  single	  
molecule	  of	  ATP	  producing	  a	  force	  of	  6-­‐8	  pN.48,49	  On	  the	  contrary,	  Ncd	  (kinesin-­‐14),	  a	  MT	  
minus	  end	  directed	  non-­‐processive	  kinesin,	  dissociates	  from	  the	  MT	  track	  after	  each	  step.	  
It	  works	  as	  an	  organised	  collection	  of	  multiple	  motors	  in	  a	  cluster	  that	  alternatively	  bind	  
to	  the	  MT	  to	  generate	  motility.	  	  
Several	   alternative	  models	   have	   been	   proposed	   for	   conventional	   kinesin	  motility	   along	  
MTs.	   	   Each	   one	   relies	   on	   the	   oligomeric	   nature	   of	   conventional	   kinesin	   and	   they	   are	  
summarised	  in	  Figure	  1-­‐6.	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Figure	  1-­‐6:	  Different	  models	  depicting	  conventional	  kinesin	  motility.	  	  
a)	  In	  the	  symmetric	  hand-­‐over-­‐hand	  model,	  the	  lagging	  head	  passes	  the	  leading	  head	  on	  the	  same	  
side	   (red	   arrows	   in	   front	   of	   the	   coiled	   coil	   neck).	   b)	   In	   an	   asymmetric	   hand-­‐over-­‐hand	  model,	  
torsion	  force	  around	  a	  flexible	  hinge	  domain	  above	  the	  neck	  (red	  arrow)	  causes	  movement	  of	  the	  
lagging	  head	   from	   the	  other	   side	  of	   the	   leading	  head	  as	   shown	  by	   the	  green	  arrow	  behind	   the	  
neck.	  c)	  In	  a	  symmetric	  inchworm	  model,	  both	  heads	  hydrolyses	  ATP	  in	  the	  lagging	  head	  thereby	  
pushing	  the	  leading	  head	  forward.	  d)	  In	  the	  asymmetric	  inchworm	  model,	  only	  the	  leading	  head	  
hydrolyses	  ATP	  while	  the	  lagging	  head	  is	  pulled	  up	  passively.	  The	  term	  'asymmetric'	  refers	  to	  ATP	  
hydrolysis	  occurring	  in	  one	  head.	  Figure	  adapted	  from	  Manfred	  et	  al,	  2000	  and	  2003.20	  
	  
1.2 Function of Kinesins 
Kinesins	  have	  multiple	  roles	  and	  can	  be	  divided	  into	  the	  mitotic	  kinesins,	  which	  form	  the	  
focus	  of	   this	   thesis,	   and	  kinesins	   involved	   in	   intracellular	   transport.	  The	   roles	  played	  by	  
these	  cytoplasmic	   transport	  kinesins	  are	  beyond	   the	   scope	  of	   this	   thesis	  but	  are	  briefly	  
outlined	   here.	   Kinesins	   have	   been	   implicated	   in	   normal	   functioning	   of	   neurons	   by	  
transporting	   vesicles,	   protein	   complexes	   and	   membranous	   organelles.	   Synaptic	  
transmission	   in	   dendrites	   requires	   kinesins	   to	   transport	   mRNP	   (messenger	  
ribonucleoprotein).50	  Kinesins	  transport	  vesicles,	  such	  as	  endosomes	  and	  lysosomes,	  and	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organelles,	   such	   as	   the	   endoplasmic	   reticulum	   and	   Golgi	   apparatus	   to	   their	   respective	  
destinations	  in	  the	  cell	  via	  movement	  along	  MTs.51	  Kinesins	  also	  transport	  components	  of	  
the	  cilia	  in	  intraflagellar	  transport.52,53,54,55	  
1.2.1 Mitotic Kinesins 
At	  least	  16	  human	  kinesins	  are	  involved	  in	  various	  steps	  of	  mitosis.	  Kinesins	  are	  involved	  
in	   spindle	  assembly,	  maintenance,	   chromosome	  segregation,	  mitotic	   checkpoint	   control	  
and	   cytokinesis	   (Table	   1-­‐1).56	   Initial	   experiments	   on	   immunodepletion	   of	   kinesins	   in	  
Xenopus	  eggs	  provided	  the	  first	  evidence	  on	  the	  function	  of	  kinesins	  in	  the	  various	  stages	  
of	  mitosis.57	  Sequence	  similarity	  analysis	  reveals	  high	  sequence	  similarity	  between	  KLP61F	  
and	  human	  Eg5	  and	  a	  study	  on	  Drosophila	  kinesin-­‐5	  member,	  KLP61F,	  identified	  its	  role	  in	  
cross-­‐linking	   MTs.58	   Another	   study	   of	   the	   yeast	   kinesin	   genes	   provided	   additional	  
evidence	  on	  the	  involvement	  of	  six	  kinesin	  genes	  in	  mitosis	  and	  cytokinesis.59	  A	  summary	  
of	   kinesins	   involved	   in	  mitosis	   is	   shown	   in	   Table	   1-­‐1.	   Among	   different	   roles	   of	   kinesins	  
mentioned	  above,	   Eg5	   (kinesin-­‐5)	   is	   responsible	   for	   the	   separation	  of	   centrosomes	   and	  
formation	  of	   the	  bipolar	   spindle.56	  CENP-­‐E	   (kinesin-­‐7)	   is	   responsible	   to	  establish	  bipolar	  
connections	  for	  monopolar	  chromosomes	  and	  align	  them	  at	  the	  spindle	  equator;60	  MCAK	  
(kinesin-­‐13)	   is	  responsible	  for	  chromosome	  alignment	  during	  prometaphase	  transition,61	  
Kif14	   (kinesin-­‐3)	   is	   required	   for	   chromosome	   congression	   and	   alignment38	   and	   also	   for	  
cytokinesis,21	   Kif18A	   controls	   chromosome	  movement	   to	   regulate	  mitotic	   chromosome	  
positioning62	  &	  Kif18B	   (kinesin-­‐8)	  controls	  MT	  dynamics	  during	  metaphase	  alignment	  of	  
bipolar	   spindle.63,64	   Other	   kinesins	   such	   as	   members	   of	   the	   kinesin-­‐6	   family,	   MKLP-­‐1,	  
MKLP-­‐2	   and	  MPP1	   are	   involved	   in	   cytokinesis.38,65-­‐67	  Most	   of	   the	  mitotic	   kinesins	  work	  
exclusively	  during	  cell	  division	  but	  there	  is	  also	  evidence	  that	  some	  have	  a	  limited	  role	  in	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Table	  1-­‐1:	  Tabular	  representation	  of	  molecular	  motors	  during	  mitosis.	  	  
Mitotic	   kinesins	   are	   involved	   in	   various	   stages	   facilitating	   spindle	   assembly,	   chromosome	  
alignment	  and	  cytokinesis.	  Table	  adapted	  from	  Good	  et	  al,	  2011.15	  
 
Stages	  of	  cell	  
cycle	  
Kinesins	  involved	   References	  
Interphase	   -­‐-­‐-­‐-­‐	   -­‐-­‐-­‐-­‐	  
Prophase	  /	  
Prometaphase	  
Eg5,	  KifC1,	  Kif2A,	  Kif15	   Le	   Guellec	   et	   al,	   199157	  
Oguchi	  et	  al,	  201169	  
Metaphase	   MCAK,	  CENP-­‐E,	  Kif14,	  
Kif18A,	  Kif18B,	  Kid	  
Ems-­‐McClung	  et	  al,	  
201070	  
Gruneberg	  et	  al,	  200621	  
Huang	  et	  al,	  200971	  
Lee	  et	  al,	  201072	  
Anaphase	   Kif4A,	  Kif4B	   Kurasawa	  et	  al,	  200473	  
Telophase/	  
Cytokinesis	  
MKLP-­‐1,	  MKLP-­‐2,	  MPP1,	  
Kif4A,	  Kif4B,	  Kif14	  
Li	  et	  al,	  201065	  
Fontijin	  et	  al,	  200166	  
Abaza	  et	  al,	  200367	  
	  
1.2.2 Kinesin-5 family 
During	  a	  study	  on	  Aspergillus	  nidulans,	  a	  gene	  was	  found	  to	  play	  a	  central	  role	  in	  nuclear	  
division.74	   It	   was	   observed	   that	   the	   temperature-­‐sensitive	   mutant	   of	   this	   gene	   caused	  
mitotic	   arrest.	   The	   gene	   was	   named	   ‘bim’	   (blocked	   in	   mitosis).	   A	   few	   years	   later,	   a	  
homologue	  of	  bim	  was	  discovered	  during	  a	  differential	   screening	  of	  Xenopus	  egg	  cDNA	  
for	  identifying	  genes	  necessary	  for	  nuclear	  division	  and	  cell	  proliferation.57	  This	  gene	  was	  
later	   classified	   as	   a	  member	   of	   the	   kinesin-­‐5	   family	   along	  with	   the	   human	   homologue	  
called	  Eg5/KSP/KIF11	  (Figure	  1-­‐7).	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Figure	  1-­‐7:	  Phylogenetic	  tree	  representing	  members	  of	  the	  kinesin-­‐5	  family.	  	  
The	  tree	  of	  kinesin-­‐5	  family	  members	  was	  built	  from	  a	  kinesin	  motor	  domain	  sequence	  alignment	  
using	  the	  heuristic	  search	  method	  of	  PAUP	  v4.0b10.18	  
 
1.2.2.1 Human Eg5 
1.2.2.1.1 Structure and organisation 
	  
Human	  Eg5	  consists	  of	  the	  conserved	  motor	  domain	  of	  ~350	  residues	  at	  the	  N-­‐terminus,	  
an	   interrupted	  α-­‐helical	  coiled	  coil	   stalk	  domain	  of	  around 460	  residues,	  and	  a	  putative	  
globular	  C-­‐terminal	  tail	  domain	  of	  ~220	  residues	  (Figure	  1-­‐8a).	  	  	  
	  
Figure	  1-­‐8:	  Eg5	  structural	  organisation	  and	  homotetramerisation.	  	  
a)	  Domain	  organisation	  of	  full	  length	  Eg5.	  b)	  Homotetrameric	  model	  of	  Eg5	  showing	  its	  quaternary	  
structure.	  Figure	  adapted	  from	  http://www.cellbio.duke.edu/kinesin/BE5a_BimC.html.	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Eg5	   functions	   as	   a	   homotetramer	   (Figure	   1-­‐8b),	   in	   contrast	   to	  many	  other	   kinesins.75,76	  
Many	   kinesins	   function	   as	   dimers	   but	   some	   function	   as	   monomers	   or	   in	   alternative	  
oligomeric	   states.77	   Studies	   on	   electron	   micrographs	   of	   rotary-­‐shadowed	   Eg5	   have	  
generated	  evidence	  on	  this	  physiological	  behaviour	  of	  Eg5.78	  The	  tetramer	   is	   formed	  by	  
two	  anti-­‐parallel	  dimers	  of	  Eg5	  assembling	  into	  a	  “dumbbell-­‐shaped	  bipolar	  kinesin”	  with	  
two	  motor	   domains	   at	   each	   end,	   which	   allows	   it	   to	   bind	  MTs	   at	   both	   its	   ends	   of	   the	  
oligomer.	   
The	  structure	  of	  the	  Eg5	  motor	  domain	  in	  complex	  with	  Mg2+ADP28	  provides	  insights	  into	  
the	  catalytic	  domain	  of	  the	  protein	  (Figure	  1-­‐9a).	  The	  core	  of	  the	  motor	  domain	  consists	  
of	  an	  eight-­‐stranded	  β-­‐sheet,	  skirted	  by	  six	  major	  α-­‐helices	  on	  each	  side24	  typical	  of	  the	  
conserved	  motor	  domain	  of	  the	  conventional	  kinesins.	  A	  crystal	  structure	  of	  Eg5	  bound	  to	  
AMPPNP	  (a	  slowly-­‐hydrolysable	  ATP	  analogue)	  reveals	  a	  docked	  neck	  linker	  similar	  to	  that	  
of	   kinesin-­‐1.27	   A	   number	   studies	   have	   tried	   to	   understand	   the	   different	   stages	   of	   the	  
ATPase	  cycle	  in	  kinesins.79	  In	  particular	  Ryo	  et	  al,	  2004	  compared	  the	  crystal	  structures	  of	  
various	  nucleotide	  bound	  states	  of	  Kif1a	  revealing	  the	  mechanism	  of	  interaction	  between	  
kinesin	  and	  MTs	  necessary	  for	  kinesin	  motility.33,80	  However,	  Kif1a	  is	  a	  monomeric	  kinesin	  
and	   the	  mechanism	   of	   oligomeric	   kinesins	  may	   be	   different.	   The	   structure	   of	   different	  
states	  in	  the	  ATPase	  cycle	  of	  dimeric	  or	  other	  higher	  oligomeric	  kinesin	  may	  give	  a	  better	  
understanding	  of	  this.	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Figure	  1-­‐9:	  Crystal	  structure	  of	  the	  motor	  domain	  of	  Eg5	  and	  the	  loop	  L5.	  	  
Overall	  structure	  of	  Eg5	  motor	  domain	  containing	  eight	  β-­‐strands	  flanked	  by	  six	  major	  α-­‐helices.	  
a)	  Front	  view	  and	  b)	  back	  view	  of	  the	  motor	  domain.	  c)	  Sequence	  alignment	  of	  α2-­‐L5	  regions	  of	  12	  
kinesins	   that	   can	   be	   expressed	   and	   purified	   under	   in	   vitro	   conditions	   and	   loop	   L5	   in	   Eg5/Kif11	  
marked	  in	  red.	  
 
A	  unique	  feature	  of	  the	  motor	  domain	  of	  Eg5	  is	  the	  length	  of	  loop	  L5,	  which	  is	  a	  loop	  that	  
interrupts	   helix	   α2	   and	   consists	   of	   ~18	   residues	   (Glu116	   to	   Ile133)	   and	   is	   the	   longest	  
among	   all	   kinesins	   (Figure	   1-­‐9b).	   Kinetic	   studies	   have	   confirmed	   the	   role	   of	   loop	   L5	   in	  
regulating	  the	  ATPase	  cycle	  of	  Eg5	  and	  MT-­‐binding.81,82	  During	  the	  ATPase	  cycle,	  loop	  L5	  
moves	  between	  an	  ‘open’	  conformation,	  when	  ADP	  is	  bound,	  and	  a	  ‘closed’	  conformation	  
in	  the	  ATP	  bound	  state	  which	  is	  relayed	  to	  the	  neck	  linker	  region	  of	  the	  protein	  for	  further	  
conformational	  changes	  and	  affects	  force	  generation	  and	  movement	  of	  Eg5	  along	  the	  MT	  
track.	   Further	   experimental	   evidence	   links	   loop	   L5	   with	   the	   initial	   acceleration	   of	   ADP	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release	   during	   the	  MT-­‐binding	   along	  with	   loop	   L5	  mediating	   the	   slow	   isomerisation	   of	  
Eg5	  dimer	  heads	  by	  preventing	  them	  from	  binding	  the	  MTs	  until	  ADP	  is	  released.83 	  
Structural	   information	  on	  the	  stalk	  and	  the	  tail	  domain	  of	  Eg5	   is	   limited.	  Evidence	   from	  
kinesin-­‐1	   and	  other	   kinesins	   shows	   that	   the	   stalk	   domain	   facilitates	   dimerisation.84	   The	  
PAIRCOIL2	  program85	  predicts	  a	  disrupted	  coiled	  coil	   region	  of	  Eg5	   from	  residues	  400	  –	  
850	   (Figure	  1-­‐10).	  The	  stalk	  domain	  has	   regions	  with	  high	  and	   low	  probability	   scores	  of	  
forming	  a	  coiled	  coil	  but	  without	  high	  resolution	  structural	  data	  the	  exact	  structure	  is	  still	  
obscure.	  	  
	  
Figure	  1-­‐10:	  Prediction	  of	  quaternary	  structure	  of	  the	  Eg5	  stalk	  domain.	  	  
Output	  from	  the	  PAIRCOIL	  program	  of	  p-­‐value	  versus	  residue	  number	  shows	  that	  the	  stalk	  domain	  
of	   Eg5	   spans	   from	   around	   residue	   400	   to	   850	   and	   residues	   400-­‐500	   have	   a	   high	   probability	   of	  
coiled	   coil	   formation	   with	   a	   p-­‐value	   <0.02	   whereas	   the	   rest	   of	   the	   stalk	   domain	   has	   a	   lower	  
probability.85	  
	  
1.2.2.1.2 Functions and interactions  
	  
The	  main	  function	  of	  Eg5	  is	  to	  separate	  the	  duplicated	  centrosomes	  bound	  to	  the	  mitotic	  
spindle	   by	   cross-­‐linking	   anti-­‐parallel	   MTs	   and	   sliding	   them	   apart	   to	   form	   the	   bipolar	  
spindle	   (Figure	  1-­‐11	   a-­‐b).56,86,87	   This	   has	  been	   investigated	  using	   various	   studies	   for	   the	  
last	  two	  decades.75,88	  An	  initial	  study	  on	  human	  Eg5	  revealed	  that	  the	  inhibition	  of	  Eg5	  by	  
antibodies	   caused	   HeLa	   cells	   to	   arrest	   in	   mitosis	   with	   a	   characteristic	   formation	   of	  
monoastral	   spindles	   with	   an	   array	   of	   MTs	   emanating	   from	   a	   pair	   of	   non-­‐separated	  
centrosomes,	  which	  eventually	  led	  to	  apoptotic	  cell	  death	  (Figure	  1-­‐11c).89	  Another	  study	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using	   siRNA	   to	   knockdown	   Eg5	   in	   PtK	   cells	   also	   resulted	   in	   the	   monoastral	   spindle	  
phenotype	  and	  mitotic	  arrest.90	  	  
The	  C-­‐terminal	  tail	  domain	  of	  Eg5	  has	  multiple	  roles.	  Phosphorylation	  of	  Thr927	  of	  the	  tail	  
domain	  by	  protein	  kinase	  p34cdc2/cyclin-­‐dependent	  kinase	  1	  (Cdk1)	  helps	  to	  regulate	  the	  
association	  of	  Eg5	  with	  MTs	  during	  early	  prophase	  and	   it	   is	  essential	   for	  Eg5	  activity.	   	  A	  
single	   point	   mutation	   of	   Thr927	   in	   the	   tail	   domain	   is	   able	   to	   inhibit	   the	   interaction	  
between	  Eg5	  and	  the	  spindle	  apparatus.56	  Among	  other	  roles,	   the	  tail	  domain	  has	  been	  
shown	  to	  interact	  with	  p150	  (Glued),	  a	  subunit	  of	  the	  dynactin	  complex	  that	  mediates	  the	  
association	   of	   Eg5	   with	   MTs	   and/or	   the	   spindle	   apparatus.91,92	   Other	   experimental	  
evidence	   suggests	   that	   the	   tail	   domain	   of	   Eg5	   might	   also	   bind	   to	   MTs	   allowing	   more	  
efficient	  separation	  of	  spindle	  MTs.93	  Whether	  this	  role	   is	  played	  alone	  or	   in	   interaction	  
with	  the	  other	  proteins	  is	  still	  unknown.94	  
	  
	  
Figure	  1-­‐11:	  Eg5	  function	  in	  the	  formation	  of	  the	  bipolar	  spindle.	  	  
a)	  Normal	  cell	  in	  a	  control	  setup	  showing	  chromosomes	  (blue)	  aligned	  at	  the	  metaphase	  plate	  of	  a	  
bipolar	   spindle	   (yellow).	   b)	  Monoastral	   spindle	   caused	   due	   to	   treatment	  with	   the	   Eg5	   inhibitor	  
monastrol	  or	   siRNA	   to	   inhibit	   Eg5.	   c)	   Eg5	  homotetramer	   cross-­‐linking	  MTs	  and	   separating	   them	  
while	  moving	  towards	  the	  MT	  plus-­‐end.	  Figure	  taken	  from	  Stout	  et	  al,	  2006.89,90	  
 
There	  is	  also	  evidence	  that	  Eg5	  has	  some	  function	  in	  addition	  to	  mitosis.	  Eg5	  plays	  a	  role	  
in	   developing	   neurons,	   where	   it	   was	   shown	   to	   express	   in	   dividing	   neuroblasts.	   Eg5	  
expression	   in	   postmitotic	   neurons	   has	   been	   shown	   using	   immunofluorescence	  
microscopy	  with	  an	  antibody	  against	  Eg5.	   It	   is	  generally	   localised	   in	   the	  cell	  body	  along	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the	  length	  and	  distal	  region	  of	  axon	  or	  dendrites.	  As	  in	  mitosis,	  Eg5	  in	  neurons	  is	  involved	  
in	  regulating	  MT	  organisation	  and	  behaviour,	  which	  can	  help	  in	  neuronal	  migration,	  axon	  
regeneration	   and	   axonal	   growth	   although	   the	   exact	   mechanism	   is	   still	   unclear	   (Figure	  
1-­‐12).95-­‐97	  	  
	  
Figure	  1-­‐12:	  Role	  of	  kinesin-­‐5	  (Eg5)	  in	  neuronal	  migration.	  	  
Cultured	   neuron	   cells	   after	   3	   hr	   and	   6	   hr	   of	   siRNA	   treatment.	   Cells	   treated	  with	   control	   siRNA	  
shows	   diminished	   migration	   whereas	   cells	   treated	   with	   siRNA	   against	   Eg5	   shows	   accelerated	  
migration	   depicting	   the	   role	   of	   Eg5	   in	   controlling	   neuronal	   cell	   migration.	   Figure	   taken	   from	  
Falnikar	  et	  al,	  2011.96	  
	  
1.2.2.1.3 Clinical relevance of Eg5 
	  
The	   important	   role	   of	   Eg5	   in	   cell	   division	   raises	   the	   possibility	   of	   Eg5	   being	   a	   potential	  
therapeutic	  target	  and	  correlations	  between	  aberrant	  Eg5	  expression	  and	  certain	  cancers	  
have	  been	  observed.98-­‐101	  	  Eg5	  over-­‐expression	  has	  been	  implicated	  in	  tumourigenesis	  in	  
blast	  crisis	  chronic	  myeloid	  leukaemia	  in	  transgenic	  mice.102,103 It	  has	  also	  been	  shown	  to	  
be	   involved	   in	   the	  anti-­‐proliferative	  action	  of	  all-­‐trans-­‐retinoic	  acid	   in	  pancreatic	  cancer	  
cells.104,105	  In	  addition,	  Eg5	  promotes	  pancreatic	  cancer	  cell	  proliferation,	  colonisation	  and	  
tumour	  malignancy	  based	  on	  the	  up-­‐regulation	  of	  both	  mRNA	  and	  protein	  levels	  (Figure	  
1-­‐13).100	   More	   recently,	   in	   non-­‐muscle	   invasive	   urinary	   bladder	   cancer,	   Eg5	   over-­‐
expression	   is	   seen	   as	   a	   potential	   prognostic	   clinicopathological	   factor,	   which	   can	   be	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related	   to	   tumour	   recurrence	   and	   progression.106	   These	   findings	   suggest	   that	   Eg5	  may	  
play	  a	  role	  in	  the	  pathogenesis	  of	  multiple	  cancers	  with	  an	  essential	  role	  during	  mitosis.	  
Eg5	  as	  a	  drug	  candidate	   for	   cancer	  chemotherapy	  can	  be	  used	   for	   targeting	   slow-­‐down	  
and	  regression	  of	  tumour	  growth	  with	  higher	  mitotic	  index.	  	  	  
	  
Figure	  1-­‐13:	  Over-­‐expression	  of	  Eg5	  in	  pancreatic	  cancer.	  	  
a)	  Western	  blot	  analysis	  of	  Eg5	  protein	  in	  different	  cancer	  cell	  lines	  and	  compared	  to	  normal	  cell	  
(control)	   reveals	   its	   over-­‐expression.	   b)	   Analysis	   of	   Eg5	   mRNA	   in	   normal	   cells	   and	   pancreatic	  
adenocarcinoma	  cell	   lines	  shows	  a	  correlation	  between	  mRNA	  and	  protein	   levels.	  Adapted	  from	  
Liu	  et	  al,	  2010.100	  	  
 
Mayer	   et	   al	   107	   were	   the	   first	   to	   discover	   an	   inhibitor	   of	   Eg5	   while	   conducting	   a	  
phenotypic	  screen	  for	  small	  molecules	  that	  inhibit	  the	  formation	  of	  bipolar	  spindle	  (Figure	  
1-­‐14).	  They	  identified	  5	  hits	  out	  of	  more	  than	  16000	  compounds	  that	  specifically	  affected	  
proliferating	   cells	   undergoing	  mitosis	   but	   did	   not	   affect	   tubulin	   polymerisation	   or	  MTs.	  
One	   of	   these	   5	   compounds,	   named	   monastrol,	   was	   proposed	   to	   inhibit	   Eg5	   function	  
because	  of	   the	   characteristic	  monoastral	   spindle	  phenotype	   in	  dividing	   cells.	  Monastrol	  
exhibits	   relatively	   weak	   potency	   in	   biochemical	   assays	   (IC50	   =	   14	   μM)	   but	   is	   a	   widely	  
accepted	  Eg5	  inhibitor	  used	  for	  further	  studies.108	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Figure	  1-­‐14:	  Phenotypic	  screen	  to	  identify	  inhibitors	  of	  bipolar	  spindle	  formation.	  	  
Screening	  of	  more	  than	  16000	  compounds	  identified	  five	  inhibitors	  that	  specifically	  block	  bipolar	  
spindle	   formation	   with	   characteristic	   monoastral	   spindles	   and	   mitotic	   defects.	   One	   of	   the	  
inhibitors	  was	  later	  found	  to	  inhibit	  Eg5.	  Figure	  taken	  from	  Mayer	  et	  al,	  1999.107	  
 
A	  later	  study	  on	  small	  molecule	  libraries	  from	  NCI	  (National	  Cancer	  Institute)	  using	  in	  vitro	  
assays	   led	   to	   the	   discovery	   of	   S-­‐trityl-­‐L-­‐cysteine	   (STLC),	   which	   is	   more	   potent	   than	  
monastrol	   with	   an	   IC50	   of	   ~200	   nM.109	   STLC	   and	   monastrol	   inhibit	   basal	   and	   MT-­‐
stimulated	   Eg5	   ATPase	   activity	   by	   preventing	   ADP	   release	   and	   MT	   gliding	   in	   motility	  
assays.110	   Tumour	   cell	   lines	   treated	   with	   STLC	   undergo	   mitotic	   arrest	   through	   the	  
activation	  of	   the	  spindle	  assembly	  checkpoint	  by	   the	  phosphorylation	  of	  BubR1.111	   	  The	  
resulting	  prolonged	  mitotic	  arrest	  led	  to	  the	  activation	  of	  caspase	  pathways	  for	  eventual	  
apoptosis.112	  
Crystal	   structures	   of	   the	   ternary	   complex	   of	   Eg5	   and	  Mg2+ADP	  with	  S-­‐monastrol113	   and	  
STLC114	  provide	  a	  greater	   insight	   into	   the	   inhibitor-­‐binding	  pocket.	  The	   inhibitor-­‐binding	  
pocket	   of	   Eg5	   is	   an	   allosteric	   site	   about	   12	   Å	   away	   from	   the	   nucleotide	   pocket.	  
Comparison	   with	   the	   apo	   Eg5-­‐ADP	   structure	   reveals	   the	   conformational	   changes	   that	  
occur	  upon	   inhibitor	  binding.	   First,	   to	   accommodate	   the	   inhibitor,	  Arg119	   (on	  helix	  α2)	  
and	  Tyr211	  (on	  helix	  α3)	  move	  outwards,	  while	  Trp127	  of	  loop	  L5	  swings	  downwards,	  by	  
about	  7	  Å,	  from	  a	  solvent	  exposed	  region	  to	  form	  an	  aromatic	  C-­‐H-­‐π-­‐interaction	  with	  the	  
inhibitor	  (STLC).	  These	  conformational	  changes	  by	  the	  so-­‐called	  gatekeeper	  residues	  close	  
the	  entrance	  of	  the	  induced-­‐fit	  inhibitor-­‐binding	  pocket	  (Figure	  1-­‐15).	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Figure	  1-­‐15:	  Figure	  showing	  the	  conformational	  changes	  of	  the	  inhibitor-­‐binding	  region.	  	  
The	   conformational	   changes	   in	   the	   loop	   L5	   region	   on	   binding	   of	   a)	   STLC	   (native/apo	   =	   grey,	  
inhibitor	  bound	  =	  blue	  and	  inhibitor=red)	  b)	  Monastrol	  (native/apo	  =	  grey,	  inhibitor	  bound	  =	  blue	  
and	  monastrol	  =	  yellow)	  that	  take	  place	  upon	  inhibitor-­‐binding	  where	  loop	  L5	  swings	  downwards	  
to	  close	  the	  pocket.	  Adapted	  from	  Yan	  et	  al,	  2004	  113	  and	  Kaan	  et	  al,	  2010.114	  
 
Second,	   the	   switch	   I	   cluster	   sways	   outward	   towards	   the	   solvent	   by	   around	   6	   Å	   in	   the	  
inhibitor	  bound	  structures.	  Changes	  in	  the	  inhibitor-­‐binding	  pocket	  are	  translated	  to	  shifts	  
in	  helix	  α4,	  α5	  (switch	   II	  cluster)	  and	  the	  neck	   linker,	  where	  the	  helix	  α4	  shifts	  upwards	  
creating	  space	  for	  the	  neck	  linker	  to	  adopt	  a	  docked	  conformation	  parallel	  to	  the	  helix	  α6	  
(Figure	   1-­‐16).	  Maliga	  et	   al.	   used	   spectroscopic	   probes	  dissecting	   the	   structural	   changes	  
caused	  by	  monastrol	  binding	  and	  observed	  structural	  changes	  consistent	  with	  those	  seen	  
in	  the	  crystal	  structure.114,115	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Figure	  1-­‐16:	  	  Conformational	  changes	  in	  the	  switch	  II	  cluster	  on	  inhibitor	  binding.	  	  
The	   switch	   II	   cluster	   consisting	  helix	  α4	  along	  with	  helix	  α6	  and	   the	  neck	   linker	   region	  undergo	  
conformational	   changes	   from	   native	   to	   intermediate	   to	   final	   inhibitor	   bound	   state.	   Helix	   α4	  
rotates	  to	  open	  up	  space	  for	  the	  neck	  linker	  to	  adopt	  a	  docked	  conformation,	  parallel	  to	  helix	  α6.	  
The	  native	  state	  is	  represented	  in	  yellow,	  the	  intermediate	  state	  in	  blue	  and	  the	  final	  docked	  state	  
in	  magenta.	  Adapted	  from	  Kaan	  et	  al,	  2010.114	  
 
Interaction	   studies	   of	   Eg5	   and	   the	   inhibitors	   reveal	   the	   key	   residues	   important	   for	  
inhibitor	   binding	   (Figure	   1-­‐18).	   This	   provides	   evidence	   towards	   the	   development	   of	  
inhibitor	  analogues	  with	  higher	  potency.	  In	  the	  monastrol	  bound	  structure	  of	  Eg5,	  the	  3-­‐
hydroxy	   group	  on	   the	  phenyl	   ring	   forms	  hydrogen	  bonds	  with	  Glu118	  and	  Arg119.	   The	  
phenyl	   ring	   forms	   a	  C—H-­‐-­‐-­‐π	   interaction	  with	   Pro137	   and	  π-­‐π	   interactions	  with	   Trp127	  
and	   Tyr211	   and	   the	   carbonyl	   oxygen	   of	   the	   ester	   forms	   a	   long-­‐range	   polar	   interaction	  
with	  Arg119	  (Figure	  1-­‐17-­‐	  A).	  
In	   the	   STLC-­‐bound	   structure	   of	   Eg5,	   the three	   phenyl	   rings	   in	   STLC	   display	   several	  
hydrophobic	   interactions	  with	  the	  alkyl	  moieties	  of	  the	  Glu215,	  Glu116	  and	  Arg119	  side	  
chains.	   	  The	   first	   phenyl	   group	  of	   STLC	   forms	   an	   edge–face	   interaction	  with	   the	  phenyl	  
ring	  of	  Trp127	  and	  a	  C–H–π	  interaction	  with	  the	  pyrrolidine	  ring	  of	  Pro137,	  a	  stacked	  π–π	  
interaction	   is	   formed	   between	   the	   second	   phenyl	   group	   and	   Tyr211	   and	   a	   C–H–π	  
interaction	   forms	  between	   the	   third	  phenyl	  group	  and	   the	   side-­‐chain	  of	   Leu214	   (Figure	  
1-­‐17	   -­‐	  B).	  The	  hydrophilic	  part	  of	  STLC	  containing	   the	  cysteine	  moiety	  has	   several	  polar	  
interactions:	   the	   amine	   group	   hydrogen-­‐bonds	  with	   the	  main-­‐chain	   carbonyl	   oxygen	   of	  
Gly117	   and	   a	   carboxyl	   oxygen	   of	   Glu116,	   while	   an	   oxygen	   atom	   of	   the	   STLC	   carboxyl	  
group	   forms	   a	   salt	   bridge	   with	   the	   guanidinium	   group	   of	   Arg221.	   This	   contrasts	   with	  
monastrol	  where	  polar	  interactions	  are	  much	  more	  limited.	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Figure	  1-­‐17:	  Stereo	  plot	  of	  monastrol	  and	  STLC	  bound	  in	  the	  allosteric	  pocket.	  	  
a)	   Monastrol	   and	   b)	   STLC	   interactions	   in	   the	   inhibitor-­‐binding	   pocket	   showing	   the	   interacting	  
residues,	  which	  determine	  the	  potency	  of	  the	  inhibitors.113,114	  
 
	  
Figure	  1-­‐18:	  Schematic	  representation	  of	  the	  contacts	  between	  monastrol	  (a)	  and	  STLC	  (b)	  and	  
residues	  of	  the	  Eg5	  inhibitor-­‐binding	  pocket.	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Using	  the	  LIGPLOT116	  programme	  the	   interactions	  between	  the	   inhibitors	  and	  Eg5	  residues	  from	  
the	   inhibitor-­‐binding	  pocket	  are	  depicted.	  Hydrophobic	  contacts	   (up	   to	  a	  distance	  of	  3.9	  Å)	  and	  
hydrogen	  bonds	  are	  depicted	  with	   red	  and	  green	  dashed	   lines,	   respectively.	  The	  ethyl	  group	  of	  
(S)-­‐monastrol	   points	   toward	   the	   solvent	   with	   major	   hydrophobic	   interactions	   around	   the	  
inhibitor-­‐binding	   pocket.	   In	   the	   STLC	   structure	   the	   hydrophilic	   parts	   of	   the	   inhibitor	  within	   the	  
cysteine	  moiety	  have	   several	  hydrogen	  bond	   interactions	  with	  Gly117,	  Glu116	  and	  Arg221.	   The	  
buried	  trityl	  group	  forms	  multiple	  hydrophobic	  interactions.	  
 
Other	   known	   inhibitors	   of	   Eg5	   like	   ispinesib117,	   tetrahydroisoquinolines118,	   C2-­‐
hydroxymethyl	  dihydropyrrole119	  and	  pyrrolotriazine-­‐4-­‐one	  based	  inhibitors120	  bind	  to	  the	  
same	  site	  as	  monastrol	  and	  STLC	  but	  demonstrate	  greater	  potency	  (Figure	  1-­‐19).	  	  
	  
Figure	  1-­‐19:	  Chemical	  structures	  of	  Eg5	  inhibitors.	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Allosteric	   loop	  L5,	  Eg5	  inhibitors	  pyrrolotriazine-­‐4-­‐one	  based	  inhibitor	  (a),	  MK-­‐0731	  (b),	   ispinesib	  
(c),	  (S)-­‐monastrol	  (d),	  and	  (R)-­‐STLC	  (e)	  with	  their	  respective	  IC50	  measured	  under	  MT-­‐stimulation.	  
	  
1.2.2.1.4 Progress in Eg5 drug development 
	  
Currently,	   several	   Eg5	   allosteric	   inhibitors	   are	   in	   Phase	   I	   and	   II	   clinical	   trials.	   Ispinesib,	  
developed	   by	   Cytokinetics	   and	   GlaxoSmithKline,	   was	   the	   first	   to	   enter	   into	   human	  
trials.121,122	   Other	   compounds	   like	  MK-­‐0731119	   by	  Merck	   and	   ARRY-­‐520	   are	   also	   highly	  
potent	  against	  tumour	  cell	  proliferation	  with	  IC50	  in	  the	  low	  nanomolar	  range.	  The	  Phase	  I	  
study	   of	   ispinesib	   and	   other	   drugs	   have	   showed	   that	   these	   drugs	   have	   tolerable	   side-­‐
effects	  such	  as	  fatigue,	  nausea	  and	  neutropenia	  and	  Phase	  II	  studies	  are	  ongoing.	  Some	  of	  
these	   compounds	   are	   presented	   in	   Figure	   1-­‐19.7,123-­‐125	   However,	   resistance	   is	   a	   key	  
challenge	   in	   cancer	   chemotherapy	   and	   evidence	   of	   resistance	   to	   first	   generation	  
molecules	   such	   as	   ispinesib	   is	   emerging	   in	   tumour	   cell	   lines	   in	   the	   form	   of	   Eg5	  
mutants.126,127	  To	  identify	  these	  mutants,	  HTC116	  cells	  have	  been	  cultured	  in	  presence	  of	  
ispinesib.	   Two	   point	   mutants	   namely	   D130V	   and	   A133D	   of	   Eg5	   were	   identified.	   These	  
mutants	   reduced	   the	   potency	   of	   the	   inhibitor	   by	   about	   100	   –	   200	   fold.	   These	   two	  
mutations	   are	   located	   close	   to	   the	   inhibitor-­‐binding	   region	   (loop	   L5)	   and	   contribute	  
towards	   the	   hydrophobic	   interactions	   with	   different	   inhibitors	   binding	   this	   pocket.	  
Studies	   to	   understand	   the	   mechanism	   of	   resistance	   have	   provided	   very	   limited	  
information.126	  	  
In	   order	   to	   overcome	   resistance	   generated	   by	  mutations	   at	   the	   loop	   L5	   allosteric	   site,	  
identification	   of	   inhibitors	   binding	   at	   alternative	   sites	   has	   attracted	   attention.	   New	  
benzimidazole	   inhibitors	   have	   been	   identified	   which	   bind	   to	   a	   different	   allosteric	   site	  
between	  helix	  α4	  and	  α6	  without	  being	  competitive	  with	  ATP.128	  These	  new	  inhibitors	  of	  
Eg5	   provide	   an	   avenue	   towards	   novel	   site	   binding	   that	   can	   be	   used	   as	   an	   alternative	  
chemotherapy	  addressing	  either	  drug	  resistance	  against	  Eg5	  inhibitors	  binding	  to	  loop	  L5	  
or	  in	  combined	  chemotherapy.	  	  
In	  addition	  to	  these	  allosteric	   inhibitors,	  a	  series	  of	  ATP	  competitive	  Eg5	   inhibitors	  have	  
also	  been	   identified.129-­‐131	  However	   their	   specificity	   towards	  Eg5	   is	  questionable	  due	   to	  
the	  conserved	  nature	  of	  the	  ATP	  binding	  pocket	  of	  the	  kinesin	  superfamily.15	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Phase	   II	   trials	  of	   ispinesib	  and	   its	  more	  potent	  analogue	  SB743921	  on	  patients	  suffering	  
from	  Hodgkin	  and	  non-­‐Hodgkin	   Lymphoma have	   revealed	  promising	   results.	   The	   future	  
directions	   towards	   these	   drugs	   would	   be	   to	   test	   them	   as	   a	   single	   agent	   or	   in	  
combinational	   therapy	   in	   Phase	   III,	   in	   the	   hope	   of	   achieving	   synergistic	   effects	   and	  
identification	  of	  tumours,	  which	  can	  be	  treated	  with	  such	  drugs.8	  
1.2.3 Kinesin-6 family 
The	   kinesin-­‐6	   family	  members	   (Figure	   1-­‐20)	   are	   unique	   among	   the	   kinesin	   superfamily	  
because	  of	  a	  particularly	  long	  insertion	  of	  100	  aa	  (8	  kD–10	  kD)	  into	  loop	  L6	  of	  the	  motor	  
domain	   (Figure	  1-­‐21b).	  The	   three	  members	  belonging	   to	   this	   family	  are	  mitotic	  kinesin-­‐
like	   protein	   1	   (MKLP-­‐1,	   KIF23,	   KNSL5,	   CHO1),	   mitotic	   kinesin-­‐like	   protein	   2	   (MKLP-­‐2,	  
KIF20A,	  RAB6KIFL,	  rabkinesin-­‐6)	  and	  M	  phase	  phosphoprotein	  1	  (MPP1,	  KIF20B,	  KRMP1,	  
M-­‐phase	   phosphoprotein	   1,	   MPHOSPH1)	   (Figure	   1-­‐21a,	   Figure	   1-­‐20).	   They	   are	   all	   N-­‐
terminal	  motors	  and	  move	   towards	   the	  plus-­‐end	  of	  MTs	   (Figure	  1-­‐20).67,132,133	  Kinesin-­‐6	  
members	   are	   involved	   in	   the	  metaphase-­‐to-­‐anaphase	   transition	   leading	   to	   the	   physical	  
division	  of	  the	  cell	  into	  two	  daughter	  cells	  via	  cytokinesis.	  	  
	  
Figure	  1-­‐20:	  Phylogenetic	  tree	  representing	  the	  kinesin-­‐6	  family.	  	  
The	  phylogenetic	  tree	  of	  the	  kinesin-­‐6	  family	  shown	  above	  was	  built	  from	  a	  kinesin	  motor	  domain	  
sequence	  alignment	  using	  web-­‐based	  Phylogeny.fr.134,135	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Figure	  1-­‐21:	  Bar	  diagram	  of	  H.	  sapiens	  kinesin-­‐6	  family	  members	  and	  sequence	  alignment	  of	  the	  
loop	  L6	  region.	  	  
a)	  The	  figure	  depicts	  the	  domain	  structure	  of	  full-­‐length	  kinesin-­‐6	  members.	  MKLP-­‐1	  and	  MKLP-­‐2	  
are	  of	  similar	  length	  where	  MPP1	  is	  almost	  double	  the	  size.	  The	  difference	  in	  length	  is	  caused	  due	  
to	  the	  longer	  discontinuous	  stalk	  domain	  of	  MPP1.	  b)	  Sequence	  alignment	  of	  the	  motor	  domain	  of	  
Eg5	   with	   kinesin-­‐6	   members	   showing	   the	   location	   of	   the	   long	   loop	   L6	   insertion	   (blue	   arrow)	  
following	  the	  helix	  α2.	  
 
1.2.3.1 MPP1 
MPP1	   is	   proposed	   to	   be	   a	   potential	   new	   target	   for	   cancer	   chemotherapy.	   The	   initial	  
identification	  of	  MPP1	  and	  its	  link	  to	  mitosis	  was	  made	  using	  the	  MPM2	  antibody,	  which	  
specifically	   recognises	  a	  phosphorylated	   threonine	   residue,	   in	   the	  M-­‐phase	   cells	   (Figure	  
1-­‐22).	   Subsequent	   investigations	   identified	   the	   full-­‐length	   MPP1	   and	   it	   role	   in	  
cytokinesis.67,136	  
The	   MPM2	   monoclonal	   antibody	   binds	   to	   a	   phospho	   amino	   acid-­‐containing	   epitope	   of	  
about	  10	  residues	  present	  on	  more	  than	  40	  proteins	  of	  M-­‐phase	  eukaryotic	  cells.	  During	  
cDNA	  analysis	  of	  one	  such	  protein,	  MPP1	  was	  identified	  with	  a	  distinct	  ‘FTPLQ’ peptide	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sequence	   near	   its	   C-­‐terminus	   that	   provided	   the	   first	   evidence	   that	   the	   protein	   is	  
exclusively	  phosphorylated	  during	  mitosis.136,137	  	  
	  
Figure	  1-­‐22:	  Identification	  of	  the	  phospho	  epitope	  of	  MPP1.	  	  
MPP1	  was	  identified	  in	  cells	  at	  G2/M	  transition	  using	  antibodies	  binding	  specific	  phosphorylated	  
epitopes	  (amino	  acids	  highlighted	  in	  yellow	  and	  red).	  
	  
1.2.3.1.1 Structure and organisation 
	  
MPP1	   is	   a	   large	  protein	  of	   about	  1900	   residues	  being	  approximately	  double	   the	   size	  of	  
both	  MKLP-­‐1	  (850	  aa)	  and	  MKLP-­‐2	  (890	  aa)	   (Figure	  1-­‐21a).	   In	  addition	  to	  the	  conserved	  
motor	  domain,	  MPP1	  and	  the	  other	  kinesin-­‐6	  members	  contain	  an	  extension	  of	  around	  
50	   residues	   at	   the	  N-­‐terminus	   preceding	   the	  motor	   domain.	   These	   are	   predicted	   to	   be	  
structurally	   disordered	   based	   on	   secondary	   structure	   prediction	   servers	   such	   as	   Phyre	  
(ver.	  2.0)	  and	  Jpred3.138-­‐140	  
Much	  of	  the	  motor	  domain	  of	  MPP1	  (residues	  54	  to	  480)	  can	  be	  modelled	  using	  widely	  
available	   homology	  modelling	   software	   such	   as	   the	   Swissmodel	   server140	   using	   the	   Eg5	  
native	  structure	  as	  a	  template	  (PDB	  code:	  1II628).	  The	  key	  structural	  difference,	  the	  long	  
insertion	   of	   loop	   L6,	   can	   only	   be	   modelled	   with	   low	   confidence	   leading	   to	   a	   low	  
confidence	  for	  the	  model	  as	  a	  whole	  (Z-­‐value	  =	  -­‐4.508).	  Predictions	  in	  this	  loop	  are	  limited	  
to	  secondary	  structure	  modelling.	  Secondary	  structure	  predictions	  also	  suggest	   that	   the	  
loop	   (Figure	  1-­‐23)	   is	   dominated	  by	  disordered	   regions.139,140.	   Very	   little	   is	   known	  about	  
the	  10-­‐15	  residues	  long	  neck	  linker	  of	  MPP1	  following	  the	  motor	  domain	  and	  is	  thought	  
to	  be	  involved	  in	  controlling	  MT-­‐binding	  and	  motility.	  	  
The	  α-­‐helical	   coiled	   coil	   stalk	   of	  MPP1	   is	   connected	   to	   the	  motor	   domain	   via	   the	   neck	  
linker	  region.	  The	  coiled	  coil	  of	  MPP1	  is	  predicted	  to	  span	  the	  region	  from	  residue	  500	  to	  
residue	  152067	  (Figure	  1-­‐23)	  and	  is	  extraordinarily	  long	  compared	  to	  most	  other	  kinesins.	  
It	   is	   also	   substantially	   longer	   than	   the	   coiled	   coil	   regions	   of	   its	   closely	   related	   family	  
members	  MKLP-­‐1	  and	  MKLP-­‐2.85	  	  The	  stalk	  domain	  is	  likely	  to	  be	  involved	  in	  dimerisation	  
of	  MPP1,	  which	  is	  a	  physiological	  requirement	  for	  proper	  functioning	  of	  MPP1.141	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The	   C-­‐terminal	   tail	   domain	   of	   MPP1	   has	   a	   unique	   sequence	   and	   spans	   around	   200	  
residues.	   Unlike	   in	   other	   kinesin-­‐6	  members,	   there	   is	   no	   leucine	   zipper	   present	   in	   the	  
sequence	  of	  MPP1.	  	  
	  
Figure	  1-­‐23:	  Structural	  prediction	  into	  various	  domains	  of	  MPP1.	  	  
a)	   Structural	   modelling	   of	   the	   MPP1	   motor	   domain	   (shown	   in	   pale	   blue)	   predicts	   structural	  
similarity	  with	  other	  kinesins.	  The	  long	  loop	  L6	  insertion	  is	  mostly	  disordered	  with	  few	  broken	  α-­‐
helices	   as	   shown	   in	   blue.	   In	   addition,	   the	   confidence	   score	   for	   the	   region	   is	   around	   -­‐5.46	  
suggesting	   poor	   structural	   prediction	   in	   the	   region.	   The	   modelling	   analysis	   suggests	   a	   poor	  
modelling	  of	  the	  MPP1	  structure	  emphasising	  the	  need	  for	  a	  crystal	  structure.	  b)	  The	  coiled	  coil	  
prediction	  using	  PAIRCOIL2	  where	  the	  x-­‐axis	  represents	  the	  amino	  acid	  residue	  number	  versus	  P-­‐
value	   (probability	  of	  being	  coiled	  coil)	  on	   the	  y-­‐axis.	  The	  graph	  shows	   that	   residues	  500	  –	  1600	  
form	  the	  discontinuous	  stalk	  domain	  of	  MPP1	  that	  is	  longest	  among	  the	  kinesin-­‐6	  members.85,140	  
 
1.2.3.1.2 Physiological function and interactions  
	  
To	  identify	  the	  function	  of	  MPP1,	  fluorescence	  microscopy,	  FACS	  and	  siRNA	  studies	  were	  
performed	   showing	   MPP1	   expression	   is	   increased	   during	   G2/M	   phase,	   with	   an	  
interspersed	  behaviour	  in	  the	  cell	  during	  interphase.	  MPP1	  is	  found	  to	  be	  concentrated	  at	  
the	  midbody	  during	   the	  metaphase-­‐to-­‐anaphase	   transition,	   until	   the	   completion	  of	   cell	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Figure	  1-­‐24:	  Interactions	  of	  MPP1.	  	  
Using	   the	   EMBL	   data	   mining	   software,	   STRING	   8,	   MPP1	   interactions	   with	   other	   proteins	   in	  
published	  research	  were	   identified.	  Proteins	  that	  may	  be	  controlled,	  or	  may	  regulate,	  MPP1	  are	  
shown	  here.141-­‐144	  
	  
Figure	  1-­‐24	  depicts	  MPP1	   interactions	  with	  other	  proteins	  based	  on	  previous	  published	  
research.141-­‐144	   The	   interactions	   shown	   above	  were	   based	   on	   different	   observations.	   In	  
2001	  a	  protein	  named	  KRMP1	  was	   identified	  with	   an	  N-­‐terminal	   kinesin	  motor	  domain	  
and	   a	   sequence	   similar	   to	   kinesin-­‐6	   family	   members.	   The	   protein	   was	   phosphorylated	  
both	  at	  the	  head	  and	  tail	  domain	  for	   its	  proper	   localisation	  and	  function	  during	  mitosis.	  
Thr1604	   in	   the	   tail	   domain	   was	   identified	   by	   alanine	   scanning	   mutagenesis	   to	   be	   the	  
candidate	   for	   phosphorylation	   by	   cdc2	   kinase.	   This	   chemical	   alteration	   induces	   Pin1	   to	  
bind	   to	   MPP1	   via	   the	   Pin1	   WW	   domain.	   This	   is	   in	   agreement	   with	   other	   kinesins	  
phosphorylated	  by	  cdc2	  kinase,	  as	  the	  motifs	  are	  similar,	  e.g.	  Eg5	  (Figure	  1-­‐25).	  Thus,	  Pin1	  
can	  bind	  to	  MPP1	  only	  when	  it	  is	  activated	  by	  phosphorylation.	  On	  the	  other	  hand,	  casein	  
kinase	  II	  is	  thought	  to	  phosphorylate	  the	  head	  domain	  of	  MPP1	  but	  the	  exact	  importance	  
of	  such	  a	  phosphorylation	  is	  yet	  to	  be	  understood.67,141	  Among	  other	  known	  studies,	  over-­‐
expression	  of	  MPP1	  in	  COS-­‐7	  cells	  led	  to	  mitotic	  arrest	  at	  G2-­‐M	  phase	  but	  co-­‐expression	  
of	  Pin1	  reversed	  the	  process	  suggesting	  the	  role	  of	  Pin1	  in	  regulation	  of	  MPP1.141	  	  	  
1.2.3.1.3 Clinical relevance of MPP1 
	  
Studies	  on	  MPP1	  over-­‐expression	  in	  a	  set	  of	  bladder	  cancer	  cell	   lines	  exhibited	  evidence	  
of	  MPP1	  and	  PRC1	  interaction	  during	  late	  anaphase	  to	  early	  telophase	  but	  the	  interaction	  
was	  more	  pronounced	  in	  cells	  about	  to	  undergo	  cytokinesis	  suggesting	  the	  importance	  of	  
this	   interaction	   during	   cytokinesis	   (Figure	   1-­‐26).	   To	   support	   this,	   exogenous	   PRC1	   was	  
transfected	   into	   cells	   and	   analysed	   by	   immuno-­‐precipitation	   where	   it	   was	   seen	   to	  
coprecipitate	  with	  endogenous	  MPP1.145	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Figure	  1-­‐25:	  Interaction	  and	  function	  of	  MPP1.	  	  
a)	   Localisation	   of	   exogenous	   GFP-­‐MPP1	   during	   cytokinesis	   depicting	   the	   role	   of	   MPP1	   in	  
cytokinesis.	   As	   seen	   MPP1	   is	   concentrated	   at	   the	   mid-­‐body	   during	   late	   mitosis	   until	   the	   cell	  
physically	  divides	  into	  two	  daughter	  cells.	  b)	  The	  relationship	  between	  different	  proteins	  based	  on	  
the	   sequence	   similarity,	  which	  displays	  C-­‐terminal	  phosphorylation	   sites,	  which	   is	   important	   for	  
the	  regulation	  of	  these	  proteins.	  “*”	  represent	  the	  site	  for	  phosphorylation.	  c)	  MPP1	  localises	  to	  
mitotic	  structures	  in	  HeLa	  cells	  stained	  with	  the	  anti-­‐MPP1	  antibody.	  MPP1	  is	  more	  interspersed	  
during	  prophase	  and	  metaphase	  stage	  but	  becomes	  concentrated	  at	   the	  midbody	  region	  during	  
the	   transition	   into	  anaphase.	  The	  highest	  concentration	  of	  MPP1	  at	   the	  midbody	   is	   seen	  during	  
telophase	  suggesting	  it	  role	  during	  cytokinesis.	  Adapted	  from	  Abaza	  et	  al,	  2003	  and	  Kamimoto	  et	  
al,	  2001.	  67,141	  
 
	  
Figure	  1-­‐26:	  Co-­‐localisation	  and	  interaction	  of	  MPP1	  and	  PRC1.	  	  
In	  UM-­‐UC-­‐3	  cells,	  endogenous	  MPP1	  (green)	  co-­‐localises	  with	  exogeneous	  PRC1	  (red).	  The	  panel	  
of	   images	  on	  the	   left	  shows	  the	   localisation	  of	  MPP1	  and	  PRC1	  during	  various	  stages	  of	   the	  cell	  
cycle.	   The	   figure	   on	   the	   right	   shows	   the	   localisation	   of	  MPP1	   and	   PRC1	   at	   the	  midbody	   during	  
telophase.	  Adapted	  from	  Kanehira	  et	  al,	  2007.145	  
 
Bladder	   cancer	   has	   high	   incidence,	   poor	   prognosis	   and	   low	   survival	   rate.146	   In	   order	   to	  
provide	  a	  marker	  for	  identifying	  the	  disease	  Kanehira	  et	  al,	   identified	  the	  genes	  that	  are	  
upregulated	  both	  at	  mRNA	  and	  protein	  levels	  in	  a	  subset	  of	  bladder	  cancer	  cell	  lines	  like	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J82	  and	  UM-­‐UC-­‐3.	  They	  identified	  that	  MPP1	  is	  up	  regulated	  at	  both	  levels	  (Figure	  1-­‐27).	  
MPP1	  up-­‐regulation	  also	  coincided	  with	  PRC1	  over-­‐expression	  suggesting	  PRC1	  and	  MPP1	  
interaction	  during	  cytokinesis.	  	  MPP1	  or	  PRC1	  inhibition	  resulted	  in	  decreased	  cell	  viability	  
with	   cytokinetic	   defects.	  With	   an	   exclusive	   role	   in	  mitosis	   and	   cancer	   cells	  with	   higher	  
mitotic	   index	   in	   cancer	   cells,	  MPP1	  has	   been	  proposed	   as	   a	   potential	   target	   for	   cancer	  
treatment	  with	  a	  particular	  focus	  on	  bladder	  cancer.145	  
	  
Figure	  1-­‐27:	  Over-­‐expression	  and	  siRNA	  treatment	  of	  MPP1.	  	  
a)	  Northern	  blot	  showing	  over-­‐expression	  of	  MPP1	   in	  bladder	  cancer	  cell	   lines	   in	  comparison	  to	  
normal	   cell	   lines.	  b)	   siRNA	  against	  MPP1	   in	   cells	  where	   it	   is	  over-­‐expressed	   leads	   to	   cytokinesis	  
defects	   with	   bi-­‐	   and	   multi	   nucleated	   cells	   which	   eventually	   die	   by	   apoptosis.	   Adapted	   from	  
Kanehira	  et	  al,	  2007.145	  	  
 
In	   addition	   to	   its	   role	   in	   cytokinesis,	   one	   study	   has	   shown	   that	   MPP1	   plays	   a	   role	   in	  
polyneuropathy	   in	   patients	   suffering	   from	   CIDP	   (Chronic	   Inflammatory	   Demyelinating	  
Polyneuropathy).	   Immunoprecipitation	   and	   immunohistochemistry	   on	   tissue	   samples	  
from	  these	  patients	  identified	  a	  strong	  presence	  of	  MPP1.147	  	  
The	   importance	   of	   MPP1	   has	   been	   identified	   during	   the	   late	   stages	   of	   mitosis	   and	  
cytokinesis,	  but	  structural	  information	  of	  MPP1	  is	  still	  elusive.	  Thus,	  structural	  analysis	  of	  
MPP1	   will	   not	   only	   provide	   information	   about	   the	   core	   motor	   domain	   structure	   but,	  
importantly,	  insights	  into	  loop	  L6	  region	  which	  would	  be	  particularly	  interesting	  given	  its	  
extreme	  length	  and	  unknown	  function.	  The	  low	  degree	  of	  predicted	  order	  in	  the	  L6	  loop	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may	   create	   challenges	   in	   crystallising	   the	   motor	   domain	   and	   structural	   investigations	  
could	  also	  include	  solution-­‐based	  methods	  such	  as	  small	  angle	  X-­‐ray	  scattering	  (SAXS)	  or	  
electron	   cryo-­‐microscopy	   in	   combination	   with	   3D	   image	   reconstruction	   to	   provide	  
additional	  structural	   insights.	  Structures	  of	   the	  other	  domains	  of	  MPP1	  will	  also	  help	   to	  
decipher	   the	   relation	   between	   the	   structure	   and	   function	   but	   to	   date	   no	   structural	  
evidence	  is	  available	  for	  any	  of	  the	  domains	  of	  MPP1.	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1.2.3.2 MKLP-2 
MKLP-­‐2	  shares	  structural	  similarity	  with	  the	  other	  kinesin-­‐6	  family	  members,	  MKLP-­‐1	  and	  
MPP1.	  MKLP-­‐2	  is	  concentrated	  in	  the	  cells	  undergoing	  mitosis	  and	  is	  mostly	  interspersed	  
during	   the	   interphase	   stage	   of	   mitosis.	   The	   role	   of	   MKLP-­‐2	   has	   been	   observed	   in	   the	  
transport	   of	   different	   proteins	   from	   kinetochores	   to	   the	   central	   spindle	   during	   the	  
metaphase-­‐to-­‐anaphase	   transition	   and	   it	   plays	   an	   important	   role	   during	  
cytokinesis66,132,148	   (Figure	  1-­‐28).	   siRNA	  studies	  of	  MKLP-­‐2	  have	  shown	  that	  depletion	  of	  
the	  protein	  leads	  to	  cytokinetic	  defects	  with	  formation	  of	  binucleated	  or	  multinucleated	  
cells.	  38,149	  MKLP-­‐2	  function	  in	  higher	  eukaryotes	  is	  distinct	  from	  MKLP-­‐1	  whereas	  in	  lower	  
organisms	   (Xenopus,	   C.	   elegans,	   Drosophila)	   the	   MKLP-­‐1	   homologue	  
CHO1/Pavarotti/Zen4	  performs	  the	  functions	  of	  both	  proteins.65,150 
	  
Figure	  1-­‐28:	  Localisation	  of	  MKLP-­‐2	  during	  cell	  division.	  	  
Antibodies	   against	   MKLP-­‐2	   (red)	   display	   that	   MKLP-­‐2	   is	   concentrated	   during	   anaphase	   until	  
completion	  of	  cytokinesis.	  Adapted	  from	  Hill	  et	  al,	  2000.132	  	  
 
1.2.3.2.1 Structure and organisation 
	  
MKLP-­‐2	  has	  (Figure	  1-­‐21)	  very	  limited	  structural	   information	  available.	  Like	  conventional	  
kinesin,	   it	   is	  predicted	  to	  contain	  three	  distinct	  domains:	  the	  conserved	  motor,	  followed	  
by	   the	   central	   stalk	   domain	   connected	   to	   the	  motor	   domain	   via	   a	   neck	   linker	   and	   a	  C-­‐
terminal	  tail	  domain	  following	  the	  stalk	  domain.	  	  
There	   are	   many	   crystal	   structures	   of	   the	  motor	   domain	   of	   at	   least	   7	   different	   mitotic	  
kinesins	  available6	  but	  to	  date	  there	  is	  no	  structural	  information	  available	  for	  MKLP-­‐2	  or	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for	   any	   other	   kinesin-­‐6	   member.	   As	   previously	   mentioned	   for	   MPP1	   a	   key	   feature	   of	  
interest	  in	  the	  kinesin-­‐6	  family	  is	  the	  long	  L6	  loop.	  The	  biological	  significance	  of	  this	  loop	  
is	  yet	  to	  be	  understood.	  Molecular	  modeling	  using	  Swissmodel140	  reveals	  that	  the	  motor	  
domain	  has	  similar	  structural	  features	  as	  other	  conventional	  kinesins.	  The	  only	  difference	  
is	   the	   long	   loop	   L6	   that	   is	   predicted	   to	   comprise	   of	   β-­‐strands	   connected	   by	   loops	   and	  
show	  a	  higher	  degree	  of	  structural	  order	  than	  MPP1	  (Figure	  1-­‐29).	  	  
Similar	   to	  MPP1,	  MKLP-­‐2	   also	   has	   around	   50	   residues	   at	   the	  N-­‐terminus	   preceding	   the	  
motor	  domain	  and	  is	  predicted	  to	  be	  disordered	  based	  on	  secondary	  structure	  prediction	  
programs.138-­‐140	  
The	  motor	  domain	  of	  MKLP-­‐2	  is	  connected	  to	  the	  coiled	  coil	  region	  via	  10	  to	  15	  residues	  
of	  the	  neck	  linker	  region.	  The	  function	  and	  physiological	  role	  of	  the	  neck-­‐linker	  region	  of	  
MKLP-­‐2	   is	   still	   unknown.	   The	   coiled	   coil	   region	   as	  predicted	  by	  PAIRCOIL85	   ranges	   from	  
residue	  550	  to	  750.	  The	  C-­‐terminal	  150	  residues	  are	  predicted	  to	  form	  the	  tail	  domain.	  	  By	  
analogy	   with	   other	   kinesins,	   it	   is	   thought	   that	   the	   coiled	   coil	   plays	   an	   integral	   part	   in	  
oligomerisation	  (dimerisation)	  whereas	  the	  tail	   is	   involved	   in	  binding	  and	  carrying	  cargo	  
proteins	   along	  MTs.	   Interestingly,	   among	   other	   interactions,	   the	   C-­‐terminal	   coiled	   coil	  
domain	  of	  Drosophila	  orthologue	  of	  MKLP-­‐2,	  subito,	  can	  also	  bind	  to	  MTs	  independent	  of	  
the	   motor	   domain.151	   The	   secondary	   structure	   prediction	   of	   the	   tail	   domain	   using	  
PSIPRED	   also	   shows	   that	   the	   tail	   domain	   might	   be	   a	   part	   of	   the	   coiled	   coil	   region.152	  
Interestingly,	   a	   leucine	   zipper	   was	   also	   identified	   in	   the	   MKLP-­‐2	   tail	   domain	   between	  
residues	  660	  to	  720.	   	   Its	  role	   is	  not	  well	  demonstrated	  but	  may	  assist	   in	  dimerisation	  of	  
MKLP-­‐2.153	  
An	  atomic	  resolution	  structure	  of	  MKLP-­‐2	  or	  other	  structural	  information	  would	  provide	  a	  
firmer	   understanding	   of	   the	   loop	   L6	   region	   along	   with	   confirming	   that	   the	   rest	   of	   the	  
catalytic	  domain	  is	  conserved	  as	  in	  other	  kinesins.	  It	  is	  still	  unknown	  whether	  the	  loop	  L6	  
plays	  any	  role	  in	  kinesin	  function	  but	  more	  structural	  information	  may	  provide	  clues	  and	  
also	  assist	  in	  the	  design	  of	  experiments	  to	  probe	  its	  function.	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Figure	  1-­‐29:	  Structural	  prediction	  of	  MKLP-­‐2.	  	  
Structural	  modelling	  of	   the	  MKLP-­‐2	  motor	  domain	  using	   the	  Eg5	  structure,	  1II628,	  as	  a	   template	  
predicts	   a	  high	  degree	  of	   structural	   similarity	  with	  other	   kinesins	   represented	   in	  blue.	   The	   long	  
loop	  L6	  insertion	  (red)	   is	  predicted	  to	  contain	  β-­‐sheets.	  However	  the	  confidence	  of	  the	  model	   is	  
low	  with	  a	  Z-­‐score	  of	  -­‐4.312	  due	  to	  the	  difficulty	  of	  modelling	  loop	  L6.	  b)	  The	  coiled	  coil	  prediction	  
using	  PAIRCOIL2	  shows	  that	  residues	  550	  –	  800	  forms	  an	  interrupted	  coiled	  coil	  stalk	  domain.	  c)	  
Leucine	  zipper	  of	  MKLP-­‐2	  stalk	  domain	  that	  may	  assist	  in	  oligomerisation.140,152-­‐154	  
 
1.2.3.2.2 Physiological functions and interactions  
	  
MKLP-­‐2	   was	   first	   identified	   to	   be	   involved	   in	   intracellular	   transport	   mainly	   through	  
interaction	   with	   the	   Golgi	   complex.155	   Later	   investigations	   using	   immunofluorescence	  
microscopy	  showed	  that	  MKLP-­‐2	  was	  detected	  in	  mitotic,	  but	  not	  in	  interphase	  cells.	  	  
Detailed	  experiments	  by	  Hill	  et	  al132,	   using	   rabbit	   and	   sheep	  antibodies	   against	  MKLP-­‐2	  
provides	   evidence	  of	   the	   involvement	  of	   the	  protein	  during	  mitosis	   especially	   from	   the	  
beginning	  of	   the	  anaphase-­‐to-­‐metaphase	   transition	  until	   the	   completion	  of	   cell	   division	  
by	  cytokinesis,	  until	  the	  cell	  divides	  into	  two	  daughter	  cells.	  During	  metaphase,	  MKLP-­‐2	  is	  
thought	  to	  be	  cytosolic,	  but	  as	  the	  spindle	  starts	  to	  elongate,	  the	  protein	  localises	  in	  the	  
spindle,	  parallel	  to	  its	  axis	  with	  short	  linear	  structures	  of	  the	  MTs.	  	  
Intense	  MKLP-­‐2	   staining	   was	   noted	   at	   the	   midbody	   region	   of	   dividing	   HeLa	   cells.	   This	  
provides	  evidence	  that	  MKLP-­‐2	   levels	   reach	   its	  peak	  during	  mitosis	  and	  rapidly	  diminish	  
thereafter.132	  
Human	  MKLP-­‐2	  might	  have	  two	  MT-­‐binding	  domains	  as	  observed	  for	  subito,	  a	  Drosophila	  
orthologue	   of	   MKLP-­‐2.151	   MT	   binding	   is	   necessary	   for	   localisation	   of	   MKLP-­‐2	   to	   the	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midbody	  region.	  MKLP-­‐2	  also	  has	  MT-­‐bundling	  activity	  which	  is	  regulated	  by	  Plk1.	  MKLP-­‐2	  
phosphorylation	   decreases	   the	  MT-­‐bundling	   capacity	   of	  MKLP-­‐2.149	   Thus	   interaction	   of	  
MKLP-­‐2	  with	  MTs	  plays	  an	  important	  role	  in	  the	  proper	  function	  of	  MKLP-­‐2.	  	  	  
 
	  
Figure	  1-­‐30:	  Interactions	  of	  MKLP-­‐2.	  	  
Using	   the	   EMBL	   data	   mining	   software,	   STRING	   8,	   MKLP-­‐2	   interactions	   with	   other	   proteins	   in	  
published	  research	  were	  identified.	  Proteins	  that	  may	  be	  controlled,	  or	  may	  regulate,	  MKLP-­‐2	  are	  
shown	  here.142,148,149,156,157	  
 
Figure	   1-­‐30	   summarises	   the	   interactions	   of	   MKLP-­‐2	   with	   other	   proteins	   during	   the	  
different	   phases	   of	  mitosis.65,142,148,149,157-­‐161	   Immunohistochemistry	   studies	   have	   shown	  
that	  MKLP-­‐2	   is	   localised	   at	   the	   central	   spindle	   from	  metaphase	   to	   late	   anaphase.148	   To	  
maintain	  an	  association	  with	  the	  central	  spindle	  during	  the	  latter	  stages	  of	  cell	  cycle,	  CPC	  
(chromosome	   passenger	   complex)	   protein	   Plk1	   first	   phosphorylates	   Ser528	   of	   MKLP-­‐2	  
and	   then	   binds	   to	   this	   phosphorylated	   protein.	   Neef	   et	   al,	   used	   siRNA	   and	  
immunoprecipitation	  on	  HeLa	  cells	   to	  provide	  evidence	  of	   the	  direct	   interaction	  of	  Plk1	  
with	  MKLP-­‐2.	  PRC1,	  a	  protein	  essential	  for	  the	  formation	  of	  midzone	  during	  late	  mitosis	  
and	  completion	  of	  cell	  cycle	  by	  cytokinesis	  interacts	  with	  MKLP-­‐2,	  for	  timely	  recruitment	  
of	  Plk1	  to	  the	  central	  spindle.21,65	   Interfering	  with	  either	  of	  these	  three	  proteins	  hinders	  
their	  overall	   function	   leading	  to	  mitotic	  defects.	  Other	   interactions	   like	  that	  of	  Kif4162,	  a	  
chromokinesin	  important	  for	  cytokinesis	  and	  PRC1	  and	  its	  relation	  to	  MKLP-­‐2	  and	  Plk1	  is	  
still	   unknown	   but	   understanding	   the	   relationship	   between	   these	   proteins	   will	   help	   to	  
understand	  their	  role	  during	  cytokinesis.65,149	  	  
Another	   CPC	   protein,	   Aurora	   B	   kinase	   is	   associated	   with	   MTs	   during	   chromosome	  
movement	   and	   segregation.163	   Inhibition	   of	   Aurora	   B	   function	   by	   RNA	   interference	   or	  
microinjection	   of	   antibodies	   impairs	   the	   alignment	   of	   chromosomes	   at	   the	   spindle	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equator.164	   Aurora	   B	   has	   variety	   of	   functions	   during	   various	   stages	   of	   mitosis	   and	   is	  
associated	  with	  a	  number	  of	  different	  kinesins.	  Relocation	  of	  Aurora	  B	  along	  with	  INCENP	  
and	  survivin	  from	  the	  centromere	  to	  the	  central	  spindle	  during	  anaphase	  is	  mediated	  by	  
MKLP-­‐2.148	  The	  exact	   interacting	   region	  of	  MKLP-­‐2	  with	  Aurora	  B	   is	   still	  unknown	  but	  a	  
mutant	   of	   MKLP-­‐2	   lacking	   the	   motor	   domain	   demonstrates	   concentration	   of	   the	   CPC	  
complex	   at	   the	   centrosomes	   and	   not	   the	   central	   spindle.165	   In	   addition,	   Aurora	   B	  
phosphorylates	   MKLP-­‐1	   at	   two	   distinct	   sites	   at	   the	   N-­‐terminus	   and	   C-­‐terminus	   of	   the	  
protein	  but	  its	  role	  in	  regulating	  MKLP-­‐2	  is	  still	  unclear.	  Therefore,	  the	  role	  of	  MKLP-­‐2	  is	  
vital	  at	  the	  later	  stages	  of	  cell	  cycle	  but	  the	  whole	  process	  still	  remains	  indistinct.156	  
There	  is	  also	  evidence	  that	  MKLP-­‐2	  and	  the	  CPC	  complex	  depend	  on	  each	  other	  for	  their	  
association	   with	   midzone	   MTs.	   Studies	   have	   shown	   that	   interfering	   with	   any	   of	   the	  
proteins	  of	  the	  CPC-­‐MKLP-­‐2	  complex	  hinders	  their	  localisation	  to	  the	  central	  spindle.148,166	  
Phosphorylation	  of	  INCENP	  by	  Cdk1-­‐cyclin	  B	  inhibits	  INCENP	  binding	  to	  Aurora	  B	  impairing	  
the	   proper	   localisation	   of	   the	   CPC-­‐MKLP-­‐2	   complex	   to	   central	   spindle.157	   On	   the	   other	  
hand,	   Cdc14A	   dephosphorylates	   INCENP	   enabling	   its	   interaction	   with	   Aurora	   B.	   Thus,	  
Cdk1	  and	  Cds14A	  exert	  an	  indirect	  control	  on	  MKLP-­‐2.	  Alternatively,	  a	  study	  by	  Gruneberg	  
et	   al,	   2004	   have	   shown	   that	   localisation	   of	   Cdc14A	   to	   the	   central	   spindle	   is	   MKLP-­‐2	  
dependent.148	  	  
To	   help	   in	   successful	   completion	   of	   the	   bipolar	   spindle	   attachment,	   Mad2	   forms	   an	  
inactive	   complex	   with	   Cdc20	   to	   capture	   cells	   in	   metaphase.	   Therefore	   deregulation	   of	  
Mad2	   induces	   failure	   in	   cytokinesis.167	   In	   this	   connection,	   Mad2	   in	   HeLa	   cell	   lines	   has	  
been	   observed	   to	   be	   closely	   associated	   with	   MKLP-­‐2	   for	   its	   function.	   Mad2	   helps	   to	  
correctly	  localise	  MKLP-­‐2	  to	  the	  central	  spindle	  after	  metaphase.	  This	  is	  brought	  about	  by	  
Mad2	  keeping	  MKLP-­‐2	  in	  a	  folded	  inactive	  state	  inhibiting	  the	  latter	  from	  binding	  to	  MTs	  
until	   the	  completion	  of	  metaphase.	  The	   interactions	  of	  Mad2	  to	  MKLP-­‐2	   is	  mediated	  by	  
the	  C-­‐terminal	  amino	  acids	  ranging	  from	  871-­‐880	  of	  the	  former	  with	  residue	  number	  871	  
of	  the	  latter.165	  It	  has	  also	  been	  reported	  that	  MKLP-­‐2	  recruitment	  to	  the	  central	  spindle	  
during	  early	  anaphase	  is	  also	  dependent	  on	  Mob1,	  a	  protein	  that	  acts	  as	  kinase-­‐activating	  
subunit	  during	  various	  stages	  of	  mitosis.168	  	  
Another	   role	   of	   MKLP-­‐2	   has	   been	   associated	   with	   virus	   duplication	   and	   cytokinesis	   of	  
virus	   infected	  host	  cells.	   In	  HPV	   infection	  the	   integration	  of	   the	  viral	  DNA	  with	  the	  host	  
DNA	   is	   followed	   by	   ubiquitin-­‐mediated	   degradation	   of	   p53	   by	   papillomavirus	   E6	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protein.169	   This	   leads	   to	   the	   activation	   of	   papillomavirus	   E2	   that	   is	   responsible	   for	  
regulating	  viral	  replication,	  transcription	  and	  is	  responsible	  for	  partitioning	  viral	  episomes	  
into	   host	   daughter	   cell	   during	   cell	   division.	  	   Yeast	   hybrid	   screens	   and	   spectroscopy	  
provides	   evidence	   of	   the	   association	   of	   E2	   protein	   with	   MKLP-­‐2	   specifically	   with	  
interactions	  mediated	  by	  the	  C-­‐terminal	  residues	  of	  MKLP-­‐2	  during	  the	  host	  cell	  division.	  
Though	  this	  interaction	  has	  been	  studied,	  the	  exact	  role	  of	  MKLP-­‐2	  during	  this	  process	  of	  
viral	  hijack	  of	  the	  host	  life	  cycle	  is	  yet	  to	  be	  determined.	  It	  has	  been	  proposed	  that	  MKLP-­‐
2	  binds	  E2	  and	  transports	  E2	  to	  segregate	  viral	  episomes.170	  
1.2.3.2.3 MKLP-2 as a potential anti-cancer drug target 
	  
Aberrant	  MKLP-­‐2	   expression	   has	   been	   linked	   to	   a	   number	   of	   aggressive	   tumour	   types.	  	  
Pancreatic	  ductal	  adenocarcinoma	  (PDAC)	  is	  an	  aggressive	  cancer	  with	  a	  very	  low	  survival	  
rate.171	  The	  principal	  approach	  to	  treat	  patients	  affected	  with	  PDAC	  is	  either	  by	  surgery	  or	  
chemotherapy,	   including	   5-­‐fluorouracil	   or	   gemcitabine,	   with	   or	   without	   radiation.	   New	  
avenues	   of	   treatment,	   particularly	   with	   fewer	   side	   effects	   would	   not	   only	   provide	   an	  
alternative	  but	  also	  enhance	  the	  quality	  of	  life	  of	  the	  patients	  and	  there	  is	  some	  evidence	  
that	   MKLP-­‐2	   is	   a	   potential	   target	   for	   PDAC.	   Using	   genome-­‐wide	   cDNA	   microarrays	   of	  
approximately	  27,000	  genes,	  MKLP-­‐2	  was	   identified	  as	  one	  among	   several	  others	   to	  be	  
over-­‐expressed	   in	   PDACs.172	   Interestingly,	   a	   recent	   study	   by	   Imai	   and	   others173	   have	  
revealed	  that	  MKLP-­‐2	  is	  a	  tumour-­‐associated	  antigen,	  which	  may	  form	  the	  basis	  of	  anti-­‐
cancer	  therapy	  in	  pancreatic	  cancer.	  The	  expression	  of	  MKLP-­‐2	  in	  pancreatic	  cancer	  cells	  
is	  about	  100-­‐fold	  higher	  than	  in	  normal	  cells.	  RNA	  interference	  and	  immunofluorescence	  
studies	  have	  confirmed	  such	  over-­‐expression	  in	  cancer	  cells	  (Figure	  1-­‐31).173	  Higher	  levels	  
of	  MKLP-­‐2	  were	  also	  observed	  in	  western	  blot	  and	  immuno-­‐histochemical	  analyses.	  	  
In	  addition,	  quantitative	  proteomics	  study	  provides	  information	  about	  the	  role	  of	  MKLP-­‐2	  
in	  gastric	   cancer	  cells.174	  Mouse	  models	  and	  gene	  expression	  profiling	  of	  human	  gastric	  
cancer–specific	   genes	   have	   shown	   up-­‐regulation	   of	   MKLP-­‐2	   along	   with	   several	   other	  
genes.175,176	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Figure	  1-­‐31:	  Expression	  profile	  of	  MKLP-­‐2	  in	  pancreatic	  adenocarcinoma	  cells	  (PDAC).	  	  
a)	  Relative	  expression	  levels	  of	  MKLP-­‐2	  in	  normal	  cells	  compared	  to	  PDAC	  cells	  indicated	  the	  over-­‐
expression	  of	  MKLP-­‐2	  by	  30,000-­‐fold.	  b)	  Tabular	  representation	  showing	  higher	  expression	  levels	  
of	  MKLP-­‐2	  in	  pancreatic	  cancer.	  Adapted	  from	  Imai	  et	  al,	  2011.173	  
 
Another	   disease,	   HCC	   (hepatocellular	   carcinoma)	   is	   a	   common	   fatal	   malignant	   tumour	  
that	   is	   characterised	   by	   a	   high	   incidence	   of	   recurrence,	   development	   of	   resistance	   to	  
chemotherapy,	   and	   low	   sensitivity	   to	   radiation	   therapy.	   In	   HCC,	   MKLP-­‐2	   mRNA	  
transcription	   and	   protein	   expression	   have	   been	   shown	   to	   be	   up-­‐regulated	   during	  
hepatocarcinogenesis	   in	   both	   human	   and	   mouse	   and	   high	   levels	   are	   linked	   to	  
chromosome	  instability.177	  	  
Based	   on	   all	   the	   above	   studies,	  MKLP-­‐2	   is	   considered	   to	   be	   a	   potential	   new	   target	   for	  
cancer	   chemotherapy.	   In	   response	   to	   these	   findings,	   paprotrain	   (PAssenger	   PROtein	  
TRAnsport	  INhibitor)	  has	  been	  identified	  as	  the	  first	  inhibitor	  of	  MKLP-­‐2166.	  The	  inhibitor	  is	  
thought	   to	   bind	   to	   an	   allosteric	   site	   in	   the	  motor	   domain	   as	   it	   does	   not	   compete	  with	  
either	  ATP	  or	  MTs.166	  In	  vitro	  and	  cell-­‐based	  studies	  have	  confirmed	  the	  low	  micromolar	  
affinity	   of	   the	   inhibitor	   to	   MKLP-­‐2.	   Further	   studies	   would	   be	   to	   determine	   drug-­‐like	  
properties	  and	  develop	  more	  potent	  analogues	  of	  this	  inhibitor	  (Figure	  1-­‐32).	  
Contrary	   to	   what	   has	   been	   presented	   in	   different	   research	   publications,	   it	   can	   be	  
predicted	   that	  MKLP-­‐2	  can	  emerge	  a	  potential	   target	  with	   its	   important	   role	   in	  mitosis.	  
Cancer	   cells	   with	   higher	   mitotic	   index	   can	   be	   potentially	   inhibited	   from	   dividing	   by	  
targeting	  proteins	   involved	  in	  mitosis	  therefore	  making	  MKLP-­‐2	  an	   interesting	  target	  for	  
future	  cancer	  chemotherapy.	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Figure	  1-­‐32:	  Inhibition	  of	  MKLP-­‐2	  by	  paprotrain.	  	  
a)	   Chemical	   structure	   of	   paprotrain,	   the	   first	   inhibitor	   of	  MKLP-­‐2	   with	   low	  micromolar	   IC50.	   b)	  
Immunostaining	   of	   untreated	   control	   cells.	   c)	   Cells	   treated	   with	   paprotrain	   induce	   binucleated	  
cells	   and	   inhibit	   the	   relocation	   of	   the	   CPC	   from	   the	   inner	   centromeres	   to	   the	   central	   spindle	  
during	  anaphase.	  MTs	  (TUB)	  are	  represented	  in	  green,	  Aurora B	  (AurB),	  survivin	  (SRV),	  and	  PRC1	  
in	  red	  and	  DNA	  in	  blue.	  Adapted	  from	  Tcherniuk	  et	  al,	  2010.166	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1.3 Kinesins as potential drug targets for cancer 
chemotherapy 
Although	  strong	  evidence	  is	  emerging	  for	  kinesins	  representing	  valid	  or	  at	  least	  potential	  
cancer	  targets,	  a	  number	  of	  existing	  marketed	  drugs	  such	  as	  the	  vinca	  alkaloids	  and	  taxol	  
are	   already	   available	   which	   interfere	   with	   MT	   dynamics.178,179	   The	   question	   therefore	  
arises	  as	  to	  whether	  kinesin–targeting	  therapies	  offer	  the	  prospect	  of	  an	  advantage	  over	  
these	   compounds.	   Particular	   problems	  with	   these	   existing	   drugs	   are	   considerable	   side-­‐
effects,	   including	   peripheral	   neuropathy,	   and	   drug-­‐resistant	   tumours.178,180	   The	  
indications	  are	  that	  Eg5-­‐targeting	  compounds	  do	  indeed	  have	  advantages,	  particularly	  at	  
the	   level	  of	   side-­‐effects.111,124,179	  This	   is	  probably	  due	   to	   the	  more	   restricted	  expression	  
profile	   of	   Eg5,	   which	   contrasts,	   with	   the	   ubiquitous	   expression	   of	   tubulin.	   Currently,	  
neutropenia	   (abnormally	   low	  number	  of	  neutrophils)	   is	   the	  major	   side	  effect	  of	  existing	  
Eg5	  inhibitors.	  Combined	  with	  the	  continuing	  progress	  of	  Eg5	  inhibitors	  in	  Phase	  II	  clinical	  
trials	  where	   their	   efficacy	   is	   showing	  promising	   results,	   the	   interest	   in	   kinesin-­‐targeting	  
therapies	  continues	  to	  grow.	  	  Important	  challenges	  remain	  such	  as	  finding	  tumour	  types	  
and	   subtypes	   that	   respond	   to	   Eg5	   targeting	   drugs	   and	   also	   subsequently	   addressing	  
resistance	   to	   Eg5	   inhibitors	   that	   has	   been	   observed	   in	   cell	   culture.	   A	   large	   part	   of	   the	  
work	   presented	   in	   this	   thesis	   aims	   to	   further	   our	   understanding	   of	   the	   molecular	  
mechanism	  of	  kinesin	  inhibition	  by	  clinically	   interesting	  compounds.	  This	  knowledge	  will	  
be	   useful	   in	   understanding	   the	   causes	   of	   resistance	   and	   also	   provide	   a	   detailed	  
understanding	   of	   new	   inhibitor	   pockets,	   which	   may	   assist	   in	   slowing	   the	   onset	   of	  
resistance.	  
The	  clinical	  significance	  of	  MPP1	   is	   less	  well	  understood	  but	  there	  have	  been	  studies	  to	  
show	  that	   it	   is	  plays	  a	  certain	  role	   in	  different	  types	  of	  cancer.145,181	  To	  date	  one	  patent	  
has	   been	   deposited	   for	   MPP1	   inhibitors	   but	   has	   not	   been	   pursued.182	   Therefore,	   to	  
contribute	  towards	  developments	   in	  this	  area,	  an	   inhibitor	  of	  MPP1	  has	  been	   identified	  
and	   presented	   in	   this	   thesis.	   This	   could	   be	   a	   useful	   tool	   compound	   to	   further	   validate	  
MPP1	  as	  a	  clinically	  relevant	  target.	  	  	  
MKLP-­‐2	  has	  only	  recently	  gained	  importance	  as	  an	  anti-­‐cancer	  target.	  This	  has	  led	  to	  the	  
discovery	  of	   the	  first	  specific	   inhibitor	  causing	  cell	  cycle	  arrest	  and	  apoptotic	  cell	  death.	  
The	  work	   presented	   in	   this	   thesis	   on	  MKLP-­‐2	   is	   towards	   improving	   the	   potency	   of	   the	  
drug	  candidate.166	  It	  forms	  a	  basis	  for	  future	  MKLP-­‐2	  drug	  design	  and	  in	  validating	  MKLP-­‐2	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as	  a	   cancer	  chemotherapeutic	   target.	  Also,	   the	  work	   lays	   the	   foundations	   for	   structural	  
studies	  to	  understand	  the	  role	  of	  loop	  L6.	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2 Material and methods 
2.1 Materials 
Codon-­‐optimised	   cDNAs	   were	   purchased	   from	   GenScript.	   pET28a	   (non	   cleavable	   C-­‐
terminal	  his-­‐tag)	  	  vector	  was	  obtained	  from	  previous	  lab	  members.	  The	  pSUMO	  (with	  a	  N-­‐
terminal	  SUMO	  fusion	  tag,	  Ulp1	  cleavage	  site	  and	  his-­‐tag)	  vector	  was	  obtained	  from	  Dr.	  
Kristal	   Kaan	   (previous	   lab	  member).	   pProExHT	   (precision	   protease-­‐cleavable	  N-­‐terminal	  
his-­‐tagged)	  expression	  vector	   	  was	  bought	  from	  Invitrogen.	  All	  restriction	  enzymes	  were	  
obtained	   from	   New	   England	   Biolabs,	   Inc.	   DNA	   ligation	   kit	   were	   bought	   from	   Qiagen.	  
Primers	  for	  sub-­‐cloning,	  TB	  medium,	  IPTG	  (isopropyl	  β-­‐D-­‐thiogalactoside),	  TBS-­‐T,	  Tris-­‐HCl,	  
NaCl,	   MgCl2,	   imidazole,	   Urea,	   Methanol,	   DTT,	   P20,	   β-­‐mercaptoethanol,	   Guanidine	  
hydrochloride	   and	   PIPES	   were	   bought	   from	   Sigma.	   The	   accessories	   for	   the	   QiaCube™	  
robot	  (NTA	  columns	  and	  the	  HotStar	  HiFidelity	  PCR	  kit)	  were	  obtained	  from	  Qiagen.	  1	  ml	  
His-­‐Trap	  FF,	  1	  ml	  HiTrapQ	  FF,	  1	  ml	  HiTrapQ	  FF,	  Superose	  12	  10/300	  GL	  and	  Superose	  S75	  
columns	   were	   purchased	   from	   GE	   Healthcare.	   BL21(DE3)pLysS,	   BL21(DE3),	   Rosetta-­‐
gami(DE3)pLysS,	  Origami2(DE3)pLysS	  cells,	  Bug	  Buster™	  and	  Benzonase™	  Nuclease	  were	  
bought	   from	   Novagen.	   Amicon	   Ultra	   filtrations	   units	   for	   the	   concentration	   of	   proteins	  
were	  obtained	  from	  Millipore.	  SDS-­‐PAGE	  gels,	  running	  and	  NuPAGE	  transfer	  buffers	  were	  
obtained	   from	   Invitrogen.	   BL21-­‐CodonPlus	   (DE3)-­‐RIPL	   and	   ArcticExpress	   cells	   were	  
purchased	   from	   Agilent	   Technologies.	   The	   Cytophos	   assay	   kit	   was	   obtained	   from	  
Cytoskeleton.	   Lyophilised	   tubulin	   (Tebu-­‐Bio,	   Cat.	   No.	   -­‐	   027T240-­‐B)	   was	   used	   for	   all	  
experiments	  involving	  MTs.	  Ispinesib	  and	  SB743921	  were	  bought	  from	  Selleck	  Chemicals.	  
BI8	  and	  paprotrain	  were	  obtained	  from	  Sai	  Advantium.	  Crystallisation	  screens:	  Index,	  PEG	  
Ion,	  Natrix	  and	  Crystal	  Screen	  HT	  were	  obtained	  from	  Hampton	  Research	  whereas	  JCSG+	  
and	  PACT	  were	  obtained	  from	  Qiagen.	  96	  well	  crystallisation	  plates	  were	  obtained	  from	  
Greiner	  Bio-­‐one	  and	  24	  well	  linbro	  VDX	  plates	  from	  Hampton	  Research.	  
All	  cloned	  expression	  constructs	  were	  verified	  by	  DNA	  sequencing.	  All	  purification	  steps	  
were	  performed	  using	  an	  ÄKTA	  purifier	  at	  4°C	  (GE	  Healthcare)	  and	  purified	  proteins	  were	  
analysed	  by	  SDS-­‐PAGE	  after	  each	  step	  of	  purification.	  Finally,	  the	  purified	  proteins	  were	  
analysed	  by	  mass	  spec	  fingerprint	  analysis.	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The	  buffers	  used	  are	  as	  follows:	  
Buffer	  A:	  50	  mM	  PIPES,	  pH	  6.8,	  2	  mM	  MgCl2,	  200	  mM	  NaCl	  and	  10	  mM	  imidazole	  
Buffer	  B:	  50	  mM	  PIPES,	  pH	  6.8,	  2	  mM	  MgCl2,	  200	  mM	  NaCl	  and	  500	  mM	  imidazole	  
Buffer	  C:	  50	  mM	  PIPES	  pH	  6.8	  and	  200	  mM	  NaCl	  
Buffer	  D:	  50	  mM	  PIPES,	  pH	  6.8,	  50	  mM	  KCl,	  1	  mM	  DTT	  and	  1	  mM	  MgCl2	  
Buffer	  E:	  50	  mM	  PIPES,	  pH	  6.8,	  2	  mM	  MgCl2	  
Buffer	  F:	  20	  mM	  PIPES,	  pH	  6.8,	  300	  mM	  NaCl,	  and	  2	  mM	  β-­‐mercaptoethanol	  
Buffer	  G:	  50	  mM	  Tris,	  pH	  7.0,	  200	  mM	  NaCl,	  1	  mM	  MgCl2,	  0.5	  mM	  EDTA	  and	  0.05%	  P20	  
Buffer	  H:	  10	  mM	  HEPES,	  pH	  8.3,	  150	  mM	  NaCl,	  350	  mM	  EDTA,	  0.005%	  P20	  
Buffer	  I:	  50	  mM	  PIPES,	  pH	  6.8,	  1	  mM	  MgCl2	  and	  1	  mM	  	  
Buffer	  J:	  50mM	  PIPES,	  pH	  6.8,	  1	  mM	  MgCl2,	  1	  mM	  Mg2+ATP	  and	  250	  mM	  NaCl	  
Buffer	  K:	  20	  mM	  PIPES,	  pH	  7.3,	  250	  mM	  NaCl,	  1	  mM	  PMSF,	  1	  mM	  Na-­‐EGTA,	  1	  mM	  MgCl2,	  	  
2	  mg/ml	  lysozyme,	  10	  mg/ml	  DNAse	  and20	  mM	  imidazole	  
Buffer	   L:	   20	   mM	   PIPES,	   pH	   7.3,	   250	  mM	   NaCl,	   1	   mM	   Na-­‐EGTA,	   2	   mM	  MgCl2,	   10	   mM	  
imidazole	  	  
Buffer	   M:	   20	   mM	   PIPES,	   pH	   7.3,	   250	   mM	   NaCl,	   1	   mM	   Na-­‐EGTA,	   2	   mM	   MgCl2,	   1	   M	  
imidazole	  
Buffer	  N:	  20	  mM	  PIPES,	  pH	  7.3,	  1	  mM	  Na-­‐EGTA,	  1	  mM	  MgCl2	  
Buffer	  O:	  20	  mM	  PIPES,	  pH	  7.3,	  1	  mM	  Na-­‐EGTA,	  1	  mM	  MgCl2,	  1	  M	  NaCl	  
Buffer	  P:	  20	  mM	  PIPES,	  pH	  7.3,	  1	  mM	  Na-­‐EGTA,	  1	  mM	  MgCl2	  and	  200	  mM	  NaCl	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2.2 Human kinesin, Eg5 
2.2.1 Sub-cloning into E. coli expression vectors  
The	  motor	  domain	  of	  human	  Eg5	   (residues	  1-­‐368)	  was	  obtained	  from	  the	   initial	  cloning	  
into	  the	  modified	  pProEx	  expression	  vector	  using	  NcoI	  and	  XhoI	  restriction	  sites,	  yielding	  a	  
PreScission	  protease-­‐cleavable	  N-­‐terminal	  hexa	  his-­‐	  tagged	  protein.114	  
2.2.1.1 Cloning of ispinesib resistant mutants of Eg5  
Single	   Eg5	   mutants	   for	   D130V	   (named	   Eg5D130V),	   A133D	   (named	   Eg5A133D)	   and	   an	  
expression	   clone	   carrying	   both	  mutations	   (Eg5DM)	   were	   introduced	   using	   the	   following	  
forward	  and	   reverse	  primers	  according	   to	   the	   recommendations	  of	   the	  QickChange	  kit:	  
Eg5D130V	   (Forward:	   5’-­‐G	   TAT	   ACC	   TGG	   GAA	   GAG	   GTT	   CCC	   TTG	   GCT	   GGT	   ATA	   AT-­‐3’;	  
Reverse:	   5’-­‐AT	   TAT	   ACC	   AGC	   CAA	   GGG	   AAC	   CTC	   TTC	   CCA	   GGT	   ATA	   C-­‐3’),	   Eg5A133D	  
(Forward:	  5’-­‐GG	  GAA	  GAG	  GAT	  CCC	  TTG	  GCT	  GGT	  ATA	  ATT	  CCA	  CGT	  ACC	  C-­‐3’;	  Reverse:	  5’-­‐
G	  GGT	  ACG	  TGG	  AAT	  TAT	  ACC	  ATC	  CAA	  GGG	  ATC	  CTC	  TTC	  CC-­‐3’);	  	  Eg5DM	  (Forward:	  5’-­‐GAG	  
TAT	  ACC	  TGG	  GAA	  GAG	  GTT	  CCC	  TTG	  GAT	  GGT	  ATA	  ATT	  CCA	  CG–3’;	  Reverse:	  	  5’	  -­‐CG	  TGG	  
AAT	   TAT	   ACC	   ATC	   CAA	   GGG	   AAC	   CTC	   TTC	   CCA	   GGT	   ATA	   CTC-­‐3’).	   Each	   mutant	   was	  
confirmed	  by	  DNA	  sequencing	  and	  subsequently	  expressed	  and	  purified	  as	  described	  for	  
Eg5WT.	  	  
2.2.1.2 Cloning of wild-type and Eg5 mutants with a double hexa 
histidine tag for Ni-NTA immobilisation 
A	   modified	   expression	   vector	   to	   generate	   N-­‐terminal	   histidine	   tagged	   protein	   was	  
created.	  	  DNA	  coding	  for	  a	  double	  histidine	  tag	  separated	  by	  a	  ten	  amino	  acid	  linker	  was	  
cloned	  into	  the	  pET28a.	  The	  forward	  and	  reverse	  inserts	  with	  both	  blunt	  and	  sticky	  ends	  
created	  by	  restriction	  digests	  of	  NcoI	  and	  XhoI	  are	  (Forward:	  5’-­‐C	  ATG	  CAT	  CAC	  CAT	  CAC	  
CAT	  CA	  C	  GGA	  GCG	  ACA	  GCT	  GGC	  TCA	  GGG	  ACC	  GCC	  ACG	  CAT	  CAC	  CAT	  CAC	  CAT	  CAC	  ACC	  
ATG	  GAG	  CAG	  CGG	  CCT	  GCT	  CGA	  GTG	  AG-­‐	  3’;	  Reverse:	  5’-­‐TC	  GAC	  TCA	  CTC	  GAG	  CAG	  GCC	  
GCT	  GCT	  CCA	  TGG	  TAT	  GAT	  GAT	  GGT	  GGT	  GGT	  GCG	  TGG	  CGG	  TCC	  CTG	  AGC	  CAG	  CTG	  TCG	  
CTC	   CGT	  GGT	  GAT	  GAT	  GGT	  GAT	  G-­‐	   3’).	   The	   blunt	   ends	   of	   the	   inserts	   and	   the	   original	  
pET28a	   vector	  were	   cleaved	   using	   restriction	   enzymes	  NcoI	   and	  XhoI	   at	   37°C	   for	   2	   hr.	  
Running	  on	  a	  1.2%	  agarose	  gel	  separated	  the	  restricted	  plasmid	  and	  insert.	  Subsequently,	  
the	   double	   histidine	   tag	   insert	   was	   ligated	   to	   create	   a	   modified	   double	   histidine	   tag	  
pET28a	  vector	  using	  the	  DNA	  ligation	  kit.	  The	   inserts	  for	  Eg5	  wild-­‐type	  and	  the	  mutants	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were	  then	  subsequently	  cloned	  into	  the	  newly	  created	  modified	  pET28a	  vector	  using	  the	  
created	  cloning	  site	  between	  NcoI	  and	  XhoI	  sites.	  	  
2.2.2 Protein expression and purification  
The	  plasmids	  were	  transformed	  into	  BL21-­‐CodonPlus-­‐RIL	  Competent	  E.	  coli	  and	  grown	  in	  
6	  L	  of	  Terrific	  Broth	  (TB)	  at	  37°C,	  supplemented	  with	  100	  mg/L	  ampicillin,	  to	  an	  A600	  of	  0.6	  
and	   induced	  overnight	  with	  0.5	  mM	   IPTG	  at	  20°C.	  Harvested	  cells	  were	   resuspended	   in	  
buffer	   A	   supplemented	   with	   1	   mM	   PMSF,	   1	   mM	  Mg-­‐ATP,	   and	   2	  mg/ml	   lysozyme	   and	  
subjected	   to	   one	   cycle	   of	   freeze-­‐thaw	   before	   1	   mM	   DNaseI	   and	   10	   mM	   MgCl2	   were	  
added.	  Sonication	  was	  then	  carried	  out	  using	  the	  Vibra-­‐Cell	  VCX	  750	  sonicator	  (Sonics	  &	  
Materials,	  Inc.)	  with	  a	  13	  mm	  probe,	  at	  90	  %	  amplitude	  and	  8	  x	  8	  secs	  ON	  and	  OFF	  pulses	  
and	  centrifuged	  (1h,	  4°C,	  31400	  g). 
2.2.2.1 Wild-type and mutants of Eg5 
Supernatant	  from	  centrifuged	  lysate	  were	  pooled	  and	  loaded	  onto	  a	  5	  ml	  Ni-­‐NTA	  HisTrap	  
FF	  column	  that	  has	  been	  equilibrated	  in	  buffer	  A.	  The	  proteins	  were	  eluted	  on	  a	  gradient	  
of	  buffer	  B	  after	  washing	  the	  bound	  protein	  with	  a	  mixture	  of	  4%	  and	  96%	  of	  buffer	  B	  and	  
A	  respectively.	  Fractions	  with	  protein	  of	  interest	  as	  seen	  by	  the	  UV	  trace	  were	  pooled	  and	  
the	  buffer	  was	  exchanged	  using	  Desalting	  26/10	  column	  for	  buffer	  C.	  1	  mg	  of	  PreScission	  
protease,	   1	  mM	  Mg2+ATP,	   and	   2	  mM	  MgCl2	  were	   added	   to	   the	   protein	   and	   incubated	  
overnight	   at	   4°C.	   To	   remove	   uncleaved	   protein	   and	   protease	   a	   second	   Ni-­‐NTA	   affinity	  
chromatography	  was	  performed.	   The	   cleaved	  protein	   that	   came	  as	   a	   flow-­‐through	  was	  
then	   subjected	   to	   size	   exclusion	   chromatography	   on	   a	   Superdex	   200	   16/60	   column	  
equilibrated	  in	  gel	  filtration	  buffer	  D. Fractions	  containing	  the	  protein	  of	  interest	  from	  the	  
UV	   trace	  were	   pooled	   and	   concentrated	   on	   an	   Amicon	  Ultra	   filtration	   device	  with	   size	  
exclusion	   limit	  of	  30	  kDa,	   to	  a	   final	  concentration	  of	  approximately	  10	  mg/ml,	   frozen	   in	  
liquid	  nitrogen,	  and	  stored	  at	  -­‐80°C.	  	  
Eg5	  wild-­‐type	   and	  mutants	  were	   purified	   following	   the	   above	   protocol	   apart	   for	   Eg5DM	  
where	   buffer	   D	   contained	   150	  mM	  KCl	   instead	   of	   50	  mM.	   All	   the	   steps	   of	   purification	  
were	  checked	  by	  SDS-­‐PAGE	  for	  the	  protein	  by	  running	  10	  ul	  of	  the	  fractions	  obtained.	  
Eg5	   wild-­‐type	   and	   mutant	   protein	   after	   the	   final	   gel	   filtration	   chromatography	   were	  
obtained	  at	  approximately	  95%	  purity.	  One	  representative	  SDS-­‐PAGE	  for	  Eg5D130V	  is	  shown	  
is	  Figure	  2-­‐1.	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Figure	  2-­‐1:	  Protein	  purification	  of	  Eg5D130V.	  	  
The	  figure	  shows	  an	  example	  of	  the	  protein	  obtained	  from	  purification	  of	  Eg5D130V.	  
	  
2.2.2.2 Eg5 with double hexa-histidine tag 
Supernatant	  were	  pooled	  from	  the	  centrifuged	  bacterial	  cell	  cultures	  and	  loaded	  onto	  a	  5	  
ml	  Ni-­‐NTA	  HisTrap	  FF	  column	  that	  has	  been	  equilibrated	   in	  buffer	  A.	  The	  proteins	  were	  
eluted	  on	  a	  gradient	  of	  buffer	  B	  after	  washing	  the	  bound	  protein	  with	  a	  mixture	  of	  4%	  and	  
96%	  of	   buffer	   B	   and	  A	   respectively.	   Fractions	   of	   protein	  were	   pooled	   and	   diluted	  with	  
buffer	   E.	   Ion	   exchange	   chromatography	   was	   then	   performed	   to	   separate	   recombinant	  
protein	  from	  other	  contaminants	  that	  were	  not	  separated	  during	  the	  affinity	  purification.	  
The	  protein	  from	  ion	  exchange	  was	  then	  subjected	  to	  size	  exclusion	  chromatography	  on	  a	  
Superdex	   200	   16/60	   column	   equilibrated	   in	   gel	   filtration	   buffer	   D.	   Fractions	   containing	  
the	   protein	   of	   interest	   were	   pooled	   and	   concentrated	   on	   an	   Amicon	   Ultra	   filtration	  
device,	  with	  a	  size	  exclusion	  limit	  of	  30	  kDa,	  to	  a	  final	  concentration	  of	  approximately	  1	  
mg/ml,	  frozen	  in	  liquid	  nitrogen,	  and	  stored	  at	  -­‐80°C.	  
2.2.2.3 Determination of protein concentration and mass 
spectrometry fingerprint analyses  
Protein	  concentrations	  were	  determined	  using	  two	  independent	  methods.	  The	  Bradford	  
reagent	  was	  used	  as	  an	   initial	  estimation	  of	   the	  protein	  concentration	  according	   to	   the	  
supplier’s	   instructions.	   For	   ATPase	   assays,	   ITC	   measurements	   and	   SPR	   assays	   the	  
concentration	   of	   native	   and	   denatured	   proteins	   (6.7	   M	   GuHCl	   with	   20	   mM	   sodium	  
phosphate	   to	  pH	  7.0)	  were	  measured	  at	  280	  nM	  using	  a	  molar	  extinction	  coefficient	  of	  
23150	  M-­‐1cm-­‐1	  (Eg5	  wild-­‐type	  and	  mutants:	  20650	  M-­‐1cm-­‐1	  and	  ADP:	  2500	  M-­‐1cm-­‐1).	  	  
The	   presence	   of	   the	  mutants	  was	   confirmed	   by	  mass	   spectrometry	   peptide	   fingerprint	  
analysis	  with	  coverage	  of	  78%,	  88%	  and	  70%	  for	  D130V,	  A133D	  and	  DM,	  respectively.	  In	  
all	  cases	  the	  peptide	  carrying	  the	  mutation	  was	  identified.	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2.2.2.4 Polymerisation of tubulin into MTs 
Lyophilised	  tubulin	  was	  solubilised	  in	  100	  μl	  of	  G-­‐PEM	  buffer	  (1	  mM	  GTP,	  80	  mM	  PIPES,	  1	  
mM	  Na-­‐EGTA,	  1	  mM	  MgCl2,	  pH	  7.0)	  to	  a	  final	  concentration	  of	  10	  mg/ml.	  To	  polymerise	  
and	  stabilise	  MTs,	  1	  μl	  of	  taxol	  (10	  mM	  stock	  in	  DMSO)	  was	  added	  to	  100	  μl	  of	  tubulin	  and	  
incubated	  overnight	  at	  37°C.	  
2.2.3 Steady state ATPase assay 
Steady	   state	   basal	   and	  MT-­‐stimulated	  ATPase	   rates	  were	  measured	   using	   the	   pyruvate	  
kinase/lactate	   dehydrogenase-­‐linked	   assay.183	   For	   each	   measurement	   a	   concentration	  
series	  of	  either	  ATP	  or	  MTs	  or	  inhibitor	  was	  used.	  The	  amounts	  of	  Eg5	  were	  optimised	  at	  
80-­‐100	  nM	  for	  basal	  and	  5	  nM	  for	  MT-­‐stimulated	  activity	  assays.	  The	  mixture	  of	  ATPase	  
buffer	  along	  with	  inhibitor/MTs/ATP	  in	  increasing	  concentration	  was	  added	  to	  each	  well.	  
The	  enzyme	  was	  added	   just	  before	  the	  start	  of	  each	  experiment.	  The	  reaction	  mixtures	  
were	  measured	  for	  30	  min	  in	  a	  TEECAN	  Sunrise™	  at	  340	  nm.	  	  
The	   raw	   data	   was	   processed	   using	   the	   equation	   in	   2.2.3.1	   and	   the	   data	   plotted	   using	  
either	  Michaelis-­‐Menten	  equation	   for	  enzyme	  kinetics.	  Data	  were	  plotted	  and	  analysed	  
using	  Kaleidagraph	  4.0	  (Synergy	  Software).	  
2.2.3.1 Measurement of kinetic parameters  
The	  kinetic	  parameters	  kcat	  ,	  Km,	  ATP	  ,	  Km,	  MTs	  were	  initially	  calculated	  and	  optimised	  for	  wild-­‐
type	  and	  mutants,	  based	  on	  the	  rates	  computed	  from	  the	  following	  equation.	  	  
OD/min	  (s-­‐1)	  =	  (2	  •	  ΔA/min	  )	  /	  (ƐNADH	  •	  60	  •	  Cenzyme)	  	  
where,	  εNADH	  corresponds	  to	  the	  molar	  extinction	  coefficient	  of	  NADH	  (6220	  ΔA/mol/cm),	  
ΔA/min	   is	   the	   absorbance	   decrease	   at	   340	   nm	   per	   min,	   and	   Cenzyme	   is	   the	   molar	  
concentration	  of	  kinesin	  used	  in	  the	  assay.	  The	  factor	  2	  is	  a	  correcting	  factor	  taking	  into	  
account	  the	  length	  of	  the	  optical	  path	  in	  the	  96-­‐well	  plate,	  normalised	  to	  a	  path	  of	  1	  cm.	  	  
2.2.3.2 Measurement of inhibition of Eg5WT and mutants 
The	  IC50	  values	  for	  the	  inhibition	  of	  the	  basal	  and	  MT-­‐stimulated	  ATPase	  activities	  of	  Eg5	  
were	  measured	   for	   ispinesib	   and	  SB743921	  between	   concentrations	  of	   0	   and	  1	  µM	  for	  
Eg5WT	  and	  between	  0	  and	  120	  µM	  for	  the	  Eg5	  mutants.	  STLC	  was	  measured	  from	  0	  µM	  to	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12	   µM	   for	   Eg5WT	   and	   from	   0	   µM	   to	   150	   µM	   for	   the	   Eg5	   mutants.	   The	   Mg2+ATP	  
concentration	   was	   fixed	   at	   1	  mM	   for	   all	   measurements.	   For	   the	   inhibition	   of	   the	  MT-­‐
stimulated	  ATPase	  activity,	  the	  MT	  concentration	  was	  fixed	  at	  2	  µM.	  	  
2.2.4 Isothermal titration calorimetry (ITC) 
ITC	   was	   performed	   as	   previously	   described	   by	   Sheth	   et	   al,	   2009126	   with	   certain	  
modifications.	  Purified	  Eg5	  was	  subjected	  to	  gel	  filtration	  chromatography	  in	  buffer	  F	  to	  
remove	  excess	  ATP	  and	  then	  dialysed	  overnight	  against	  buffer	  A	  supplemented	  with	  0.5	  
mM	  ADP	  and	  5	  mM	  MgCl2.	  The	  protein	  was	  diluted	  to	  a	  final	  concentration	  of	  20	  μM	  with	  
dialysis	   buffer.	   Its	   concentration	  was	   then	   verified	  by	   absorption	  measurements	   at	   280	  
nm	  using	  an	  extinction	   coefficient	   as	  mentioned	  previously.	   Two	   independent	  methods	  
were	  used	  for	  concentration	  determination,	  the	  first	  was	  by	  using	  Eg5	  denatured	  in	  6.7	  M	  
guanidine	  hydrochloride	  with	  20	  mM	  phosphate	  at	  pH	  7.0,	  second	  was	  by	  measuring	  the	  
concentration	  of	  the	  folded	  protein	  in	  solution	  directly	  obtained	  after	  dialysis.	  Finally	  1%	  
DMSO	  was	  added	  to	  the	  protein	  solution.	  The	  inhibitor	  was	  prepared	  in	  100%	  DMSO	  and	  
then	  diluted	  in	  dialysis	  buffer	  to	  a	  final	  concentration	  of	  250	  µM	  or	  500	  µM	  of	   ispinesib	  
with	  1%	  DMSO.	  All	  solutions	  were	  centrifuged	  for	  5-­‐10	  min	  at	  room	  temperature	  prior	  to	  
loading	  of	  the	  samples	  into	  either	  a	  Microcal	  VP-­‐ITC	  or	  an	  iTC200	  titration	  calorimeter.	  	  
The	  heat	  of	  dilution	  was	  estimated	  by	  titrating	  into	  protein-­‐free	  buffer	  subtracted	  prior	  to	  
data	   analysis.	   The	   thermodynamic	   parameters	   N	   (stoichiometry),	   Ka	   (association	  
constant),	   and	  ΔH	   (enthalpy	  change)	  were	  obtained	   through	   fitting	  of	   the	  experimental	  
data	   using	   the	   single-­‐site	   binding	   model	   of	   the	   Origin	   software	   package	   (version	   7.0),	  
whereas	   the	   free	  energy	  of	  binding	   (ΔG)	  and	  entropy	  change	   (ΔS)	  were	   then	  calculated	  
from	   the	   fitted	   values.	   For	   each	   experiment,	   at	   least	   two	   independent	   titrations	   were	  
performed,	   which	   were	   analysed	   independently.	   The	   resulting	   thermodynamic	   values	  
were	   then	   averaged.	   Data	   fitting	   was	   done	   with	   either	   one	   site	   binding	   or	   two	   site	  
sequential	  binding	  model	  as	  described	  previously	  by	  Freyer	  et	  al,	  2008.184	  	  
2.2.4.1 Study of wild-type Eg5 with ispinesib 
ITC	  experiments	  were	  performed	  with	   a	  Microcal	  VP-­‐ITC	   titration	   calorimeter	   (Microcal	  
Inc.,	  North	  Hampton,	  MA).	  All	  titrations	  were	  carried	  out	  at	  25°C	  with	  a	  stirring	  speed	  of	  
around	   350	   rpm.	   In	   total	   26	   injections	   were	   performed	   per	   titration	   with	   the	   first	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injection	  of	  5	  μl	  followed	  by	  25	  injections	  of	  10	  μl	  for	  20	  s	  with	  a	  gap	  of	  240	  s	  between	  
them.	  	  
2.2.4.2 Study of wild-type and mutant Eg5 with SB743921, BI8, 
ispinesib and monastrol 
ITC	   experiments	   were	   performed	   with	   an	   iTC200	   (GE	   Healthcare).	   All	   titrations	   were	  
carried	  out	  at	  25°C	  with	  a	  stirring	  speed	  of	  around	  1000	  rpm.	  In	  total	  20	  injections	  were	  
performed	  per	  titration	  with	  the	  first	  injection	  of	  0.5	  μL	  followed	  by	  19	  injections	  of	  2	  μl	  
for	  4	  sec	  with	  a	  gap	  of	  240	  s	  between	  them.	  	  
2.2.5 Surface plasmon resonance  
All	   experiments	   were	   performed	   using	   a	   Biacore	   T200	   (Biacore)	   with	   running	   buffer	   G	  
supplemented	  with	  fresh	  1%	  DMSO	  before	  each	  run.	  The	  experiments	  were	  carried	  out	  at	  
25°C.	   Experiments	   for	   each	   protein-­‐inhibitor	   set	   were	   performed	   at	   least	   in	   duplicate.	  
Double	   His-­‐tagged	   Eg5	   (200	   nM)	   was	   immobilised	   on	   the	   surface	   of	   NTA	   sensor	   chip	  
charged	   with	   Ni2+	   to	   approximately	   2,000	   RU.	   The	   sensor	   surface	   was	   regenerated	  
between	  each	  experiment	  with	   a	  60s	   and	  120s	   injection	  of	   1M	   imidazole	   and	   stripping	  
buffer	  H	  respectively.	  
For	   analyte	   preparation,	   each	  of	   the	   compounds	   analysed	  were	  prepared	   in	  DMSO	   (50	  
mM).	  A	  concentration	  series	   for	  each	   inhibitor	  was	  prepared	  ensuring	  a	  consistent	   final	  
DMSO	   concentration	   of	   1%.	   To	   correct	   for	   the	   minor	   DMSO	   volume	   effect,	   a	   DMSO	  
calibration	  series	  was	  prepared	  and	  measured	  using	  0.5%	  and	  1.8%	  of	  DMSO	  in	  running	  
buffer.	   Protein	   immobilisation	   on	   the	   chip	   was	   carried	   out	   at	   a	   flow	   rate	   of	   5	   μl/min	  
whereas	  for	  the	  experiments	  a	  flow	  rate	  of	  30	  μl/min	  was	  used.	  	  	  
The	  steady	  state	  analyses	  of	  molecular	   interactions	  were	  calculated	  after	  subtraction	  of	  
backgrounds	   (inhibitor-­‐binding	   to	   a	   control	   flow	   cell)	   using	   BIAcore	   T200	   Evaluation	  
software	  and	  Kaleidagraph	  4.0.	  The	  binding	  constant	  KD	  was	  evaluated	  according	  to	  the	  
appropriate	   binding	   model.	   For	   two	   site	   binding,	   two	   sequential	   first-­‐order	   binding	  
model185	  was	  used	  whereas	   for	  one	  site	  binding	   the	  pseudo-­‐first-­‐order	  kinetic	  model186	  
was	   applied	   assuming	   one	   molecule	   of	   the	   ligand	   (Eg5)	   binds	   to	   one	   molecule	   of	   the	  
analyte	  (BI8	  -­‐	  Benzimidazole	  number	  8).	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2.2.5.1 Study of two site binding of BI8 to Eg5 
To	  investigate	  two	  site	  binding	  and	  analyse	  the	  affinity	  for	  both	  sites,	  BI8	  was	  measured	  
for	  a	  range	  from	  0	  to	  528	  µM.	  BI8	  was	  injected	  first	  to	  determine	  the	  binding	  affinity	  of	  
two	   sites	   followed	   by	   single	   ispinesib	   injection	   at	   10	  µM	   to	   competitively	   displace	   BI8	  
from	  the	  site	  around	  loop	  L5.	  BI8	  was	  then	  injected	  for	  the	  second	  time	  using	  the	  same	  
concentration	  range	  to	  determine	  the	  KD	  only	  for	  the	  second	  novel	  site.	  	  
2.2.6 Crystallisation of Eg5-ADP mutants and Eg5-ADP- 
inhibitor complexes 
2.2.6.1 Crystallisation of the “ispinesib mutants”: Eg5D130V, 
Eg5A133D and Eg5DM  
Crystals	   for	   the	   three	   Eg5	  mutants	   (the	   “ispinesib	   mutants”)	   appeared	   after	   3	   days	   in	  
hanging	   drops	   containing	   a	   mixture	   of	   1	   μl	   of	   protein	   and	   1	   μl	   of	   reservoir	   solution.	  
Eg5D130V	  crystals	  were	  obtained	  in	  14%	  w/v	  PEG	  (polyethylene	  glycol)-­‐3350,	  0.2	  M	  sodium	  
nitrate	   and	   0.1	   M	   MES	   (pH	   5.6).	   Eg5A133D	   crystals	   appeared	   in	   a	   reservoir	   solution	  
containing	  16%	  w/v	  PEG-­‐3350,	  0.2	  M	  sodium	  nitrate	  and	  0.1	  M	  MES	  (pH	  5.6).	  The	  crystals	  
of	   these	   two	   single	   mutants	   only	   appeared	   after	   micro	   or	   macro	   seeding	   using	   Eg5WT	  
crystals	   grown	   under	   similar	   conditions.	   Eg5DM	   crystals	   grew	   in	   completely	   different	  
solution	   containing	   0.02	   M	   Calcium	   chloride	   dehydrate,	   0.02	   M	   Cadmium	   chloride	  
hydrate,	   0.02	   M	   Cobalt(II)	   chloride	   hexahydrate	   and	   20%	   w/v	   PEG-­‐3350.	   For	   data	  
collection	  crystals	  were	  immersed	  in	  a	  solution	  containing	  1.2	  times	  the	  concentration	  of	  
components	   in	   well	   condition	   supplemented	  with	   15%	   glycerol	   as	   cryoprotectant	   then	  
subsequently	  flash	  frozen	  in	  liquid	  nitrogen.	  
2.2.6.2 Crystallisation of Eg5WT-ispinesib, Eg5WT-SB743921 and 
Eg5A133D-SB743921 complexes 
Eg5WT	   or	   Eg5A133D	   were	   incubated	   with	   1	   mM	   of	   ispinesib	   or	   SB743921	   (diluted	   into	  
protein	  from	  a	  50	  mM	  stock	  in	  DMSO)	  for	  2	  hr	  at	  4°C.	  Before	  setting	  up	  crystal	  trays,	  the	  
sample	  was	  centrifuged	  at	  14000	  g	  for	  5	  min	  at	  4°C	  to	  pellet	  undissolved	  inhibitor.	  Small	  
crystals	  for	  all	  three	  complexes	  (Eg5WT-­‐ispinesib,	  Eg5WT-­‐SB743921	  and	  Eg5A133D-­‐SB743921)	  
appeared	   after	   two	   to	   three	   days	   in	   hanging	   drops	   by	  mixing	   1	   μl	   of	   protein-­‐inhibitor	  
complex	   (11	   mg/ml)	   with	   1	   μl	   of	   reservoir	   solution.	   For	   Eg5WT-­‐ispinesib	   crystals,	   the	  
reservoir	  solution	  contains	  0.1	  M	  Tris,	  pH	  8.5,	  0.02	  M	  MgCl2	  and	  20%	  (w/v)	  PEG	  8000. For	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Eg5WT-­‐SB743921	   and	   Eg5A133D-­‐SB743921	   the	   reservoir	   solution	   contains	   0.02	  M	   calcium	  
chloride	   dehydrate,	   0.02	   M	   Cadmium	   chloride	   hydrate,	   0.02	   M	   Cobalt(II)	   chloride	  
hexahydrate	  and	  20%	  w/v	  PEG-­‐3350.	  All	  crystals	  were	  grown	  in	  24	  well	  Linbro	  plates	  by	  
vapour	  diffusion	  at	  4°C	  in	  hanging	  drops.	  	  
To	   obtain	   good	   diffraction	   quality	   single	   crystals,	   streak	   seeding	   were	   performed	   into	  
drops	   containing	   1:1	   ratio	   of	   protein-­‐inhibitor	   complex	   to	   well	   solution.	   Single	   crystals	  
appeared	   overnight	   and	   were	   allowed	   to	   grow	   for	   several	   days	   before	   immersing	   in	  
cryoprotectant	   solution	   containing	   1.2	   times	   the	   concentration	   of	   components	   in	   well	  
condition	   supplemented	   with	   15%	   glycerol	   as	   cryoprotectant	   then	   subsequently	   flash	  
frozen	  in	  liquid	  nitrogen.	  
2.2.6.3 Crystallisation of Eg5WT- BI8 
In	  collaboration	  with	  Dr.	  Venkat	  Ulaganathan,	  Eg5	  (10	  mg/mL)	  was	  mixed	  well	  with	  2	  μL	  
BI8	   (50	   mM)	   and	   the	   mixture	   was	   incubated	   at	   4°C	   for	   2	   hr.	   The	   mixture	   was	   then	  
centrifuged	  at	  13000	  g	  for	  5	  min	  to	  remove	  any	  undissolved	  inhibitor.	  Diffraction	  quality	  
single	  crystals	  of	  the	  complex	  were	  obtained	  in	  sitting	  drop	  by	  vapour	  diffusion	  using	  1	  μL	  
of	  protein	  complex	  and	  1	  μL	  of	  the	  reservoir	  solution	  (0.1	  M	  HEPES	  buffer,	  pH	  7.5,	  20	  %	  	  
(w/v)	  PEG-­‐3350	  and	  0.1	  M	  magnesium	  chloride)	   in	  VDX	  plates	  at	  19°	  C.	  The	  crystal	  was	  
cryoprotected	   using	   0.12	   M	   HEPES	   buffer	   at	   pH	   7.5,	   22	   %	   (w/v)	   PEG	   3350,	   0.12	   M	  
magnesium	   chloride	   and	   15	   %	   (v/v)	   PEG-­‐400	   and	   flash	   frozen	   in	   liquid	   nitrogen	   for	  
diffraction	  measurements.	  	  	  
2.2.7 Data collection, processing, structure determination, 
refinement and model quality 
2.2.7.1 Eg5 in complex with ispinesib  
Diffraction	   data	   were	   collected	   at	   100	   K	   on	   beamline	   I02	   of	   Diamond	   Light	   Source	  
(Oxfordshire).	  Data	  were	  processed	  and	  scaled	   to	  2.6	  Å	  using	  XDS/XSCALE187,	   truncated	  
and	  processed	  with	  the	  CCP4	  suite	  of	  programs.188	  The	  Matthews	  Coefficient189	  was	  used	  
to	  determine	  the	  number	  of	  molecules	   in	   the	  asymmetric	  unit	  and	  the	  solvent	  content. 
Then	  structure	  of	  the	  Eg5-­‐ispinesib	  complex	  was	  solved	  in	  space	  group	  P21	  by	  molecular	  
replacement	   with	   MOLREP	   using	   the	   Eg5	   tetramer	   of	   PDB	   entry	   2GM1	   as	   the	   search	  
model.120	   Improvement	  of	   this	  structure	  then	  proceeded	  using	   iterative	  cycles	  of	  model	  
building	   with	   Coot190	   and	   reciprocal	   space	   refinement	   using	   PHENIX	   or	   REFMAC5.191	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Simulated	   annealing	   refinement	   was	   performed	   using	   PHENIX192,	   resulting	   in	   a	   final	  
model	   with	   an	   Rfree	   of	   25.4%	   and	   overall	   reasonable	   geometry.	   Coordinates	   and	  
dictionaries	   for	   ispinesib	  were	   obtained	   from	   the	   Dundee	   PRODRG	   server193.	   Data	   and	  
refinement	  statistics	  are	  given	  in	  Table	  2-­‐1.	  
Table	  2-­‐1:	  Data	  collection	  and	  refinement	  statistics	  for	  the	  Eg5–ispinesib	  complex.	  	  
Values	   in	  parentheses	  pertain	  to	  the	  highest-­‐resolution	  shell.	  Ramachandran	  plot	  statistics	  were	  
obtained	  with	  MolProbity	  194.	  
 
Statistics	   Eg5-­‐ispinesib	  
Unit	  cell	  dimensions	   a	  =	  64.7	  Å,	  b	  =	  112.6	  Å,	  c	  =	  106.9	  Å,	  	  
α=	  90.0˚,	  β	  =	  90.0˚,	  γ	  =	  90.0˚	  
Space	  group	   P21	  
Molecules	  per	  asymmetric	  unit	   4	  
Resolution	  range	  (Å)	   30.0–2.6	  
Total	  reflections	   134457	  
Unique	  reflections	   45511	  
Completeness	  (%)	   95.7	  (91.0)	  
Multiplicity	   3.0	  (2.7)	  
Rsym	  (%)	   6.9	  (62.2)	  
I/σ(I)	   13.3	  (2.0)	  
Rwork	  /	  Rfree	  (%)	   20.4	  /	  25.3	  
Wilson	  B	  (Å2)	   59.9	  
Average	  B	  (Å2):	   	  
-­‐	  Overall	   57.7	  
-­‐	  Protein	   58.2	  
-­‐	  Solvent	   48.1	  
-­‐	  ADP	   33.8	  
-­‐	  ispinesib	   44.9	  
r.m.s.d.	  bond	  lengths	  (Å)	   0.016	  
r.m.s.d.	  bond	  angles	  (˚)	   1.47	  
Ramachandran	  plot	  statistics	  (%):	   	  
-­‐	  Favoured	   98.1	  
-­‐	  Allowed	   01.9	  
-­‐	  Outliers	   00.0	  
	  
Coordinates	  and	  structure	  factors	  have	  been	  deposited	  with	  the	  Worldwide	  Protein	  Data	  
Bank	   (PDB	   ID:	   4AP0).	   In	   the	   Ramachandran	   plot,	   97.8%	   of	   residues	   are	   in	   preferred	  
regions,	  2.3%	  are	  in	  allowed	  regions	  and	  there	  are	  no	  outliers.	  
2.2.7.2 Eg5 mutants 
Diffraction	   data	   were	   recorded	   at	   Diamond	   Light	   Source.	   Data	   were	   processed	   using	  
iMosflm195	  and	  SCALA	  from	  the	  CCP4	  suite	  of	  programs196.	  The	  structures	  of	  the	  three	  Eg5	  
mutants	  were	  solved	  by	  molecular	  replacement	  (MOLREP)	  using	  the	  native	  Eg5	  structure	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(PDB	  ID:	  1II628)	  as	  a	  search	  model.	  The	  Eg5D130V,	  Eg5A133D	  and	  Eg5DM	  structures	  do	  not	  have	  
any	  density	   for	  most	  of	   the	   loop	  L5	   region.	  Loops	  L2	  and	  L11	  are	  missing	   in	  all	   the	  apo	  
mutant	   structures.	   PDB	   IDs	   for	   the	   mutants	   are:	   4A1Z	   (Eg5A133D),	   4A28	   (Eg5D130V)	   and	  
4B7B	  (Eg5DM).	  Data	  collection	  and	  refinement	  statistics	  for	  the	  three	  crystal	  structures	  are	  
shown	  in Table	  2-­‐2	  and	  the	  quality	  of	  the	  models	  is	  summarised	  in	  Table	  2-­‐3.	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   Eg5D130V	   Eg5A133D	   Eg5DM	   Eg5WT-­‐SB743921	   Eg5A133D-­‐SB743921	  
Unit	  cell	  dimensions:	  
a,	  b,	  c,	  α,	  β,	  γ	  (Å,	  deg)	  
52.0,	   78.4,	   93.3,	   90.0,	  
93.5,	  90.0	  
52.9,	   78.4,	   92.7,	   90.0,	  
93.2,	  90.0	  
81.5,	   81.5,	   114.9,	   90.0,	  
90.0,	  120.0	  
81.4,	   81.4,	   115.2,	   90.0,	  
90.0,	  120.0	  
81.0,	   81.0,	   123.6,	   90.0,	  
90.0,	  120.0	  
Space	  group	   P21	   P21	   P65	   P32	   P65	  
Molecules	  per	  AU	   2	   2	   1	   2	   1	  
Resolution	  range	  (Å)	   30.00	  -­‐	  2.80	   30-­‐2.55	   30-­‐2.5	   30-­‐2.8	   30-­‐2.4	  
No.	  of	  reflections	   78496	  (14843)	   85604	  (12271)	   110022	  (16329)	   51872	  (6882)	   64529	  (9362)	  
No.	  of	  unique	  reflections	   18389	  (2650)	   24512	  (3521)	   11958	  (1744)	   9633	  (1396)	   10595	  (1557)	  
Completeness	  (%)	   99.9	  (100)	   98.8	  (97.9)	   99.9	  (100)	   99.4(99.7)	   98.3	  (98.9)	  
Multiplicity	   3.3	  (3.4)	   3.5(3.5)	   9.2	  (9.2)	   6.5(6.0)	   7.5(7.0)	  
Rsym(%)	   14.4	  (49.8)	   8.7	  (28.6)	   9.8	  (25.2)	   8.9(50.1)	   8.9	  (35.7)	  
I/σ(I)	   12.7	  (4.6)	   10.7	  (5.5)	   18.7	  (7.8)	   17.6(2.0)	   14.8	  (5.6)	  
Wilson	  B	  (Å2+)	   48.5	   49.6	   37.0	   83.8	   52.8	  
	  	  	  	  Refinement	  statistics	  
Rwork/Rfree	  (%)	   17.6	  /	  26.7	   18.4	  /	  26.7	   17.9	  /	  25.0	   19.1/24.8	   16.1/20.8	  
	  	  	  Average	  B	  factors	  
Overall	   24.1	   46.3	   46.8	   71.9	   23.8	  
Main	  chain	   22.9	   44.5	   45.2	   72.1	   24.3	  
Side	  chain	   25.4	   48.2	   48.4	   71.6	   23.7	  
No.	  of	  Mg2+	  
ADP/inhibitor/water	  
2/0/59	   2/0/73	   1/0/123	   2/2/68	   1/1/241	  
r.m.s.d.	  in	  bond	  length	  (Å)b	   0.012	   0.016	   0.009	   0.008	   0.012	  
r.m.s.d.	  in	  bond	  angle	  (deg)	   1.456	   1.669	   1.550	   1.439	   1.625	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Table	  2-­‐3:	  Table	  representing	  the	  different	  regions	  of	  wild-­‐type	  and	  mutant	  Eg5	  as	  seen	  in	  the	  solved	  structure	  together	  with	  the	  Ramanchandram	  plot.	  
	  
	   Eg5D130V	   Eg5A133D	   Eg5DM	   Eg5WT-­‐SB743921	   Eg5A133D-­‐SB743921	  
Ramachandran	  plot	  
No	  of	  residues	  in	  preferred	  region	  [%]	   96.2	   93.4	   96.9	   86.3	   95.4	  
No	  of	  residues	  in	  allowed	  region	  [%]	   2.7	   3.8	   2.2	   11.1	   3.2	  
Outliers	  [%]	   1.1	   2.8	   0.9	   2.6	   1.5	  
Model	  	  
Chain	  A	   First	  to	  last	  residue	  [No]	  	   Gly16-­‐Val365	   Gly16-­‐Val365	   Gly16-­‐Pro363	   Gly16-­‐Glu364	   Gly16-­‐Glu364	  
Chain	  B	   First	  to	  last	  residue	  [No]	   Gly16-­‐Val365	   Gly16-­‐Val365	   -­‐-­‐	   Gly16-­‐Glu364	   -­‐-­‐	  
Missing	  residues	  
	  
Chain	  A	  	  
(Range)	  
Loop	   L5	   (120	   –	  
124)	  
Loop	   L11	   (271	   –	  
283)	  	  
Loop	  L5	  (121	  –	  127)	  
Loop	  L11	  (271	  –	  280)	  
Loop	  L2	  (56	  –	  60)	  
Loop	  L5	  (120	  –	  124)	  
Loop	  L11	  (271	  –	  285)	  
-­‐-­‐	   -­‐-­‐	  
Chain	  B	  
(Range)	  
Loop	  L2	  (56	  –	  59)	  
Loop	   L5	   (120	   –	  
125)	  
Loop	   L11	   (274	   –	  
288)	  
Loop	  L2	  (55	  –	  61)	  
Loop	  L5	  (122	  –	  127)	  
Loop	  L11	  (274	  –	  288)	  
-­‐-­‐	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2.2.7.3 Eg5WT and Eg5A133D in complex with SB743921  
Diffraction	  data	  were	  collected	  at	  Diamond	  Light	  Source	  and	  processed	  using	  iMosflm195	  
and	   SCALA	   from	   the	   CCP4	   suite.196	   The	   structure	   of	   the	   Eg5WT-­‐SB743921	   complex	   was	  
solved	   by	   molecular	   replacement	   (MOLREP)	   using	   1	   molecule	   of	   the	   Eg5-­‐monastrol	  
complex	   (PDB	   ID:	   1X88197)	   as	   a	   search	   model.	   The	   structure	   of	   the	   Eg5A133D-­‐SB743921	  
complex	  was	  solved	  using	  the	  complex	  of	  wild-­‐type	  Eg5	  as	  a	  search	  model.	  All	  structures	  
were	   initially	   refined	   with	   REFMAC5191	   subsequently	   followed	   by	   PHENIX192.	   For	  
calculating	  Rfree	  5%	  of	  data	  were	  used.	  Electron-­‐density	  and	  difference-­‐density	  maps,	  all	  
σA-­‐weighted,	  were	   inspected	  and	  model	  building	   carried	  using	  Coot190.	   The	   coordinates	  
and	  the	  cif	  dictionary	  for	  SB743921	  were	  calculated	  using	  the	  Dundee	  PRODRG	  server193.	  
Loop	  L11,	  which	  is	  usually	  missing	  in	  most	  of	  the	  other	  Eg5-­‐inhibitor	  complexes,	  is	  visible	  
in	   the	   Eg5WT-­‐SB743921	   and	   Eg5A133D-­‐SB743921	   complex	   structures.	   One	   structure	   has	  
been	   deposited	   as	   PDB	   entry	   4AS7	   (Eg5A133D-­‐SB743921).	   The	   Eg5WT-­‐SB743921	   is	  
undergoing	  deposition.	  
2.2.7.4 Structure of Eg5-BI8 quaternary structure 
The	   structure	   of	   the	   Eg5-­‐ADP-­‐BI8	   complex	   was	   determined	   at	   1.7	   Å	   resolution.	   Data	  
collection	  and	  refinement	  statistics	  are	  summarised	  in Table	  2-­‐4. 	  
Table	  2-­‐4:	  Data	  collection	  and	  refinement	  statistics	  of	  Eg5	  in	  complex	  with	  BI8	  
Statistics	   Eg5-­‐BI8	  
Unit	  cell	  dimensions	  a,	  b,	  c,	  α,	  β,	  γ	  (Å,	  °)	   107.9,	  62.9,	  75.1,	  90.0,	  117.4,	  90.0	  
Space	  group	   C2	  
Beamline	  /	  Detector	   I-­‐02	  /	  Q315R	  
Molecules	  per	  asymmetric	  unit	   1	  
Resolution	  range	  (Å)	   36.96	  –	  1.69	  
No.	  of	  unique	  reflections	   49475	  
Completeness	  (%)	  	   99.2	  (99.2)	  
Multiplicity	  	   3.9	  (3.9)	  
Rsym	  (%)	   8.4	  (65.8)	  
I/σ(I)	   9.3	  (2.0)	  	  
Wilson	  B	  (Å2)	  /	  DPI	  (Å2)	   23.07	  /	  0.10	  
Refinement	  statistics	   	  
Rwork	  /	  Rfree	  (%)	   19.4	  /	  23.3	  
Average	  B	  Factors	   	  
Overall	  	   29.8	  
Main	  Chain	  /	  Side	  Chain	   26.0	  /	  32.5	  
No.	  of	  ADP	  /	  Inhibitor	  /	  Water	   1	  /	  2	  /	  450	  
3	  r.m.s.d.	  in	  bond	  length	  (Å)	   0.011	  
3	  r.m.s.d.	  in	  bond	  angle	  (deg)	   1.414	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1	  Values	  in	  parentheses	  pertain	  to	  the	  highest	  resolution	  shell	  	  
2	  DPI:	  Diffraction-­‐component	  precision	  index198	  
3	  r.m.s.d.	  is	  the	  root-­‐mean-­‐square	  deviation	  from	  ideal	  geometry	  	  
2.3 MPP1 
2.3.1 Human MPP1 
2.3.1.1 Sub-cloning into E. coli expression vectors 
Codon-­‐optimised	  DNA	  coding	  for	  the	  motor	  domains	  of	  human	  MPP11-­‐447	  and	  MPP157-­‐491	  
was	  synthesised	  by	  Genscript	  Inc	  and	  then	  cloned	  into	  pET28a	  vector	  using	  NcoI	  and	  XhoI	  
sites.	   In	  addition,	   it	  was	  also	  cloned	   in	  pSUMO	  expression	  plasmid.	  The	  primers	   for	   the	  
two	  different	  constructs	  are	  as	  follows:	  MPP11-­‐447:	  Forward	  Primer:	  5’-­‐GCC	  ATT	  GCA	  CAA	  
TAA	  GTT	  TGT	  GTC	  CCA	  GAC-­‐3’;	  Reverse	  Primer:	  	  5’-­‐GTC	  TGG	  GAC	  ACA	  AAC	  TTA	  TTG	  TGC	  
AAT	  GGC-­‐3’;	  MPP157-­‐491:	   Forward	  Primer:	  5’-­‐GAA	  CAG	  ATT	  GGT	  GGA	  TGC	  GGA	  TCC	  AAA	  
GAT	  TAT	  CTC	  CAG	  GTT-­‐3’;	  Reverse	  Primer:	  	  5’-­‐CTT	  GAG	  AGG	  AAT	  TTA	  AAG	  TGT	  CTT	  AGA	  
CAC	  AAA	  CTT	  TTT	  GTG-­‐3’.	  The	  cloning	  strategy	  and	  the	  sequences	  were	  verified	  by	  DNA	  
sequencing.	  
Cloning	  of	  MPP1	  constructs	  were	  also	  carried	  out	  in	  other	  various	  vectors	  but	  due	  to	  lack	  
of	  protein	  expression	  capability	  they	  are	  not	  further	  pursued.	  	  
2.3.1.2 Expression and purification of protein 
Plasmids	  were	   transformed	   into	  E.	  coli	  BL21	  CodonPlus	  using	  heat	  shock	  at	  42°C.	  Then,	  
12	  L	   of	   bacterial	   culture	   were	   grown	   at	   37°C	   in	   LB	   (Luria	   Broth)	   added	   with	   100	  mg/l	  
ampicillin	  to	  an	  A600	  of	  0.7	  and	   induced	  overnight	  with	  0.5	  mM	  IPTG	  at	  20°C.	  Harvested	  
cells	  were	  resuspended	  in	  buffer	  A	  supplemented	  with	  1	  mM	  PMSF,	  1	  mM	  Mg-­‐ATP,	  1	  mM	  
DNaseI	   and	   2.5	   mg	   of	   lysozyme,	   and	   subjected	   to	   one	   cycle	   of	   freeze–thaw	   and	  
sonication.	  The	  lysate	  was	  centrifuged	  for	  1	  hr	  in	  a	  J25	  (Beckman)	  rotor	  at	  30000	  g	  at	  4°C.	  	  
Clear	   lysates	  were	   loaded	  on	   to	  a	  5	  ml	  HisTrap	  FF	  column	  equilibrated	   in	  buffer	  A.	  The	  
resin	  was	  washed	  with	  buffer	  A	  containing	  10	  mM	  imidazole	  and	  the	  proteins	  eluted	  on	  a	  
gradient	  of	  buffer	  B.	  	  
Materials and methods 
   
  Sandeep K Talapatra 
80 
For	   pSUMO	   vector,	   fractions	   containing	   the	   protein	   were	   pooled	   and	   the	   buffer	   was	  
exchanged	  for	  desalting	  buffer	  C.	  Ulp1	  protease,	  1	  mM	  Mg2+ATP	  and	  1	  mM	  MgCl2	  were	  
added	  and	   reaction	  mixtures	  were	   incubated	  overnight	   at	   4°C.	  Uncleaved	  proteins	   and	  
protease	  were	  removed	  by	  running	  the	  sample	  through	  the	  HisTrap	  FF	  column	  a	  second	  
time.	  	  
The	  protein	  without	  the	   fusion	  tag	   for	  pSUMO	  vector	  and	  the	  protein	   from	  first	  affinity	  
purification	   for	   pET28a	   vector	   were	   diluted	   using	   buffer	   I	   to	   obtain	   a	   final	   salt	  
concentration	  of	  ~30	  mM.	  The	  diluted	  sample	  was	  then	  applied	  to	  a	  5	  ml	  Hi-­‐trap	  FF	  Mono	  
S	  or	  Q	  ion	  exchange	  column	  (depending	  on	  the	  pI	  of	  the	  protein)	  to	  remove	  the	  remaining	  
contaminants.199	   The	   protein	   was	   eluted	   with	   a	   gradient	   of	   buffer	   J.	   The	   protein	  
containing	   fractions	   were	   pooled	   and	   run	   through	   a	   final	   step	   of	   size	   exclusion	  
chromatography	  on	  a	  Superdex200	  16/60	  column	  equilibrated	  in	  gel	  filtration	  buffer	  D.	  
The	  protein	  obtained	  was	  pooled	  and	  concentrated	  on	  an	  Amicon	  ultrafiltration	  device	  to	  
a	  final	  concentration	  of	  approx.	  5	  mg/ml	  and	  flash	  frozen	  in	  liquid	  nitrogen	  and	  stored	  at	  
−80°C	   after	   adding	   5%	   glycerol.	   The	   proteins	   have	   been	   used	   freshly	   purified	   where	  
possible	  with	  occasional	  use	  of	  frozen	  proteins.	  
2.3.1.3 In vitro screening for inhibitors of the human mitotic 
kinesin MPP1 
2.3.1.3.1 Steady state ATPase measurements and determination of IC50 
values 
	  
Steady	   state	   basal	   and	   MT-­‐stimulated	   ATPase	   rates	   were	   measured	   as	   previously	  
described	  for	  Eg5.183	  680	  nM	  MPP1	  was	  used	  in	  the	  basal	  assay	  while	  50	  nM	  was	  used	  in	  
the	  MT-­‐stimulated	  activity	  assay.	  For	  evaluating	  the	  Km,ATP,	  the	  concentration	  of	  ATP	  was	  
used	  within	   a	   range	   from	  0	   to	   2	  mM	   for	   both	  basal	   and	  MT-­‐stimulated	  ATPase	   assays,	  
whereas	  MTs	  were	  used	   in	   the	   range	  of	  0	   to	  20	  µM	  for	  K0.5,MTs.	  Kinetics	  measurements	  
were	   done	   at	   25°C	   using	   a	   96-­‐well	   Sunrise	   photometer	   (TECAN,	   Maennesdorf,	  
Switzerland).	  The	  data	  were	  analysed	  using	  Kaleidagraph	  4.0.	  The	  kinetic	  parameters	  kcat,	  
Km,	  ATP,	  K0.5,	  MTs	  were	  initially	  calculated	  and	  optimised.	  All	  calculations	  were	  done	  based	  on	  
the	  equation	  described	  previously	  for	  Eg5	  (section	  2.2.3.1).	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The	   IC50	   values	   for	   the	   inhibition	   of	   the	   basal	   and	   MT-­‐stimulated	   ATPase	   activities	   of	  
MPP1	  were	  calculated	   for	  depsidones	  and	  depside	  analogues	  at	   concentrations	   ranging	  
from	  0	  to	  200	  µM	  or	  0	  to	  150	  µM	  based	  on	  the	  solubility	  of	  the	  respective	  compounds.	  	  
2.3.1.3.2 Determination of the type of inhibition of physodic acid for MPP1 in 
the absence and presence of MTs 
	  
The	   type	   of	   inhibition	   for	   the	   depsidones	   in	   the	   absence	   and	   presence	   of	   MTs	   was	  
determined	  based	  on	  the	  steady	  state	  ATPase	  measurements.	  Physodic	  acid	  as	  the	  most	  
potent	  compound	  was	  selected	  for	  these	  assays.	  To	  characterise	  the	  type	  of	  inhibition	  we	  
determined	   the	   Vmax	   and	   Km	   of	   ATP	   in	   the	   absence	   and	   presence	   of	   constant	  
concentration	  of	  1	  μM	  MTs.	  For	  K0.5,	  MT,	  ATP	  concentration	  was	  fixed	  at	  1	  mM.	  	  
Inhibitor	   concentrations	   of	   0,	   1,	   5	   10	   and	   20	   μM	  were	   used	   to	   investigate	   the	   type	   of	  
inhibition	   for	   both	   basal	   and	   MT-­‐stimulated	   ATPase	   activity	   either	   with	   increasing	  
concentration	  of	  ATP	  from	  0	  to	  2	  mM	  or	  MTs	  from	  0	  to	  1	  μM.	  
2.3.1.3.3 Cytophos assay 
  
The	  Cytophos	  assay	  was	  used	  as	  a	  secondary	  screening	  method	  to	  measure	  the	  inhibition	  
of	   steady	   state	   ATPase	   activity	   of	   MPP1.	   The	   assay	   detects	   the	   release	   of	   inorganic	  
phosphate	  and	  is	  a	  modification	  of	  the	  Malachite	  green	  method.	  In	  the	  Malachite	  green	  
assay,	   the	   free	   inorganic	   phosphate	   released	   from	   the	   protein	   in	   the	   aqueous	   solution	  
reacts	   with	   the	   Malachite	   green	   producing	   a	   green	   colour	   and	   the	   absorbance	   is	  
measured	   at	   650	   nm.	   In	   the	   Cytophos	   assay,	   ATP	   is	   added	   to	   the	   solution	   and	   kinesin	  
converts	   it	   into	   ADP	   and	   inorganic	   phosphate	   by	   its	   ATPase	   activity.	   The	   amount	   of	  
inorganic	   phosphate	   released	   from	   the	   reaction	   mixture	   by	   kinesin	   ATPase	   activity	   is	  
measured	  at	  650	  nm.200	  	  
Firstly,	   a	   standard	   plot	   using	   control	   sample	   (Phosphate	   standard)	   and	   the	   Cytophos	  
reagent	  was	  generated.	  The	  control	  sample	  was	  incubated	  for	  5	  min	  followed	  by	  10	  min	  
incubation	  with	  Cytophos	  reagent	  and	  then	  measuring	  the	  end	  point	  absorbance	  at	  650	  
nm.	  
For	  measurement	  of	   the	   inhibition	  of	  MPP1	  by	  depsidones	  and	  depsides,	   the	  Cytophos	  
assay	   protocol	   was	   followed	   with	   a	   final	   reaction	   volume	   of	   100	   µl.	   Protein	  
concentrations	  of	  50,	  100,	  150,	  200	  nM	  were	  used.	  Inhibitor	  concentration	  was	  measured	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from	  0	  to	  150	  µM	  for	  each	  protein	  concentration.	  The	  ATPase	  reaction	  was	  mixed	  with	  
freshly	  prepared	  ATP	  at	  three	  different	  concentrations	  of	  100,	  200	  and	  300	  µM	  and	  the	  
reaction	  mixture	   incubated	   for	  5	  min.	  The	  compounds	  were	  analysed	  at	   three	  different	  
concentrations.	  Next,	  the	  Cytophos	  reagent	  was	  added	  and	  the	  mixture	  incubated	  for	  10	  
min.	  The	  end	  point	  measurement	  was	  carried	  out	  in	  a	  TECAN	  Sunrise	  96-­‐well	  plate	  reader	  
at	   650	   nM.	   Appropriate	   blanks	   were	   used	   for	   each	   experiment.	   All	   experiments	   were	  
done	  in	  triplicate	  and	  at	  25°C.	  	  
2.3.1.4 Crystallisation trials 
The	   initial	   trials	   for	   crystallisation	   of	   MPP154-­‐491	   in	   pET-­‐28a	   (with	   a	   non-­‐cleavable	   C-­‐
terminal	   his-­‐tag)	   were	   set	   up	   using	   different	   commercial	   screens	   from	   Hampton	   and	  
Qiagen.	  1	  µl	  of	  protein	  (10	  mg/ml)	  and	  1	  µl	  of	  screen	  solution	  were	  mixed	  and	  incubated	  
at	  4°C	  and	  19°C	  and	  drops	  checked	  for	  crystals	  for	  30	  days.	  
These	   crystallisation	   trials	   did	   not	   yield	   any	   crystals	   so	   two	   different	   approaches	   were	  
tried	  at	  this	  point.	  The	  first	  approach	  was	  reductive	  methylation	  of	  the	  solvent-­‐exposed	  
lysine	  residues	  of	  the	  protein	  in	  solution	  using	  a	  modification	  of	  the	  method	  of	  Walter	  et	  
al,	   2006	   and	   Rayment	   et	   al,	   1997.201,202	   The	   methylation	   reaction	   was	   performed	  
overnight	  in	  50	  mM	  HEPES	  (pH	  7.5),	  250	  mM	  NaCl	  using	  1	  mg/ml	  of	  protein.	  20	  µl	  freshly	  
prepared	   1	   M	   dimethylamine-­‐borane	   complex	   (ABC)	   and	   40	   ml	   of	   1	   M	   formaldehyde	  
were	  added	  per	  ml	  protein	  solution	  and	  the	  reactions	  were	  gently	  mixed	  and	  incubated	  at	  
4°C	  for	  2	  hr.	  A	  further	  20	  ml	  ABC	  and	  40	  ml	  formaldehyde	  are	  added	  and	  the	  incubation	  
continued	  for	  2	  hr.	  Finally,	  10	  ml	  of	  ABC	  was	  added	  to	  the	  mixture,	  the	  reaction	  incubated	  
overnight	  at	  4°C.	  Precipitated	  protein	  was	  removed	  by	  centrifugation	  before	  puriﬁcation	  
of	  the	  soluble	  methylated	  protein	  by	  size	  exclusion	  chromatography	  with	  buffer	  D.	  Peak	  
fractions	  were	  pooled	  and	  concentrated	  to	  10	  mg/ml	  and	  crystal	  screens	  set	  up	  as	  before	  
immediately	  with	  fresh	  protein.201-­‐203	  
The	   second	   approach	   is	   cloning	   of	   additional	   constructs	   of	   MPP1	   from	   other	   various	  
species	   based	   on	   secondary	   structure	   predictions	   and	   sequence	   alignment	   of	   human	  
MPP1.	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2.3.2 MPP1 orthologues in other species 
2.3.2.1 Sub-cloning into E. coli expression vectors 
Protein	  sequences	  of	  MPP1	  orthologues	  were	  aligned	  with	  the	  motor	  domain	  sequence	  
of	   human	   Kif5b	   to	   define	   the	   boundaries	   of	   the	   motor	   domain,	   using	   the	   ClustalW2	  
multiple	   alignment	   program	   at	   the	   European	   Bioinformatics	   Institute	   (EBI).199	   Codon-­‐
optimised	   cDNAs	   encoding	   kinesin	   motor	   domains:	   M.	   musculus	   MPP11-­‐489,	   Rattus	  
norvegicus	   MPP11-­‐490	   and	   Xenopus	   laevis	   MPP11-­‐518	   were	   purchased	   in	   vector	   pUC57	  
(GenScript).	  The	  cDNAs	  were	  double	   restricted	  with	  NcoI	   and	  XhoI	   and	  cloned	   into	   two	  
E.coli	  expression	  vectors:	  a	  modiﬁed	  pProExHT	  expression	  plasmid	  and	  pSUMO.	  	  
The	  primers	  for	  the	  cloning	  shorter	  constructs	  of	  MPP1	  orthologues	  are	  as	  follows:	  Mus	  
musculus	  MPP156-­‐489:	  Forward	  Primer:	  5’-­‐	  G	  GCC	  AAT	  TCC	  CTG	  GGA	  TCC	  AAA	  AAT	  TAT	  CTG	  
C	   -­‐3’;	   Reverse	   Primer:	   5’	   –	   G	   GTG	  GTG	  GTG	   CTC	  GAG	   TCA	   TTT	   TTC	   TTG	   AC	   -­‐3’;	  Rattus	  
norvegicus	  MPP154-­‐490:	   Forward	   Primer:	   5’	   -­‐	   CCG	  GGT	  GCA	  AAT	   TCA	  CTG	  GGA	  TCC	  AAA	  
AAC	  TAT	  CTG	  C	  -­‐	  3’;	  Reverse	  Primer:	  	  5’	  -­‐	  GTG	  GTG	  GTG	  GTG	  GTG	  CTC	  GAG	  TCA	  TTT	  TTC	  
TTG	  GG	  	  -­‐	  3’;	  Xenopus	  laevis	  MPP11-­‐409:	  Forward	  Primer:	  5’	  –	  CAG	  GCG	  TGT	  CGT	  GGA	  TCC	  
GAA	  AAA	  GCG	  AAT	  GGC	  TC	  -­‐	  3’;	  Reverse	  Primer:	  	  5’	  –	  G	  GTG	  GTG	  CTC	  GAG	  TTA	  TTT	  TTT	  
CTG	  CAC	  GCA	  CGG	  -­‐	  3’	  The	  constructs	  were	  verified	  by	  DNA	  sequencing.	  
Cloning	   of	   MPP1	   constructs	   were	   also	   carried	   out	   in	   other	   vectors	   but,	   due	   to	   poor	  
expression	  levels,	  they	  were	  not	  further	  pursued.	  	  
	  
2.3.2.2 Study of MPP1 inhibitor using steady state ATPase assay 
Steady	  state	  ATPase	  was	  measured	  for	  MPP1	  motor	  domain	  from	  the	  other	  species	  in	  a	  
similar	  way	  as	  for	  human	  MPP1.	  Kinetics	  values	  kcat,	  Km,ATP,	  K0.5,MTs	  and	  IC50	  was	  analysed	  
and	  interpreted	  as	  for	  human	  MPP1.	  
2.3.2.3 Crystallisation trials 
Crystallisation	   trials	   for	   MMP1	   constructs	   have	   been	   carried	   out	   under	   different	  
conditions;	  19°C	  and	  4°C,	  with	  or	  without	  Mg2+ATP,	   in	  presence	  or	  absence	  of	   inhibitor.	  
Protein	  was	  used	  at	  a	  concentration	  of	  10	  mg/ml.	  Crystallisation	  was	  carried	  out	  with	  the	  
same	  screens	  as	  for	  human	  MPP1	  and	  checked	  regularly	  for	  hits	  up	  to	  30	  days.	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2.4 Human MKLP-2 
2.4.1 Sub-cloning into E. coli expression vectors  
2.4.1.1 Cloning of MKLP-256-505, ΔL6 and point mutants of MKLP-2 
The	   cDNA	   of	   human	  MKLP-­‐256-­‐505	   and	  MKLP-­‐256-­‐505	   Δloop	   L6	   were	   purchased	   in	   vector	  
pUC57	  (GenScript).	  The	  cDNAs	  were	  double	  restricted	  with	  NcoI	  and	  XhoI	  and	  cloned	  into	  
two	  E.coli	  pET28a	  expression	  vectors.	  Single	  MKLP-­‐2	  mutants	  L187A	  (named	  MKLP-­‐2L187A),	  
W356A	   (named	   MKLP-­‐2W356A)	   and	   W359A	   (MKLP-­‐2W359A)	   were	   introduced	   using	   the	  
following	   forward	   and	   reverse	   primers	   according	   to	   the	   recommendations	   of	   the	  
QickChange	  kit:	  MKLP-­‐2L187A	  (Forward:	  5’-­‐	  G	  GAT	  GGA	  GGG	  ATT	  GCC	  CCC	  CGG	  TCC	  CTG	  -­‐	  
3’;	   Reverse:	   5’	   –	  CAG	  GGA	  CCG	  GGG	  GGC	  AAT	  CCC	  TCC	  CTC	  CAT	  CC	  –	  3’),	  MKLP-­‐2W356A	  
(Forward:	  5’	  –	  GAT	  GCT	  GAG	  GAG	  GCC	  GCG	  AAG	  CTC	  CTA	  AAA	  GTG	  –	  3’;	  Reverse:	  5’	  –	  CAC	  
TTT	  TAG	  GAG	  CTT	  CGC	  GGC	  CTC	  CTC	  AGC	  ATC	  –	  3’);	  MKLP-­‐2W359A	  (Forward:	  5’-­‐	  GAG	  GAG	  
GCC	  TGG	  AAG	  CTC	  GCA	  AAA	  GTG	  GGT	  CG	  –	  3’;	  Reverse:	  5’-­‐	  CG	  ACC	  CAC	  TTT	  TGC	  GAG	  CTT	  
CCA	  GGC	  CTC	  CTC	  –	  3’).	  The	  DNA	  sequences	  were	  verified	  by	  sequencing.	  
2.4.2 Expression and purification of protein of MKLP-2 
constructs 
The	  expression	  plasmids	  were	  transformed	  into	  E.	  coli	  BL21(DE3)	  pLysS.	  12	  L	  of	  bacterial	  
culture	  were	   grown	   for	   all	   the	  MKLP-­‐2	   constructs	   at	   37°C	   in	   LB	  medium	   supplemented	  
with	  50	  mg/ml	  kanamycin	  to	  an	  A600	  of	  0.7	  and	   induced	  overnight	  with	  0.5	  mM	  IPTG	  at	  
20°C.	  Cells	  were	  harvested	  and	  resuspended	  in	  lysis	  buffer	  K	  and	  then	  lysed	  by	  sonication	  
using	  8	  sec	  ON	  and	  8	  sec	  OFF	  pulses.	  Lysates	  were	  centrifuged	  at	  20,000	  rpm	  for	  1	  h	  at	  
4°C.	  The	  supernatant	  was	  supplemented	  with	  1	  mM	  Mg2+ATP	  and	  loaded	  onto	  a	  5	  ml	  Ni-­‐
NTA	   HisTrap	   FF	   column	   for	   affinity	   chromatography.	   The	   column	   was	   previously	  
equilibrated	  with	   buffer	   L	   and	   eluted	  with	   a	   gradient	   using	   buffer	  M.	   Protein	   obtained	  
was	  pooled	  and	  diluted	  with	  buffer	  N	  to	  reduce	  the	  salt	  concentration	  for	  Ion	  Exchange	  
Chromatography	  using	  5	  ml	  Hi-­‐Trap	  Mono	  S	  column.	  The	  column	  was	  pre-­‐equilibrated	  in	  
buffer	   D	   and	   proteins	   eluted	  with	   a	   gradient	   in	   buffer	  O.	   The	   final	   step	   of	   purification	  
involved	  gel	  filtration	  using	  Superose	  16/60	  S200	  column	  where	  the	  proteins	  were	  eluted	  
with	  buffer	  P.	  The	  protein	  obtained	   finally	  was	  pooled	  and	  concentrated	  on	  an	  Amicon	  
ultrafiltration	  device	  to	  a	  final	  concentration	  of	  approx.	  10	  mg/ml	  and	  either	  used	  fresh	  or	  
from	  frozen	  stock	  with	  5%	  glycerol	  for	  further	  experiments.	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2.4.3 Kinetics and inhibition measurement of MKLP-2 using 
steady state ATPase assay 
Steady	  state	  ATPase	  rates	  were	  measured	  using	   the	  same	  protocol	  as	  used	   for	  Eg5	  and	  
MPP1.	  The	  amounts	  of	  MKLP-­‐2	  proteins	  used	  for	  the	  experiments	  were	  optimised	  at	  1000	  
nM	   for	   basal	   and	   40	   nM	   for	   MT-­‐stimulated	   activity	   assays.	   The	   kinetic	   parameters	  
kcat,	  Km,ATP,	  and	  K0.5,	  MTs	  were	  also	  obtained	  in	  the	  similar	  fashion	  as	  for	  Eg5	  and	  MPP1.	  To	  
measure	   Km,ATP,	   ATP	   concentration	   was	   measured	   from	   0	   to	   2	   mM	   and	   a	   fixed	  
concentration	  of	  1	  µM	  MTs	  whereas	  for	  K0.5,MT,	  MT	  was	  measured	  from	  0	  to	  10	  µM	  and	  a	  
fixed	  concentration	  of	  1	  mM	  ATP.	  
Inhibition	  of	  MKLP-­‐2	  wild-­‐type	  and	  mutant	  by	  paprotrain	  was	  measured	  using	  an	  inhibitor	  
concentration	  ranging	  from	  0	  to	  150	  µM.	  	  All	  measurements	  were	  carried	  out	  at	  least	  in	  
triplicate.	  
2.4.4 Crystallisation trials 
The	   initial	   trials	   for	  crystallisation	  of	  MKLP-­‐2	  wild-­‐type	  and	  the	  mutants	  with	  or	  without	  
the	   inhibitor	   paprotrain	   (1	   mM	   final	   concentration)	   were	   set	   up	   using	   commercial	  
crystallisation	  screens	  from	  Hampton	  Research	  (PEG	  Ion,	  Natrix,	  Crystal	  Screen	  HT,	  Index)	  
and	  Qiagen	   (JCSG+,	  PACT).	  1	  µl	  of	  protein	   (10	  mg/ml)	  and	  1	  µl	  of	   screen	  solution	  were	  
mixed	   and	   incubated	   at	   4°C	   and	   19°C	   and	   drops	   checked	   for	   crystals	   for	   30	   days.
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3 Results 
3.1 Analysis of ispinesib as a potent inhibitor of Eg5 
While	   the	   crystal	   structure	   of	   the	   Eg5-­‐ispinesib	   complex	   has	   been	   described	   in	   the	  
literature,204	  no	  structure	  of	   this	  complex	  has	  been	  deposited	   in	   the	  Protein	  Data	  Bank.	  
There	  is	  also	  a	  lack	  of	  characterisation	  in	  the	  literature	  of	  ispinesib	  binding	  to	  Eg5	  in	  the	  
absence	  of	  MTs.	  An	  integrated	  investigation	  of	  ispinesib	  binding	  was	  therefore	  carried	  out	  
using	   structural,	   biophysical	   and	   biochemical	   methods	   to	   understand	   the	   key	  
determinants	   of	   ligand	   binding,	   to	   place	   the	   structure	   in	   the	   public	   domain205	   and	   to	  
characterise	  more	  fully	  the	  binding	  affinity	  between	  ispinesib	  and	  Eg5.	  
3.1.1 Biochemical and biophysical studies of ispinesib 
binding to Eg5 
Ispinesib	   has	   been	   shown	   to	   inhibit	   MT-­‐stimulated	   Eg5	   activity	   with	   low	   nanomolar	  
affinity	  (IC50	  =	  2.0	  ±	  0.5	  nM	  and	  Kiapp	  ≤	  10	  nM)205	  compared	  to	  monastrol	  (IC50	  =	  16	  µM)206	  
and	  STLC	  (IC50	  =	  140	  nM	  and	  Kiapp	  ≤	  150	  nM).110	  It	  was	  interesting	  to	  observe	  whether	  the	  
same	  holds	  true	  under	  basal	  conditions	  in	  the	  absence	  of	  MTs	  (Figure	  3-­‐1).	  While	  the	  IC50	  
estimate	  obtained	   for	   the	  MT-­‐stimulated	  ATPase	  activity	  agrees	  well	  with	   the	   literature	  
data,	  under	  basal	  condition	  the	  IC50	  of	   ispinesib	   increases	  by	  one	  order	  of	  magnitude	  to	  
32.8	  ±	  0.1	  nM	  (Table	  3-­‐1).	  Due	  to	   the	  higher	  protein	  concentration	   in	   the	  basal	  ATPase	  
assay	  (80-­‐100	  nM	  compared	  to	  5	  nM	  in	  MT-­‐simulated	  assay),	  it	  is	  not	  uncommon	  for	  tight	  
binding	  inhibitors	  to	  appear	  less	  potent	  against	  the	  basal	  compared	  to	  the	  MT-­‐stimulated	  
ATPase	  activity	  of	  kinesins.	  Repeating	  the	  binding	  experiment	  to	  Eg5	  by	  ITC	  according	  to	  
the	  method	  of	  Sheth	  et	  al126	  (Table	  3-­‐2,	  Figure	  3-­‐1)	  shows	  that	  even	  in	  the	  absence	  of	  MTs,	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Figure	  3-­‐1:	  Characterisation	  of	  Eg5	  inhibition	  by	  ispinesib.  
Inhibition	  of	  the	  a)	  basal	  and	  b)	  MT-­‐stimulated	  ATPase	  activity	  of	  Eg5.	  c)	  Raw	  (top)	  and	  integrated	  
(bottom)	   ITC	   data	   demonstrating	   saturable	   exothermic	   evolution	   of	   heat	   upon	   sequential	  
additions	  of	  ispinesib	  to	  Eg5.	  	  
	  
Table	  3-­‐1: Inhibition	  of	  the	  Eg5	  ATPase	  activity	  by	  ispinesib. 
	  
	   Basal	   MT-­‐stimulated	  
IC50	  (nM)	   38.0	  ±	  0.5	   3.0	  ±	  0.4	  
Eg5	  concentration	  used	  (nM)	   80	  -­‐	  100	   5	  
	  
Table	  3-­‐2: Thermodynamic	  data	  for	  binding	  of	  ispinesib	  to	  Eg5-­‐ADP.	  	  





Kdapp	  (nM)	   ∆H	  (kcal/mol)	   T∆Sapp	  (kcal/mol)	  
1.270	  ±	  0.003	   ≤	  10	   -­‐9.08	  ±	  0.04	   2.81	  ±	  0.23	  
	  
3.1.2 Structural analysis of Eg5-ispinesib complex 
The	  structure	  of	  the	  Eg5-­‐ispinesib	  complex	  was	  solved	  at	  2.6	  Å	  and	  refined	  to	  an	  Rfree	  of	  
25.3%	  with	   four	  protein	  molecules	   in	   the	  asymmetric	  unit	   (AU). 	   The	   four	   independent	  
complexes	   in	   the	   AU	   are	   mostly	   similar,	   with	   pairwise	   superpositions	   giving	   r.m.s.	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deviations	  around	  0.6	  Å	  for	  ≈300	  Cα	  atoms	  when	  chain	  A,	  C	  and	  D	  is	  compared	  to	  chain	  B.	  
Differences	  did	  exist	  between	  the	  independent	  molecules	  with 15–17	  residues	  at	  the	  N-­‐
terminus	  and	  2-­‐9	  residues	  at	  the	  C-­‐terminal	  of	  Eg51–368	  being	  disordered,	  as	  are	  a	  number	  
of	  loops.	  In	  particular	  electron	  density	  for	  loops	  L10	  and	  L11	  (Figure	  3-­‐2)	  is	  absent	  from	  all	  
four	   molecules. The	   moderate	   resolution	   of	   the	   data	   suggested	   the	   use	   of	   non-­‐
crystallographic	  symmetry	  (NCS)	  restraints	  to	  increase	  the	  observation	  :	  parameter	  ratio	  
but	  application	  of	  4-­‐fold	  NCS	  led	  to	  a	  significant	  rise	  in	  Rfree	  so	  were	  not	  used.	  The	  rest	  of	  
the	  discussion	  of	  the	  Eg5-­‐ispinesib	  complex	   is	  based	  on	  chain	  B	  unless	  stated	  otherwise	  
stated	  as	  this	  chain	  is	  structurally	  more	  ordered	  with	  more	  electron	  density	  visible.	  	  
The	  structure	  conforms	  to	  the	  canonical	  structures	  of	  the	  kinesin	  motor	  domain	  fold	  with	  
an	   eight-­‐stranded	   β-­‐sheet	   sandwiched	   between	   three	   major	   α-­‐helices	   on	   either	   side	  
(Figure	  3-­‐2	  a,b). One	  molecule	  of	  Mg2+ADP	  is	  bound	  in	  the	  nucleotide	  binding	  pocket	  with	  
the	   magnesium	   coordinated	   by	   the	   β-­‐phosphate,	   the	   hydroxyl	   side-­‐chain	   oxygen	   of	  
Thr112	   and	   three	   water	   molecules,	   resulting	   in	   the	   classic	   octahedral	   coordination	  
geometry	  observed	  with	  magnesium.	  	  One	  of	  the	  coordination	  sites	  is	  unoccupied	  and	  in	  
other	   high-­‐resolution	   kinesin	   structures,114	   a	   water	   molecule	   occupies	   this	   position.	   It	  
could	  be	  anticipated	  that	  with	  higher	  resolution	  data	  the	  water	  molecule	  would	  become	  
apparent	   in	  the	  electron	  density.	   Ispinesib	  occupies	  the	   inhibitor-­‐binding	  pocket	  formed	  
by	  helix	  α2,	  loop	  L5	  and	  helix	  α3 (Figure	  3-­‐2a). 
Comparison	  with	  Eg5	  structure	  without	  a	  bound	   inhibitor	  (PDB	  id	  1II628) shows	  that	  the	  
region	  around	  the	   inhibitor-­‐binding	  pocket	  undergoes	  major	  conformational	  changes	  on	  
ispinesib	  binding. Additional	  changes	  extend	  towards	  the	  other	  end	  of	  the	  motor	  domain	  
bringing	  about	   larger	  conformational	  changes	  at	  the	  switch	   II	  cluster	  (helix	  α4,	   loop	  L12	  
and	  helix	  α5)	  and	  the	  neck	  linker	  region113. In	  the	  present	  structure,	  all	  four	  molecules	  in	  
the	   AU	   (asymmetric	   unit)	   are	   in	   the	   final	   ispinesib-­‐bound	   state. Helix	   α4	   rotates	   and	  
moves	  by	  around	  7	  Å	  in	  the	  inhibitor	  bound	  state	  compared	  to	  the	  native	  structure. The	  
anti-­‐clockwise	  rotation	  and	  shift	  of	  helix	  α4	  rearranges	  the	  switch	  II	  cluster	  and	  opens	  up	  
space	  enabling	  the	  neck	  linker	  to	  dock	  to	  the	  motor	  domain	  locking	  the	  conformation	  of	  
the	  motor	  domain	  and	  slowing	  the	  movement	  of	  kinesin	  along	  the	  MT	  track	  (Figure	  3-­‐2	  
b,c). This	  shows	  that	  ispinesib	  brings	  about	  structural	  changes	  in	  the	  Eg5	  catalytic	  domain,	  
in	  agreement	  with	  other	  structures	  of	  Eg5	  inhibitor	  complexes	  where	  the	  inhibitor	  binds	  
to	  the	  same	  allosteric	  site.119	  
Results 
   
  Sandeep K Talapatra 
89 
	  
Figure	  3-­‐2:	  Overall	  structure	  of	  the	  ADP-­‐Eg5-­‐ispinesib	  ternary	  complex	  (chain	  B).	  	  
a)	   Front	   view	   of	   the	   Eg5	   motor	   domain	   in	   complex	   with	   Mg2+	   (red),	   ADP	   (blue)	   and	   ispinesib	  
(magenta).	  Red	  dotted	  lines	  indicate	  the	  locations	  of	  the	  disordered	  loops	  L10	  and	  L11,	  selected	  
secondary	  structure	  elements	  and	  loops	  are	  labelled.	  b)	  Back	  view	  of	  the	  Eg5	  motor	  domain	  with	  
helix	   α4	   of	   the	   switch	   II	   cluster,	   the	   neck	   linker	   region	   as	   well	   as	   the	   preceding	   helix	   α6	  
highlighted	  in	  magenta.	  c)	  Detail	  view	  of	  helices	  α4	  and	  α6	  as	  well	  as	  and	  the	  neck	  linker	  region	  of	  
the	  Eg5-­‐ispinesib	   complex	   (pink)	   superimposed	  on	   the	  apo-­‐Eg5	   structure	   (blue,	   from	  PDB	  entry	  
1II6	  28).	  
	  
3.1.2.1 Twinning and pseudotranslational symmetry 
One	  bottleneck	   in	  solving	  the	  Eg5-­‐ispinesib	  complex	  structure	  was	  the	   intrinsic	  problem	  
of	  twinning	  and	  pseudotranslational	  symmetry	  with	  the	  crystal	  formation.	  For	  this	  several	  
data	   sets	  were	   collected	   from	  Eg5-­‐ADP-­‐ispinesib	   complex	   crystals,	  most	  of	  which	   could	  
not	   be	   processed	  with	   any	   commonly	   used	   software. The	   data	   presented	   here	   can	   be	  
indexed,	   processed	   and	   scaled	   in	   primitive	   orthorhombic,	   C-­‐centred	   monoclinic	   and	  
primitive	   monoclinic	   space	   groups. Structure	   solution	   in	   orthorhombic	   and	   C-­‐centred	  
monoclinic	   space	   groups	   by	   molecular	   replacement	   in	   these	   space	   groups	   is	   possible,	  
yielding	  reasonable	  models	  initially.	  However,	  refinement	  of	  all	  but	  one	  of	  these	  solutions	  
subsequently	   fails,	   either	   because	   R-­‐values	   cannot	   be	   decreased	   or	   because	   model	  
completion	   requires	   unavoidable	   clashes	   or	   otherwise	   impossible	   molecular	  
arrangements.	  This	  narrowed	  the	  choice	  of	  the	  lattice	  symmetry	  to	  primitive	  monoclinic.	  
Molecular	  replacement	  gave	  a	  plausible	  solution	  in	  P21	  with	  all	  three	  permutations	  of	  cell	  
axis,	   indicative	   of	   pseudosymmetry	   and	   not	   unexpected	   given	   the	   reasonable	   scaling	  
statistics	   of	   the	   higher	   symmetric	   orthorhombic	   solution.	   Two	  of	   the	   three	   cell	   choices	  
allow	   for	  model	   improvement	   through	   iterative	   refinement,	   while	   the	   third	   one	   is	   yet	  
again	  unrefinable. Inspection	  of	  the	  symmetry	  relationships	  between	  protein	  molecules	  in	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the	  P21-­‐refined	  models	   reveals	   three	  orthogonal	   two-­‐fold	  symmetry	  axes,	   two	  of	  which	  
could	  individually	  function	  as	  crystallographic	  symmetry	  elements,	  while	  the	  third	  one	  has	  
a	  screw	  component	  of	  ≈0.38, and	  as	  such	  provides	  only	  non-­‐crystallographic	  symmetry. 
These	   findings	   provide	   an	   explanation	   to	   the	   lack	   of	   refinement	   for	   the	   various	  
orthorhombic	  models	  as	  well	  as	  one	  of	  the	  three	  P21	  axis	  choices.	   
In	   addition,	   the	  P21	  model(s)	   exhibit	   pure	   translational	   (non-­‐crystallographic)	   symmetry	  
based	   on	   the	   Patterson	   function	   revealing	   a	   significant	   off-­‐origin	   peak	   (32.31%)	   of	   the	  
origin	  peak	  that	  almost,	  but	  not	  quite,	  mimics	  a	  face-­‐centering	  operation,	  explaining	  why	  
scaling	   and	   molecular	   replacement	   were	   successful	   in	   C2,	   but	   again	   did	   not	   yield	   a	  
reasonable	   model. In	   addition	   to	   this	   the	   Eg5-­‐ispinesib	   complex	   crystals	   suffers	   from	  
pseudo-­‐merohedral	   twinning,	   as	   suggested	   by	   Britton	   plot207, H-­‐test208 as	   well	   as	   RvR	  
plot209 and	   supported	  by	  a	   significant	  drop	   in	  R/Rfree	  of	  over	  7%	  when	   switching	   from	  
untwinned	  to	  twin	  refinement	  in	  PHENIX,	  with	  the	  twin	  law	  a	  twofold	  axis	  orthogonal	  to	  
the	  crystallographic	  symmetry	  axis	  and	  a	  twin	  fraction	  around	  0.4.	  
Both	   translational	   non-­‐crystallographic	   symmetry	   and	   twinning	   complicate	   structure	  
solution and	  even	  for	  the	  valid	  cell	  choices	  similar,	  refinable,	  but	  non-­‐equivalent	  models	  
were	   obtained	   from	  molecular	   replacement. The	   final	   structure	  was	   selected	   based	   on	  
refinement	   statistics,	   crystallographic	   packing	   and	   precedent	   for	   this	   cell	   choice	   and	  
packing	   in	  the	  PDB	  in	  entry	  2GM122, the	  protein	  component	  of	  which	  was	  subsequently	  
used	  as	  a	  search	  model	  for	  molecular	  replacement.	  
	  
3.1.3 Comparison of ispinesib binding to Eg5 and 
comparision with other allosteric inhibitors 
Ispinesib	   is	  buried	  in	  the	  allosteric	  site	  and	  displays	  numerous	   interactions	  with	  residues	  
of	  the	  inhibitor-­‐binding	  pocket204.	  At	  the	  resolution	  obtained	  for	  our	  structure	  (2.6	  Å)	  we	  
did	   not	   observe	   any	   ordered	   water	   molecules	   in	   close	   proximity	   to	   the	   inhibitor. The	  
benzyl	  moiety	  of	  the	  ligand	  is	  buried	  deeply	  in	  the	  hydrophobic	  part	  of	  the	  pocket	  where	  
it	   stacks	   with	   the	   Pro137	   ring	   and	   has	   an	   edge-­‐to-­‐face	   interaction	   with	   the	   side-­‐chain	  
of	  Trp127,	  as	  well	  as	  hydrophobic	  interactions	  with	  the	  side	  chains	  of	  Tyr211	  and	  Leu214. 
In	   addition	   the	   benzyl	   group	   also	   forms	   an	   intramolecular	   edge-­‐to-­‐face	   stacking	  
interaction	  with	  the	  inhibitor’s	  p-­‐toluyl	  moiety, which	  in	  turn	  stacks	  extensively	  with	  the	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mostly	  flat	  protein	  backbone	  of	  Glu118/Arg119,	  and	  also	  interacts	  with	  parts	  of	  the	  side	  
chains	   of	   Arg119,	   Trp127	   and	   Asp130.	   The	   isopropyl	   group	   of	   ispinesib	   is	   only	   partly	  
buried	   between	   the	   side	   chains	   of	   Tyr211	   and	   Leu214	   as	   well	   as	   the	   backbone	   of	   the	  
latter	  residue	  and	  Glu215. The	  chlorine	  substituent	  of	   the	  7-­‐chloro-­‐3,4-­‐dihydro-­‐4-­‐oxo-­‐3-­‐
(phenylmethyl)-­‐2-­‐quinazolinyl	   sits	   in	   another	  mostly	  hydrophobic	  pocket	   formed	  by	   the	  
backbone	  of	  Gly217	  and	   the	  side	  chains	  of	  Leu160,	  Leu171	  and	  Arg221. In	   three	  of	   the	  
four	  chains	   (B/C/D)	   the	  primary	  amine	  of	   ispinesib	   is	  oriented	  towards	   the	  ADP	  binding	  
site,	  and	  while	   it	   is	  mostly	   solvent	  exposed,	   the	  amine	  can	   interact	   favourably	  with	   the	  
anionic	   Glu116	   side-­‐chain. In	   chain	   A	   on	   the	   other	   hand	   the	   aminopropyl	   moiety	   is	  
disordered. Taken	   together,	   the	   intrinsic	   flexibility	   of	   the	   aminopropyl	   group,	   together	  
with	   the	   observed	   conformational	   variability	   and	   a	   mostly	   solvent	   exposed	   position	  
suggests	   that	   this	   functional	   group	   is	   less	   important	   for	   the	  binding	  of	   ispinesib	   to	   Eg5	  
than	   for	   other	   Eg5-­‐targeting	   compounds	  which	   also	   contain	   this	   primary	   amine. This	   is	  
further	   underlined	   by	   STLC	   and	   related	   analogues:	   in	   this	   case	   the	   primary	   amine	   is	  
absolutely	   essential	   for	   Eg5	   inhibition210 and	   the	   analogue	   with	   the	   tertiary	   amine	  
completely	  abolishes	   inhibition	  whereas	  the	  tertiary	  amine	  in	   ispinesib	   is	  still	  capable	  of	  
inhibiting	   Eg5	   in	   the	   low	  nanomolar	   range211. It	   is	   remarkable	   that,	   aside	   from	   the	   salt	  
bridge	   between	   this	   primary	   amine	   and	   the	   Glu116 carboxylate,	   ispinesib	   makes	  
exclusively	   hydrophobic	   interactions	   with	   the	   protein. In	   this	   context	   it	   is	   particularly	  
noteworthy	  that	  the	  carbonyl	  oxygen	  group	  of	  the	  quinazolin-­‐4-­‐one	  ring	  system	  is	  buried	  
in	  a	  hydrophobic	  pocket	  having	  least	  possibility	  for	  its	  hydrogen	  bonding	  potential. While	  
several	  potential	  weak	  C-­‐H—O	  hydrogen	  bonds	  are	  likely	  to	  at	  least	  partially	  compensate	  
for	   this; the	   replacement	  of	   this	   group	  with	  a	   similarly	   sized	  hydrophobic	  group	   should	  
provide	   improvements	   to	   Eg5	   binding,	   though	   these	   modifications	   would	   have	   to	   be	  
carefully	  balanced	  with	  drug-­‐like	  properties	  (Figure	  3-­‐3a).	  
While	  the	  unavailability	  of	  coordinates/structure	  factors	  precludes	  a	  detailed	  analysis,	   it	  
was	  thought	  to	  be	  informative	  to	  compare	  our	  structure	  to	  the	  previously	  published	  Eg5-­‐
ispinesib	   complex204.	  Overall	   the	   two	  models	   adopt	   a	   similar	   ‘final	   state’	   conformation,	  
though	  the	  previous	  structure	  exhibits	  a	  number	  of	  features	  that	  are	  unusual	  among	  the	  
published	   Eg5	   structures	   and	   not	   replicated	   by	   our	   model. Specifically,	   the	   helices	  
between	   β1	   and	   β1a,	   as	  well	   as	   parts	   of	   the	   central	   β-­‐sheet	   around	   β6/β7	   are	   shifted	  
significantly	   with	   respect	   to	   the	   present	   complex	   structure. Additionally,	   loop	   11	   is	  
ordered	  in	  the	  former	  structure,	  while	  in	  essentially	  all	  other	  Eg5	  complex	  structures	  it	  is	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disordered. Zhang	   et	   al.	   suggest	   that	   these	   differences	   from	   the	   ‘canonical’	   Eg5	  
conformation	   are	   due	   to	   crystal	   contacts, which	   is	   likely	   given	   their	   unique	   unit	   cell	  
dimensions and	   is	   furthermore	   compatible	   with	   these	   features	   being	   absent	   from	   the	  
present	   structure. Based	   on	   the	   discussion	   and	   figures	   provided	   by	   Zhang	   et	   al.,	   the	  
conformation	  and	  binding	  mode	  of	  ispinesib	  appears	  to	  be	  virtually	  identical	  between	  the	  
two	  structures,	  down	  to	  the	  orientation	  of	  the	  flexible	  aminopropyl	  group.	   
To	   further	   investigate	   the	   binding	   mode	   of	   ispinesib, we	   compared	   the	   structure	   of	  
ispinesib-­‐bound	  Eg5	  with	  the	  Eg5	  complex	  structures	  of	  two	  other	  related	  inhibitors, the	  
pyrrolotriazin-­‐4-­‐one-­‐based	   ‘compound	   24’ (PDB	   ID:	   2GM1120)	   as	  well	   as	  MK-­‐0731 (PDB	  
ID:	  2CJO119)	  (Figure	  3-­‐3).	  
Aside	  from	  the	  differences	  in	  the	  core	  ring	  system,	  ‘compound	  24’ is	  virtually	  identical	  to	  
ispinesib	  and	  it	  is	  thus	  not	  surprising	  that	  the	  two	  molecules	  adopt	  similar	  binding	  modes,	  
with	   the	   benzyl,	   the	   p-­‐toluyl	   and	   the	   aminopropyl	   groups	   all	   adopting	   consistent	  
conformations	  and	  making	  equivalent	  interactions	  with	  the	  protein. The	  most	  significant	  
difference	  between	  these	  two	  compounds	  lies	  in	  the	  different	  attachment	  of	  the	  chlorine	  
substituent	   to	   the	   core	   ring	   system,	   partly	   necessitated	   by	   the	   change	   from	   a	  
quinazolinone	   (ispinesib)	   to	   a	   pyrrolotriazinone	   (compound	   24). While	   the	   chlorine	   of	  
ispinesib	   makes	   its	   closest	   contacts	   with	   the	   Leu160	   side-­‐chain	   and	   the	   backbone	   of	  
Gly217,	   the	   chlorine	  of	   compound	  24	  points	  deeper	   into	   the	  binding	  pocket (the	   angle	  
between	   the	   two	   C–Cl	   bonds	   after	   superposition	   is	   ≈104˚)	   where	   it	   interacts	  
predominantly	  with	  the	  side	  chains	  of	  Ile136	  and	  Phe239. Given	  that	  the	  almost	  perfect	  
alignment	  of	  the	  two	  core	  ring	  systems	  after	  superposition	  of	  the	  two	  complex	  structures	  
on	   the	   protein	   component supports	   a	   lack	   of	   excessive	   strain	   due	   to	   the	   presence	   of	  
either	   chlorine,	   thus	   might	   suggest	   that	   either	   compound	   could	   be	   improved	   in	   Eg5	  
affinity	   by	   introducing	   additional	   substitutions	   on	   the	   benzo-­‐	   and	   pyrrolo-­‐ring,	  
respectively. At	   the	   same	   time,	   compound	   24	   is	   almost	   two	   orders	   of	   magnitude	   less	  
potent	  than	  Eg5	  inhibitor	  compared	  to	  ispinesib120,	  which	  might	  mean	  that	  it	  is	  compound	  
24	  rather	  than	  ispinesib	  that	  would	  benefit	  most	  from	  such	  reciprocal	  elaboration.	  
While	   the	   3-­‐phenyl-­‐dihydropyrrole-­‐based	   MK-­‐0731	   at	   first	   glance	   shares	   few	   chemical	  
features	  with	  ispinesib,	  a	  superposition	  of	  the	  two	  Eg5	  complexes	  reveals	  the	  presence	  of	  
several	   congruent	   structural	   elements.	   The	   difluorophenyl	   ring	   of	   MK-­‐0731	   takes	   the	  
place	   of	   ispinesib’s	   quinazolinone	   system,	   with	   one	   fluorine	   mimicking	   the	   chlorine	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substituent	  of	   ispinesib	  and	  the	  second	  fluorine	  superimposing	  reasonably	  well	  with	  the	  
quinazolinone	  oxo	  group,	  though	  due	  to	  the	  smaller	  size	  of	  F	  compared	  to	  Cl	  as	  well	  as	  
the	  steric	  requirements	  of	  the	  rest	  of	  the	  molecule,	  MK-­‐0731	  inserts	  less	  deeply	  into	  the	  
binding	  pocket	   than	   ispinesib	  does.	   The	  unsubstituted	  phenyl	   ring	  of	  MK-­‐0731	  binds	   in	  
the	   general	   area	   occupied	   by	   the	   chemically	   similar	   benzyl	   and	   p-­‐toluyl	   groups	   of	  
ispinesib.	   The	   reduced	   bulk	   and	   the	   positioning	   of	   this	   phenyl	   enable	   the	   side-­‐chain	   of	  
Arg119	   to	   close	   as	   a	   lid	   over	   this	   part	   of	   MK-­‐0731,	   enabling	   favourable	   stacking	  
interactions	   not	   accessible	   to	   ispinesib.	   A	   feature	   unique	   to	   MK-­‐0731	   is	   the	  
hydroxymethyl	   attached	   to	   the	   central	   dihydropyrrole	   ring.	   Introduced	   to	   increase	  
polarity	   and	   thus	   reduce	   hERG	   binding119,	   this	   group	   can	   be	   considered	   as	   related	   in	  
purpose	   to	   the	   aminopropyl	   moiety	   of	   ispinesib, but	   its	   reduced	   intrinsic	   flexibility	  
combined	   with	   local	   steric	   hindrance	   makes	   the	   hydroxymethyl	   a	   potentially	   better	  
choice	  that	  may	  inspire	  similar	  modifications	  in	  future	  ispinesib	  derivatives, though	  they	  
will	   have	   to	   be	   monitored	   for	   possible	   phase	   II	   metabolic	   liabilities.	   Another	   feature	  
unique	  to	  MK-­‐0731	  is	   its	  fluoromethylpiperidine	  ‘side-­‐chain’. While	   it	  does	   interact	  with	  
the	  protein,	  this	  moiety	  is	  mostly	  solvent	  exposed	  and	  as	  such	  enables	  the	  modulation	  of	  
physicochemical	  properties	   and	   thus	   the	  pharmacokinetics	  of	   the	   inhibitor. Despite	   the	  
divergent	  binding	  features, ispinesib	  and	  MK-­‐0731	  are	  remarkably	  similar	  in	  their	  affinity	  
for	   Eg5	   (the	   IC50	   of	  MK-­‐0731	   for	  MT-­‐stimulated	   Eg5	   is	   2	   nM119), suggesting	   again	   that	  










   




Figure	  3-­‐3:	  Interactions	  of	  ispinesib	  with	  the	  Eg5	  inhibitor-­‐binding	  region	  and	  comparison	  with	  other	  inhibitors	  of	  Eg5.  
a)	  Chemical	  structure	  of	  ispinesib	  (left);	  stereo	  view	  of	  ispinesib	  (purple	  sticks)	  bound	  to	  the	  allosteric	  site	  of	  Eg5.	  Side	  chains	  and/or	  backbone	  atoms	  for	  interacting	  
protein	  residues	  are	  shown	  as	  grey	  sticks	  and	  labelled,	  the	  protein	  surface	  is	  displayed	  semi-­‐transparently.	  Unbiased	  (i.e.	  calculated	  prior	  to	  including	  the	  ligand	  in	  
the	  model)	  σA-­‐weighted	  Fo-­‐Fc	  electron	  density	  for	  the	  ligand	  contoured	  at	  2.5σ	  is	  shown	  in	  slate.	  b)	  Chemical	  structure	  (left)	  and	  comparison	  of	  Eg5	  binding	  mode	  
(right)	  of	  “compound	  24”	  (orange).	  c)	  Chemical	  structure	  (left)	  and	  comparison	  of	  Eg5	  binding	  mode	  (right)	  of	  MK-­‐0731	  (orange).	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3.2 Understanding the mechanism of resistance of Eg5 
towards small molecule inhibitors 
Therapeutic	  inactivation	  of	  any	  drug	  target	  in	  an	  actively	  dividing	  cell	  population	  creates	  a	  
natural	   selection	   burden,	   which	   can	   lead	   tumour	   cells	   to	   evolve	   mechanisms	   of	  
resistance. Cytokinetics	   demonstrated	   this	   process	   by	   selecting	   the	   ispinesib	   resistant	  
colorectal	   tumour	   cell	   line	   HCT116.	   This	   resistant	   cell	   line	  was	   obtained	   by	   continuous	  
treatment	   in	   the	   presence	   of	   increasing	   doses	   of	   ispinesib127. Subsequent	   sequencing	  
disclosed	  that	  resistance	  was	  affected	  by	  two	  point	  mutations	  in	  the	  loop	  L5	  region	  of	  the	  
Eg5	   catalytic	   domain,	   D130V	   or	   A133D	   revealing	   a	   possible	   resistance	   mechanism	   for	  
ispinesib. While	  these	  two	  loop	  L5	  mutations	  confer	  resistance	  to	  ispinesib,	  the	  molecular	  
mechanism	  for	  resistance	  is	  unknown.	  	  
To	  understand	  this	  I	  have	  used	  biochemical,	  biophysical	  and	  structural	  data	  to	  explain	  the	  
development	  of	   resistance	  of	   Eg5	   to	  potent	   inhibitor,	   SB743921.	   This	  work	  was	   carried	  
out	  in	  collaboration	  with	  Nahoum	  Anthony	  and	  Simon	  Mackay	  (University	  of	  Strathclyde)	  
and	   formed	   the	   experimental	   basis	   for	   their	   molecular	   dynamics	   simulations	   aimed	   at	  
linking	  experimentally	  determined	  thermodynamic	  behaviour	  with	  structural	  changes	  at	  
molecular	  level.	  	  
3.2.1 Kinetic analysis of Eg5 
The	   kinetic	   parameters	   for	   the	  basal	   and	  MT-­‐stimulated	  ATPase	  activity	   in	   the	   absence	  
and	   presence	   of	   inhibitors	   for	   the	   two	   single	   and	   the	   double	   point	  mutations	   Eg5D130V,	  
Eg5A133D	   and	   Eg5DM	   (the	   A133D,	   D130V	   double	  mutant)	  were	  measured	   and	   compared	  
with	   those	   of	  wild-­‐type	   Eg5	   (Eg5WT) Figure	   3-­‐5a. The	   kcat	   values	   for	   the	  MT-­‐stimulated	  
ATPase	  assays	  of	  the	  mutants	  show	  similar	  rates	  of	  ATP	  turnover	  to	  that	  of	  the	  wild-­‐type	  
Eg5 (5.0	  ±	  0.1	  s-­‐1) with	  about	  1.9-­‐fold	  reduction	  for	  the	  double	  mutant	  (2.7	  ±	  0.1	  s-­‐1). The	  
K0.5,MT	  and	  KM,ATP	  values	  were	  also	  very	  similar	  to	  wild-­‐type	  Eg5	  with	  a	  1.7-­‐fold	  and	  a	  1.6-­‐
fold	  decrease,	  respectively	  (Figure	  3-­‐5b	  and	  c).	  Therefore,	  the	  kinetic	  parameters for	  the	  
MT-­‐stimulated	   ATPase	   activity	   of	   the	   wild-­‐type	   and	   Eg5	  mutants	   display	   no	   significant	  
differences. SB743921 inhibited	  MT-­‐stimulated	  ATPase	  activity	  with	  and	  estimated	  IC50	  of	  
0.14	  ±	  0.001	  nM	  for	  Eg5WT,	  which	  increases	  by	  ∼4300-­‐fold	  to	  607	  ±	  18.5	  nM	  for	  Eg5D130V	  
and	  by	  ~3500-­‐fold	  to	  484	  ±	  26.9	  nM	  for	  Eg5A133D	   (Figure	  3-­‐5d	  and	  e). For	  Eg5DM	  mutant	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there	  was	  no	  inhibition	  by	  SB743921	  observed	  at	  a	  maximum	  inhibitor	  concentration	  of	  
150	  μM	  indicating	  that	  the	  mutations	  work	  synergistically	  rather	  than	  being	  additive.	  The	  
same	  behaviour	  was	  also	  observed	  for	  basal	  ATPase	  assays	  with	  similar	  kcat	  for	  the	  wild-­‐
type	   and	   mutant	   Eg5	   (Figure	   3-­‐4b).	   	   Km,ATP	   increased	   modestly	   (by	   3-­‐5	   fold)	   for	   the	  
mutants	  compared	  to	  the	  wild-­‐type	  but	  the	  effect	  of	  this	  on	  kcat	   is	  small	  compared	  with	  
the	  dramatic	  effects	  on	  inhibition	  by	  SB743921	  .	  For	  the	  single	  mutants,	  resistance	  against	  
ispinesib	   increased	  by	  10-­‐fold	  whereas	   for	   the	  Eg5DM	   it	   increased	  by	  200-­‐fold. We	  were	  
similarly	   able	   to	   demonstrate	   that	   the	   single	   and	   double	   mutants	   fully	   abolish	   the	  
inhibition	   of	   Eg5	   by	   another	   antimitotic	   inhibitor	   STLC,	   indicating	   that	   these	  mutations	  
not	  only	  confer	  resistance	  to	  SB743921,	  ispinesib	  and	  monastrol126,	  but	  also	  to	  other	  Eg5	  
targeting	  agents.	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Figure	  3-­‐4:	  Kinetic	  data	  for	  wild-­‐type	  and	  mutant	  Eg5	  (Basal	  ATPase).	  	  
a)	  Kinetic	  parameters	  for	  wild-­‐type	  and	  mutant	  Eg5	  and	  inhibition	  of	  their	  basal	  ATPase	  activity	  by	  SB743921	  and	  the	  Eg5	  inhibitor	  STLC.	  The	  kcat,	  K0.5,MTs,	  KM,ATP	  and	  
estimated	   IC50	   values	   reported	   represent	   the	  mean	   ±	   standard	   error	   from	   three	   experiments.	   The	   resistance	   factor	   could	   not	   be	   calculated	   because	  we	   did	   not	  
observe	   inhibition	   of	   Eg5DM.	   n.i.:	   no	   inhibition;	  MIA:	  maximum	   inhibition	   attained;	   Rf:	   resistance	   factor.	   b)	   kcat	   and	   KM,ATP	   values	   for	   Eg5WT	   (black),	   Eg5A133D	   (red),	  
Eg5D130V	   (blue)	   and	   Eg5DM	   (green).	   c)	   kcat	   and	   K0.5,MTs	   values	   for	   Eg5WT	   (black),	   Eg5A133D	   (red),	   Eg5D130V	   (blue)	   and	   Eg5DM	   (green).	   d)	   Inhibition	   of	   Eg5WT	   (black)	   by	  
SB743921;	  e)	  Inhibition	  of	  Eg5D130V	  (red),	  Eg5A133D	  (blue)	  and	  Eg5DM	  (green)	  by	  SB743921.	  




















   




Figure	  3-­‐5:	  Kinetic	  data	  for	  wild-­‐type	  and	  mutant	  Eg5	  (MT-­‐stimulated	  ATPase).	  	  
a)	  Kinetic	  parameters	  for	  wild-­‐type	  and	  mutant	  Eg5	  and	  inhibition	  of	  their	  MT-­‐stimulated	  ATPase	  activity	  by	  SB743921	  and	  STLC.	  The	  kcat,	  K0.5,MTs,	  KM,ATP	  and	  estimated	  
IC50	   values	   reported	   represent	   the	   mean	   ±	   standard	   error	   from	   three	   experiments.	   The	   resistance	   factor	   could	   not	   be	   calculated	   because	   we	   did	   not	   observe	  
inhibition	  of	  Eg5DM.	  n.i.:	  no	  inhibition;	  MIA:	  maximum	  inhibition	  attained;	  Rf:	  resistance	  factor.	  b)	  kcat	  and	  KM,ATP	  values	  for	  Eg5WT	  (black),	  Eg5A133D	  (red),	  Eg5D130V	  (blue)	  
and	  Eg5DM	  (green).	  c)	  kcat	  and	  K0.5,MTs	  values	  for	  Eg5WT	  (black),	  Eg5A133D	  (red),	  Eg5D130V	  (blue)	  and	  Eg5DM	  (green).	  d)	  Inhibition	  of	  Eg5WT	  (black)	  by	  SB743921;	  e)	  Inhibition	  
of	  Eg5D130V	  (red),	  Eg5A133D	  (blue)	  and	  Eg5DM	  (green)	  by	  SB743921.	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3.2.2 Calorimetric analysis of SB743921 binding to Eg5WT 
and mutants  
To	  assess	  SB743921	  binding	  to	  the	  wild-­‐type	  and	  mutants	  using	  an	  independent	  method	  
and	  to	  understand	  the	  thermodynamics	  of	  the	  process,	  we	  employed	  ITC. Figure	  3-­‐6 (a-­‐d) 
shows	   the	   calorimetric	   titrations	  of	   SB743921	  with	  Eg5WT,	   Eg5D130V,	   Eg5A133D	  and	  Eg5DM,	  
respectively, whilst	   Figure	   3-­‐6e	   summarises	   the	   measured	   parameters	   of	   SB743921	  
binding. As	  expected	  in	  all	  cases	  the	  stoichiometry	  ≅	  1,	  indicating	  binding	  of	  one	  inhibitor	  
molecule	  per	  Eg5	  catalytic	  domain. Analysis	  of	  the	  enthalpy	  change	  versus	  molar	  ratio	  of	  
SB743921,	   revealed	  an	  apparent	  Kd	   for	  SB743921	  of	  ≤10	  nM	  for	  Eg5WT,	  which	   increases	  
considerably	  to	  543	  ±	  19	  nM	  and	  778	  ±	  7	  nM	  for	  Eg5D130V	  and	  Eg5A133D	  respectively. The	  
affinity	   of	   SB743921	   is	   most	   negligible	   in	   Eg5DM,	   with	   a	   Kd	   of	   approximately	   30.0	   µM.	  
Consistent	  with	  the	  biochemical	  data	  these	  values	  show	  that	  there	  is	  a	  very	  large	  loss	  of	  
binding	  affinity	  in	  the	  mutant	  enzymes.  
The	   most	   striking	   feature	   of	   the	   ITC	   interpretation	   is	   the	   thermodynamics	   of	   binding,	  
which	  is	  distinctive	  for	  the	  Eg5WT	  and	  the	  mutants’	  complexes	  with	  SB743921. The	  ranking	  
of binding	  free	  energy	  (ΔG)	  for	  each	  compound	  replicates	  the	  order	  of	  the	  biochemically-­‐
determined	   IC50	   values	   for	   SB743921, but	   computing	   thermodynamic	   enthalpic	   and	  
entropic	   contributions	   suggests	   that	   the	   forces	   driving	   the	   binding	   processes	   are	   quite	  
different. Mutants	   binding	   to	   SB743921	   have	   enthalpic	   contributions	   that	   are	   more	  
favourable	   than	   the	  wild-­‐type, particularly	   for	   the	   single	  point	  mutations.	   This	  provides	  
evidence	  that,	  despite	  favourable	  interactions	  with	  the	  protein,	  a	  high	  degree	  of	  order	  is	  
imposed	   by	   ligand	   binding	   in	   an	   extreme	   example	   of	   entropy/enthalpy	   compensation.	  
This	  results	   in	  a	  lower	  overall	  ΔG	  and	  weaker	  binding.	   	  This	   is	  mirrored	  in	  the	  molecular	  
dynamics	  simulations	  studies	  carried	  out	  by	  our	  collaborators,	  Dr.	  Nahoum	  Anthony	  and	  
Prof.	  Simon	  Mackay,	  University	  of	  Strathclyde.	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Figure	  3-­‐6:	  ITC	  analyses	  of	  SB743921	  binding	  to	  wild-­‐type	  and	  mutant	  Eg5.	  	  
Raw	   (upper	   panels)	   and	   normalised	   ITC	   data	   for	   titrations	   plotted	   versus	   the	   molar	   ratio	   of	  
inhibitor/protein	   (lower	   panels)	   demonstrating	   saturable	   exothermic	   evolution	   of	   heat	   upon	  
sequential	  additions	  of	  SB743921	  to	  a)	  Eg5WT,	  b)	  Eg5D130V,	  c)	  Eg5A133D	  at	  250	  µM	  and	  d)	  Eg5DM	  at	  
500	  µM.	  Data	  analysis	  using	  Origin	  5.0	  software	  indicates	  that	  the	  binding	  data	  fit	  well	  to	  a	  single	  
binding	  site	  model.	  e)	  Thermodynamic	  parameters	  extracted	  from	  the	  calorimetric	  evaluation	  of	  
wild-­‐type	   or	   mutant	   Eg5	   titrated	   with	   SB743921.	   Experiments	   were	   performed	   at	   least	   in	  
duplicate	  at	  25°C.	  
 
3.2.3 Evaluation of Eg5D130V, Eg5A133D and Eg5DM structures 
and comparision to Eg5WT 
The	  crystal	  structures	  of	  the	  mutants	  were	  compared	  with	  wild-­‐type	  Eg5	  (Eg5WT)	  (PDB	  ID:	  
1II628),	   which	   crystallised	   with	   two	   molecules	   in	   the	   AU.	   In	   the	   binary	   Eg5WT-­‐ADP	  
complex28,	   Asp130	   and	   Ala133	   are	   located	   at	   the	   apex	   of	   loop	   L5. The	   carboxylic	   acid	  
group	   of	   the	  Asp130	   side-­‐chain	   forms	   hydrogen	   bond	   interactions	  with	   the	  main-­‐chain	  
nitrogen	  atom	  of	  Leu132 (2.55	  Å)	  (Figure	  3-­‐7a). Ala133	  is	  the	   last	  residue	  preceding	  the	  
second	  half	   of	   the	   interrupted	  helix	  α2. In	   the	  wild-­‐type	   structure,	   the	  Cβ-­‐atom	  of	   the	  
Ala133	   side-­‐chain	   occupies	   a	   small	   cavity	   bordered	   by	   the	   side	   chains	   of	   Tyr211	   and	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Asp130	   and	   the	   carbonyl	   main-­‐chain	   oxygen	   of	   Glu129. The	   hydroxyl	   or	   Tyr211	   and	  
carboxylate	  of	  Glu129	  do	  not	  appear	  to	  hydrogen	  bond	  directly	  to	  other	  residues	   in	  the	  
protein (Figure	   3-­‐7b).	   In	   summary,	   whereas	   the	   side-­‐chain	   of	   Asp130	   seems	   to	   play	   a	  
more	   structural	   role	   by	   stabilising	   loop	   L5,	   the	   side-­‐chain	   of	   Ala133	   does	   not.	   All	   the	  
above	  analysis	  is	  based	  on	  molecule	  A	  that	  has	  better-­‐ordered	  electron	  density.	  
In	  the	  Eg5D130V-­‐ADP	  complex	  a	  negatively	  charged	  carboxylic	  acid	  side-­‐chain	  is	  replaced	  by	  
a	  hydrophobic	   isopropyl	  group (Figure	  3-­‐7c). Therefore, the	  hydrogen	  bond	   interactions	  
with	  Arg119	  and	  Leu132	  are	  no	  longer	  present	  and	  cannot	  contribute	  to	  the	  stabilisation	  
of	   the	   loop	   L5	   conformation.	   As	   a	   consequence,	   loop	   L5	   seems	   to	   be	  more	   flexible, as	  
witnessed	  by	  the	  absence	  of	  electron	  density	  for	  part	  of	  loop	  L5	  (residues	  120	  to	  124	  in	  
molecule	  A	  and	  residues	  120	  to	  125	  in	  molecule	  B), which	  could	  not	  be	  completely	  built.	  
Despite	   the	   introduction of	   this	   mutation	   and	   the	   loss	   of	   hydrogen	   bonding	   network	  
associated	  with	  the	  wild-­‐type	  carboxylate,	  there	  are	  no	  significant	  changes	  to	  the	  overall	  
or	  local	  structure	  in	  the	  loop	  L5	  region,	  when	  compared	  to	  Eg5WT. 
In	   the	   Eg5A133D-­‐ADP	   complex,	   replacement	   of	   a	   hydrophobic	   methyl	   side-­‐chain	   with	   a	  
carboxylate	   enables	   a	   new	   hydrogen	   bond	   to	   form	   with	   the	   Tyr211	   hydroxyl	   group. 
Interestingly,	   the	  carboxylic	  acid	  group	  of	  Glu129	  sits	  adjacent	  to	  that	  of	  Asp133,	  which	  
implies	  one	  of	  the	  carboxylates	  must	  be	  in	  the	  protonated	  form	  to	  sit	  so	  closely (3.10	  Å	  
apart)	   and	   form	   a	   hydrogen	   bond. These	   new	   hydrogen	   bonds	   contribute	   to	   the	  
stabilisation	  of	   the	   interrupted	  helix	  α2	   regions	  at	   the	   start	   and	  end	  of	   loop	   L5 (Figure	  
3-­‐7d), although	  loop	  L5	  itself	  is	  disordered	  and	  mostly	  absent	  (in	  common	  with	  Eg5D130V). 
Overall,	  the	  crystal	  structure	  remains	  essentially	  unchanged	  when	  compared	  to	  Eg5WT. 
Finally,	   in	   the	  Eg5DM-­‐ADP	  complex	   the	  hydrogen	  bond	  between	   the	  Asp133	  carboxylate	  
and	   the	   hydroxyl	   group	   of	   Tyr211	   seen	   in	   the	   single	   mutant	   is	   present,	   although	   the	  
absence	  of	  Glu129	  through	  disorder	  suggests	  that	  the	  hydrogen	  bonding	  with	  Asp133	  is	  
lost.	   Val130	   appears	   to	   occupy	   a	   similar	   environment	   to	   the	   single	   mutant.	   The	  
conformation	  of	  residues	  125-­‐129	  in	  Loop	  L5	  is	  quite	  different	  to	  the	  wild-­‐type,	  but	  this	  
can	   be	   attributed	   to	   crystal	   contacts	   induced	   through	   the	   presence	   of	   cadmium	   in	   the	  
crystallisation	   buffer.	   Overall,	   there	   are	   no	   significant	   structural	   changes	   in	   the	   motor	  
domain	  of	  the	  double	  mutant	  compared	  with	  Eg5WT.	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Without	  exception,	   the	   r.m.s.	  differences	  between	  molecules	  A	  and	  B	  of	   the	  AU	  of the	  
same	   crystal	   form	   are	   larger	   than	   the	   differences	   between	  molecules	   of	  wild-­‐type	   and	  
mutant	  Eg5,	  which	  suggests	  structural	  changes	  arising	  from	  mutation	  are	  minimal	  (Table	  
3-­‐3). Furthermore,	   the	  mutations	  do	  not	  alter	   the	   conformation	  of	   the	   switch	   II	   cluster	  
(helix	   a4,	   loop	   L12,	   helix	   a5),	   which	   remains	   in	   the	   so	   called	   “obstructive”	   or	   “down”	  
position	  seen	  in	  the	  Eg5WT.	  Similarly, the	  neck	  linker	  region	  is	  undocked	  and	  structured	  in	  
all	  cases. In	  addition, there	  is	  little	  structural	  impact	  on	  the	  overall	  integrity	  of	  the	  kinesin	  
motor, which	   explains	   why	   they	   continue	   to	   function	   normally	   with	   similar	   catalytic	  
parameters	  as	  determined	  in	  the	  biochemical	  studies. Having	  corroborated	  structure	  with	  
catalytic	   function	   in	   the	   unbound	  wild-­‐type	   and	  mutated	   proteins, we	   next	   solved	   the	  
structures	  of	  the	  Eg5WT-­‐SB743921	  and	  Eg5A133D-­‐SB743921	  complexes.  
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Figure	  3-­‐7:	  Loop	  L5	  region	  of	  Eg5WT	  in	  comparison	  with	  Eg5	  mutants.	   
a)	   Loop	   L5	   region	   of	   Eg5WT	   showing	   the	   interactions	   between	   the	   carboxylate	   group	  of	   Asp130	  
with	  Arg119	  and	  Leu132.	  b)	  Loop	  L5	  region	  of	  Eg5WT	  showing	  the	   local	  residues	  close	  to	  Ala133,	  
which	  occupies	  a	  small	  cavity	  bordered	  by	  side	  chains	  of	  Tyr211	  and	  Asp130	  and	  the	  backbone	  of	  
Glu129.	  c)	  Loop	  L5	  region	  of	  Eg5D130V	  showing	  that	  the	  hydrogen	  bond	  interactions	  are	  lost	  when	  
the	  carboxylate	  side-­‐chain	  is	  changed	  to	  an	  isopropyl	  group.	  The	  loop	  becomes	  more	  flexible	  and	  
cannot	  be	  resolved	  as	  a	  consequence.	  d)	  Loop	  L5	  region	  of	  Eg5A133D	  showing	  the	  hydrogen	  bond	  
interactions	   formed	   between	   the	   new	   carboxylate	   and	   the	   side	   chains	   of	   Tyr211	   and	   Glu129.	  
Although	   these	  new	   interactions	   stabilise	   the	  base	  of	   the	   loop	  at	   its	   junction	  with	  helix	  ᾳ2,	   the	  
loop	   itself	   is	   disordered.	   e)	   Loop	   L5	   region	  of	   Eg5DM	   showing	   the	   location	  of	  D130V	  and	  A133D	  
mutations.	  	  As	  with	  the	  single	  A133D	  mutant,	  Asp133	  now	  hydrogen	  bonds	  with	  the	  side-­‐chain	  of	  
Tyr211,	   although	   the	   interaction	  with	   Glu129	   appears	   to	   be	   lost,	   the	   latter	   residue	   now	   being	  
disordered.	  The	   isopropyl	  group	  of	  Val130	  can	  no	   longer	   form	  hydrogen	  bonds	  with	   residues	   in	  
the	  loop,	  which	  reproduces	  the	  effect	  seen	  in	  the	  single	  D130V	  mutant.	  
Results 
   
  Sandeep K Talapatra 
104 
Table	  3-­‐3:	  r.m.s.	  deviations	  in	  Å	  calculated	  for	  wild-­‐type	  and	  mutant	  Eg5	  structures.	  	  
The	  deviations	  were	  calculated	  for	  each	  molecule	  of	  the	  AU.	  N.B.:	  Wild-­‐type	  and	  single	  mutant	  of	  Eg5	  crystallise	  in	  the	  same	  space	  group	  with	  2	  molecules	  
in	  the	  AU,	  while	  Eg5DM	  contains	  only	  one	  molecule	  in	  the	  AU.	  Identical	  pairs	  (A-­‐A)	  are	  coloured	  in	  blue	  (r.m.s.d.:	  0.44	  Å	  to	  0.60	  Å)	  and	  different	  pairs	  (A-­‐B	  or	  
B-­‐A)	  are	  coloured	  in	  red	  (r.m.s.d.:	  0.71	  Å	  to	  0.84	  Å).	  
	  
Coordinates	   1II6	  A	   1II6	  B	   D130V	  A	   D130V	  B	   A133D	  A	   A133D	  B	   DM	  
1II6	  A	   X	   	   	   	   	   	   	  
1II6	  B	   0.78	   X	   	   	   	   	   	  
D130V	  A	   0.60	   0.81	   X	   	   	   	   	  
D130V	  B	   0.84	   0.54	   0.82	   X	   	   	   	  
A133D	  A	   0.49	   0.75	   0.51	   0.80	   X	   	   	  
A133D	  B	   0.73	   0.44	   0.71	   0.49	   0.71	   X	   	  
DM	   0.72	   0.77	   0.80	   0.87	   0.85	   0.78	   X	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3.2.4 Structural determination and comparison of Eg5WT-
SB743921 and EgA133D-SB743921 complexes  
In	  the	  Eg5WT-­‐SB743921	  complex,	  the	  inhibitor	  binds	  in	  an	  allosteric	  pocket	  formed	  
by	  helix	  α2/loop	  L5/helix	  α3	   (Figure	  3-­‐8a).	  When	  comparing	  Eg5WT (PDB	  ID:	  1II6) 
with	  the	  Eg5WT-­‐SB743921	  complex,	  conformational	  changes	  were	  observed	  to	  be	  
similar	   to	   those	   described	   for	   other	   Eg5-­‐inhibitor	   complexes113.	   One	   major	  
difference	   was	   the	   presence	   of	   well-­‐defined	   loop	   L11	   regions	   visible	   in	   both	  
molecules	  of	  the	  AU. Loop	  11	  is	  usually	  highly	  flexible	  and	  not	  defined	  in	  most	  of	  
the	   Eg5	   structures,	   but	   is	   visible	   in	   our	   structures	   due	   to	   crystal	   contacts	   with	  
symmetry	   related	  molecules	   (Figure	   3-­‐8a). In	   the	   Eg5WT-­‐SB743921	   complex,	   the	  
carboxylic	  acid	  side-­‐chain	  of	  Asp130	   forms	  a	  hydrogen	  bond	   interaction	  with	   the	  
main-­‐chain	  nitrogen	  of	  Ser120	  in	  molecule	  A	  (2.77	  Å)	  and	  with	  backbone	  nitrogen	  
of	   Leu132	   (3.07	   Å)	   in	   molecule	   B	   stabilising	   the	   loop	   conformation. In	   the	   two	  
molecules	   of	   the	   AU,	   the	   interactions	   between	   residues	   in	   the	   inhibitor-­‐binding	  
pocket	  and	  SB743921	  are	  virtually	   identical, as	  are	  the	  conformations	  of	   the	  two	  
SB743921	   molecules	   (Figure	   3-­‐8b). SB743921	   is	  buried	   in	   the	   allosteric	   site	  
and	  displays	   a	   variety	   of	   key	   interactions	   with	  residues	   in	  the	   inhibitor-­‐binding	  
pocket	   (Figure	   3-­‐8c,d).	   The	   benzyl	   moiety	   (ring	   A)	   is	   buried	   deeply	   in	   the	  
predominantly	  hydrophobic	  part	  of	  the	  pocket	  stacking	  onto	  the	  Pro137	  ring.	  It	  is	  
also	   appears	   to	   be	   involved	   in	   an	   edge-­‐to-­‐face	   interaction	   with	   the	   side-­‐chain	  
of	  Trp127.	   Tyr211	   is	   in	   close	   proximity	   and	   completes	   the	   aromatic	   cluster.	   The	  
benzyl	  ring	  forms	  an	  intramolecular	  edge-­‐to-­‐face	  interaction	  with	  the	  p-­‐toluyl	  ring	  
(ring	  B)	  that	  occupies	  the	  part	  of	  the	  pocket	  formed	  by	  Trp127,	  Tyr211	  and	  Arg119. 
The	  side	  chains	  of	  Asp130	  and	  Ala133	  are	  4.16	  Å	  and	  5.18	  Å	  away	  and	  unlikely	  to	  
contribute	   to	   the	   binding	   of	   SB743921	   through	   hydrophobic	   interactions	   at	   this	  
distance. The	   chromen-­‐4-­‐one	   ring	  C	   sits	   in	   a	  pocket	  bordered	  by	   the	  main-­‐chain	  
carbonyl	  oxygen	  atoms	  of	  Gly217,	  Leu160,	  Leu171	  and	  the	  side	  chains	  of	  Glu116	  
and	   Leu214. The	   isopropyl	   group	   does	   not	   sit	   near	   any	   residues.	   The	   primary	  
amine	   of	   SB743921	   and	   the	   side-­‐chain	   oxygen	   of	   Glu116	   are	   within	   hydrogen	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bonding	   distance	   (3.15	   Å). At	   this	   resolution	   we	   did	   not	   observe	   any	   water	  
molecules	  in	  close	  proximity	  to	  the	  inhibitor. 	  
Surprisingly,	   in	   the	   Eg5A133D-­‐SB743921	   complex	   the	   inhibitor	   adopts	   the	   same	  
overall	  conformation	  as	  in	  the	  complex	  with	  Eg5WT	  and	  closely	  replicates	  the	  same	  
contacts	  with	  the	  residues	  of	  the	  inhibitor-­‐binding	  pocket	  (Figure	  3-­‐8e,f).	  Like	  the	  
Eg5WT-­‐SB743921	  complex,	  Eg5A133D-­‐SB743921	  has	  a	  well-­‐defined	   loop	  L11	   region.	  
The	   carboxylic	   acid	   side-­‐chain	   of	   Asp130	   forms	   hydrogen	   bond	   interactions	  with	  
Leu132	   (3.07	   Å)	   stabilising	   the	   loop	   in	   the	   mutant	   structure	   as	   in	   the	   Eg5WT	  
complex.	  Interestingly,	  a	  salt	  bridge	  is	  formed	  between	  Glu128	  and	  Lys207	  that	  is	  
not	   observed	   in	   Eg5WT	   contributing	   towards	   a	   more	   compact	   loop	   region.	   The	  
mutation	   of	   Ala133	   to	   Asp	   leads	   to	   the	   carboxylate	   side-­‐chain	   moving	   into	   the	  
inhibitor	  pocket,	  but	  this	  is	  not	  accompanied	  by	  the	  side-­‐chain	  of	  Glu129	  as	  seen	  in	  
the	   unbound	   mutant.	   Rather,	   the	   Glu129	   side-­‐chain	   is	   now	   solvent	   exposed,	  
pointing	  away	  from	  the	  binding	  pocket.	  The	  geometry	  of	  the	  benzyl	  moiety	  (ring	  A,	  
Figure	  3-­‐8c)	  appears	  to	  change	  with	  respect	  to	  the	  Pro137	  ring	  and	  the	  side-­‐chain	  
of	  Trp127.	  Ring	  B	  (Figure	  3-­‐8c)	  still	  occupies	  the	  pocket	  formed	  by	  Trp127,	  Tyr211	  
and	   Arg119	   but	   the	   aromatic	   rings	   are	   further	   apart.	   The	   chromen-­‐4-­‐one	   ring	   C	  
interacts	  with	  the	  same	  pocket	  bordered	  by	  Gly217,	  Leu160,	  Leu171	  and	  the	  side	  
chains	   of	   Glu116	   and	   Leu214,	   although	   the	   distances	   are	   slightly	   different	  
compared	   to	   the	   Eg5WT.	   As	   in	   the	  wild-­‐type	   complex,	   the	   distance	   between	   the	  
primary	  amine	  of	   SB743921	  and	   the	   carboxylate	   side-­‐chain	  of	  Glu116	   (2.64	  Å)	   is	  
compatible	   with	   hydrogen	   bond	   formation.	   We	   observed	   two	   water	   molecules	  
interacting	  with	  the	  inhibitor:	  one	  with	  the	  amide	  oxygen	  atom	  and	  the	  other	  with	  
the	  primary	  amine.	  
One	  of	  the	  unique	  structural	  features	  for	  Eg5DM	  and	  the	  inhibitor	  complexes	  is	  the	  
presence	  of	  cadmium	  ions.	  Cadmium	  is	  not	  a	  physiological	  cation	  but	  was	  found	  to	  
be	   an	   important	   ion	   required	   for	   crystallisation	   in	   these	   structures.	   Cadmium	  
forms	   strong	   co-­‐ordinations	   (4-­‐6)	   with	   the	   side	   chains	   of	   Eg5	   residues	   of	   the	  
molecules	  in	  the	  AU	  and	  symmetry	  related	  molecules	  along	  with	  interactions	  with	  
chloride,	   cobalt	   and	   calcium	   ions.	   It	   also	   has	   interactions	  with	  water	  molecules.	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Having	  greater	  ionic	  strength	  than	  magnesium,	  cadmium	  also	  replaces	  magnesium	  
in	  the	  catalytic	  site.	  
 
Figure	  3-­‐8:	  Crystal	  structures	  of	  wild-­‐type	  and	  mutant	  Eg5	  in	  complex	  with	  SB743921.	  	  
a)	  Overall	  structure	  of	  the	  Eg5	  motor	  domain	  showing	  where	  SB743921	  (magenta	  sticks)	  
binds	  with	  respect	  to	  ADP.	  The	   inhibitor	  binds	  to	  the	   loop	  L5	  region	  that	   interrupts	  helix	  
α2	  and	  is	  bordered	  by	  helix	  α3.	  b)	  Magnification	  of	  the	  allosteric	  binding	  pocket	  of	  Eg5WT	  
in	   molecules	   A	   and	   B	   of	   the	   AU	   illustrating	   that	   SB743921	   has	   a	   very	   similar	   binding	  
configuration	  in	  both	  complexes.	  c)	  Chemical	  structure	  of	  SB743921.	  d)	  View	  of	  SB743921	  
bound	  to	  the	  allosteric	  site	  of	  Eg5WT.	  The	  inhibitor	  is	  represented	  in	  magenta,	   interacting	  
residues	   are	   shown	   in	   green	   and	   the	   protein	   surface	   is	   displayed	   semi-­‐transparently.	   e)	  
Overlay	  of	  the	  allosteric	  site	  showing	  that	  SB743921	  binds	  to	  Eg5WT	  (green	  and	  magenta)	  
and	   Eg5A133D	   (navy	   blue	   and	   cyan)	   to	   form	   a	   very	   similar	   complex.	   f)	   View	   of	   SB743921	  
(cyan)	   bound	   to	   the	   allosteric	   site	   of	   Eg5A133D.	   Residues	   forming	   the	   binding	   pocket	   are	  
coloured	  in	  purple	  and	  the	  protein	  surface	  is	  displayed	  semi-­‐transparently.	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3.3 Studies on a novel allosteric inhibitor-binding 
pocket of Eg5 
As	   previously	   mentioned,	   and	   without	   exception,	   all	   structurally	   characterised	  
allosteric	   inhibitors	  of	  Eg5	  target	  an	  extensively	  studied	  allosteric	  site	  about	  10	  Å	  
away	  from	  the	  ATP	  binding	  pocket	  in	  a	  region	  formed	  by	  helix	  α2/loop	  L5	  and	  helix	  
α3113. A	  significant	  risk	  of	  generating	  multiple	  inhibitor	  resistant	  mutations	  in	  this	  
pocket	   therefore	   exists.	   Indeed,	   as	   was	   shown	   in	   the	   previous	   section,	  mutants	  
generated	   by	   cell	   culture	   in	   the	   presence	   of	   ispinesib	  were	   also	   resistant	   to	   the	  
entirely	  chemically	  unrelated	  STLC	  and	  monastrol	  series	  that	  also	  bind	  at	  this	  site.	  
This	  has	  led	  towards	  studies	  aimed	  at	  identifying	  a	  new	  site	  to	  reduce	  this	  risk.	  BI8	  
(Benzimidazole	   inhibitor	   number	   8)	  was	   among	   a	   series	   of	   new	   compounds	   first	  
identified	   to	   bind	   to	   Eg5	   motor	   domain	   in	   presence	   of	   ispinesib	   and	   ADP	  
suggesting	   that	   they	  might	  bind	   to	  a	   completely	  new	  allosteric	   site.128	   The	   study	  
below	  describes	  the	  novel	   inhibitor-­‐binding	  pocket	  where	  BI8	  binds	  and	  presents	  
the	  opportunity	  to	  develop	  new	  set	  of	  inhibitors	  that	  could	  be	  used	  either	  alone	  or	  
in	   combination	   with	   existing	   Eg5	   compounds.	   Interestingly	   it	   was	   also	   observed	  
that	  these	  inhibitors	  were	  effective	  against	  ispinesib-­‐resistant	  Eg5	  mutant,	  making	  
structural	  characterisation	  of	  the	  ligand-­‐protein	  interactions	  particularly	  valuable.	  	  	  
3.3.1 Kinetic studies of BI8 
The	  benzimidazole	  compound	  BI8	  (Figure	  3-­‐9a)	  was	  a	  potent	  member	  of	  a	  series	  of	  
compound	   identified	   in	   2009212,	  which	   binds	   to	   Eg5	   in	   the	   presence	   of	   ispinesib	  
and	   ADP.	   This	   suggested	   the	   existence	   of	   a	   previously	   undefined	   allosteric	   site,	  
which	  remains	  experimentally	  uncharacterised.	  
Initially,	  the	   inhibition	  of	  basal	  and	  MT-­‐stimulated	  ATPase	  activities	  of	  Eg5	  by	  BI8	  
was	   measured	   to	   estimate	   the	   IC50.	   	   BI8	   inhibition	   was	   shown	   to	   be	   in	   the	  
nanomolar	   range	   (~458	   ±	   28.3	   nM).	   In	   addition,	   it	   was	   observed	   that	   MT-­‐
stimulated	   ATPase	   activity	   was	   influenced	   by	   salt;	   with	   higher	   the	   salt	  
concentration	   lower	   was	   the	   potency	   of	   BI8.	   Figure	   3-­‐9	   shows	   the	   IC50	   and	   salt	  
dependent	  inhibition.	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Figure	  3-­‐9:	  Biochemical	  and	  phenotype	  characterisation	  of	  the	  Eg5-­‐BI8	  complex.	  	  
a)	  Chemical	  structure	  and	  systematic	  name	  of	  the	  benzimidazole-­‐based	  Eg5	  inhibitor	  BI8.	  
b)	  Concentration-­‐response	  plots	   for	   the	   inhibition	  of	   the	  basal	   (left	  panel;	   IC50	  =	  458.8	  ±	  
28.3	  nM)	  and	  c)	  MT-­‐stimulated	  Eg5	  ATPase	  activities	  (right	  panel)	  at	  150	  mM	  NaCl	  (IC50	  =	  
590.2	   ±	   26.0	   nM;	   blue	   circles),	   100	  mM	  NaCl	   (red,	   IC50	   =	   1.3026	   ±	   0.1127	  μM),	   50	  mM	  
(20.993	  ±	  2.02	  nM,	  olive)	  and	  without	  addition	  of	  salt	  (partial	  inhibition;	  black).	  	  
	  
3.3.2  The crystal structure of Eg5-BI8 and comparison with 
the structure of Eg5-ispinesib 
The	  crystal	  structure	  of	  Eg5-­‐BI8	  complex	  unexpectedly	  showed,	  two	  molecules	  of	  
BI8	   bound	   to	   Eg5.	   First	   molecule	   bound	   in	   a	   novel	   pocket	   and	   the	   second	   in	   a	  
pocket	   partially	   overlapping	   the	   known	   ispinesib	   site.	   Electron	   density	   for	   the	  
compound	  at	  both	  sites	  is	  well	  defined.	  
3.3.2.1 The novel Eg5 inhibitor-binding pocket for BI8 binding 
The	   crystal	   structure	   shows	   that	   BI8	   binds	   to	   a	   novel	   inhibitor-­‐binding	   pocket 
formed	   by	   helix α4	   of	   the	   switch	   II	   cluster,	   helix	  α6	   preceding	   the	   neck	   linker	  
region	  and	  β3	  (Figure	  3-­‐10a).	  The	  electron	  density	  map	  for	  the	  inhibitor	  is	  very	  well	  
defined	   (Figure	   3-­‐10b). The	   electron	   density	   map	   for	   the	   inhibitor	   is	   very	   well	  
defined	  with	  the	  entire	  molecule	  apparent	  (Figure	  3-­‐10b).	  The	  neck	  linker	  region	  is	  
undocked	   but	   ordered	   representing	   the	   intermediate	   inhibitor	   bound	   state.	   The	  
structural	  change	  observed	   is	  helices	  α4	  and	  α6	  move	  outwards	  by	  about	  2	  Å	  to	  
accommodate	   the	   inhibitor	   (Figure	   3-­‐10c).	   The	   characteristic	   feature	   of	   the	  
interaction	  between	  the	  inhibitor	  and	  novel	  binding	  pocket	  is	  that	  of	  an	  extensive	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network	   of	   aromatic	   residues	   (Figure	   3-­‐10d).	   Tyr352	   side-­‐chain	   forms	   a	   face-­‐to-­‐
face	  interaction	  with	  the	  imidazole	  ring	  and	  an	  edge-­‐to-­‐edge	  interaction	  with	  the	  
benzyl	   ring	  of	  BI8,	   the	   trifluoromethyl–benzyl	   ring	  has	   an	  edge-­‐to-­‐edge	  aromatic	  
interaction	  with	  Tyr104.	  Analysis	  of	  the	  structure	  using	  the	  Glide	  module	  from	  the	  
Schrodinger	  modelling	  software	  suite	  identified	  these	  aromatic	  residues	  as	  having	  
particularly	  favourable	  interactions	  with	  the	  ligand.	  Among	  other	  interactions,	  the	  
3-­‐fluoro-­‐4-­‐methoxyphenyl	   group	   establishes	   a	   CH-­‐π-­‐interaction	   with	   the	   Leu292	  
side-­‐chain	   (α4). The	   carboxylic	   acid	   group	   is	   solvent	   exposed	   and	   displays	  
hydrogen	  bond	   interactions	  with	  structural	  water	  molecules.	  H-­‐bond	   interactions	  
with	  side	  chains	  of	  Arg297	  and	  Thr300	  are	  mediated	  by	  one	  of	  the	  water	  molecule. 
The	  solvent	  exposed	  nitrogen	  atom	  of	  the	  imidazole	  ring	  makes	  an	  interaction	  with	  
one	   structural	   water	   molecule.	   The	   amino	   group	   of	   the	   methoxyphenyl	   moiety	  
forms	  a	  hydrogen	  bond	  interaction	  with	  the	  hydroxyl	  group	  of	  Tyr104	  (β3). The	  3-­‐
fluoro	   substituent	   of	   the	   methoxyphenyl	   group	   demonstrates	   polar	   interactions	  
with	  the	  side-­‐chain	  of	  Ile288	  and	  the	  main-­‐chain	  oxygen	  of	  Asn289	  (both	  α4). The	  
last	   observed	   H-­‐bond	   interaction	   is	   between	   the	  methoxy	   group	   and	   the	  main-­‐
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Figure	  3-­‐10:	  Characterisation	  of	  the	  novel	  inhibitor-­‐binding	  pocket	  in	  Eg5.	  	  
a)	  Back	  view	  of	  Eg5	  showing	  the	  novel	  allosteric	  binding	  pocket	  occupied	  by	  BI8	  (coloured	  
in	   green),	   formed	   by	   helix	  α4	   of	   the	   switch	   II	   cluster	   and	   helix	  α6,	   preceding	   the	   neck	  
linker.	  b)	  Electron	  density	  omit	  map	  (coloured	  in	  blue)	  contoured	  at	  3	  σ	  for	  BI8	  bound	  in	  
the	   novel	   pocket.	   c)	   Conformational	   changes	   induced	   upon	   binding	   of	   BI8	   in	   the	   helix	  
α4/α6	   pocket	   (blue),	   compared	   to	   native	   Eg5	   (gray).	   d)	   Magnification	   of	   the	   inhibitor-­‐
binding	  pocket.	  BI8	   is	   shown	   in	   green	  and	   residues	   forming	   the	   inhibitor-­‐binding	  pocket	  
are	   coloured	   in	   purple.	  Water	  molecules	   are	   shown	   as	   red	   spheres	   and	   hydrogen	   bond	  
interactions	  are	  shown	  as	  dotted	  lines.	  
 
3.3.2.2 Analysis of the second inhibitor-binding site for BI8 and 
comparison with phase II clinical candidate ispinesib binding  
The	   second	   pocket	   is	   formed	   by	   helices	  α2	   and	  α3	   and	   loops	   L7	   and	   L9	   (Figure	  
3-­‐11a)	  and	  partially	  overlaps	   the	  binding	   site	  of	  well-­‐characterised	  Eg5	   inhibitors	  
such	   as	   ispinesib	   (Figure	   3-­‐11b)	   and	   monastrol.	   Electron	   density	   for	   this	   site	  
appeared	  only	  towards	  the	  end	  of	  the	  refinement	  and	  parts	  of	  the	  molecule,	  such	  
as	   the	   methoxy	   group,	   are	   disordered	   (Figure	   3-­‐11c)	   suggesting	   either	   greater	  
flexibility	   or	   lower	   occupancy	   for	   BI8.	   Although	   loop	   L5	   does	   not	   seem	   to	   be	  
directly	   involved	   in	   inhibitor	   binding	   it	   displays	   a	   new	   conformation	   that	   differs	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from	   the	   ones	   described	   for	   the	   native	   Eg5	   structure	   or	   the	   conformation	  
described	  for	  other	  Eg5-­‐inhibitor	  bound	  complexes	  (Figure	  3-­‐11d).	  Trp127,	  which	  is	  
solvent	   exposed	   in	   the	   native	   Eg5	   structure,	   moves	   by	   7.2	   Å	   (Cα-­‐Cα)	   and	   now	  
interacts	   with	   Asp130	   (loop	   L5)	   and	   Glu215	   (α3).	   The	   upper	   part	   of	   helix	  α3	   is	  
rotated	   by	   approximately	   14° around	   an	   axis	   close	   to	   the	   apex	   of	   the	   helix	   to	  
accommodate	   the	   inhibitor	   leading	   to	  a	   shift	  of	  about	  7	  Å	  at	   the	   top	  of	  helix	  α3	  
(Figure	   3-­‐11d).	   These	   radical	   changes	   on	   BI8	   binding	   have	   not	   been	   observed	  
previously	   with	   any	   other	   Eg5	   structure	   and	   are	   most	   likely	   due	   to	   inhibitor	  
binding.	  In	  contrast	  to	  the	  novel	  site,	  BI8	  binding	  at	  this	  site	  does	  not	  demonstrate	  
the	   network	   of	   aromatic	   interactions	   and	   this	  would	   be	   expected	   to	   reduce	   the	  
binding	  energy	  by	  comparison.	  There	  are	  some	  hydrophobic	   interactions,	  notably	  
with	  the	  side	  chains	  of	  Leu160	  and	  Leu172	  and	  also	  a	  stacking	  interaction	  between	  
Arg221	  and	  the	  methoxybenzene	  group	  of	  BI8.	  Hydrogen	  bonding	  interactions	  are	  
also	  present	  with	   the	  anilinic	  nitrogen	   forming	  a	  water-­‐mediated	  hydrogen	  bond	  
to	   Ser237.	   The	   5-­‐	   carboxylic	   acid	   group	   of	   the	   benzimidazole	   moiety	   is	   solvent	  
exposed	   and	   displays	   several	   hydrogen	   bonds	   with	   nearby	   water	  molecules	   but	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Figure	  3-­‐11:	  Characterisation	  of	  the	  second	  allosteric	  binding	  pocket.  
a)	   Front	   view	   of	   Eg5	   in	   complex	   with	   Mg2+ADP	   (pink)	   and	   BI8	   (green)	   bound	   in	   the	  
allosteric	  inhibitor-­‐binding	  pocket	  formed	  by	  helices	  α2	  and	  α3	  and	  loops	  L7	  as	  well	  as	  L9.	  
BI8	   bound	   in	   the	   novel	   site	   is	   coloured	   in	   grey.	   b)	   Fo-­‐Fc	   omit	   map	   of	   BI8	   bound	   in	   the	  
inhibitor-­‐binding	  pocket,	   contoured	  at	  3σ	   (coloured	   in	  blue).	  The	  methoxy	  group	  has	  no	  
density	   in	   the	   omit	   map	   indicating	   that	   its	   position	   is	   flexible.	   c)	   Binding	   of	   BI8	   to	   the	  
allosteric	  pocket	  leads	  to	  significant	  proximal	  structural	  changes	  in	  loop	  L5	  and	  helix α3.	  d)	  
Stereoplot	  of	  the	  magnification	  of	  the	  inhibitor-­‐binding	  pocket	  showing	  residues	  involved	  
in	  BI8	  binding.	  	  
 
In	   the	   intermediate	   state	   structure,	   local	   changes	   at	  the	  inhibitor-­‐binding	   pocket	  
have	   not	   been	   transmitted	   along	   the	   structure	   to the	   switch	   II	   cluster	   and	  neck	  
linker, which	   is	   trapped	   in	  the	  same	  position	  as	   in	  the	  native	  structure	  undocked	  
and	  perpendicular	  to	  helix	  α6). The	  switch	  II	  cluster (helix	  α4/loop	  L12/helix	  α5)	  is	  
thought	  to	  be	  pivotal	  for	  force	  generation	  by	  translating	  small	  structural	  changes	  in	  
the	   nucleotide	   binding	   pocket	   into	   larger	   conformational	   changes	   in	   the	   neck	  
linker	   region, which	   is	   in	   the	   so	   called	   “down”	   or	   “obstructive”	   position. This	  
causes	  the	  neck	  linker	  region	  not	  to	  dock	  to	  the	  motor	  domain	  that	  minimises	  its	  
ATP	  hydrolysis	  capacity	  and	  in	  turn	  its	  motion.	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Figure	  3-­‐12:	  Comparison	  of	  Eg5-­‐BI8	  and	  Eg5-­‐ispinesib	  complexes.  
a)	  Overlay	  of	  Eg5-­‐BI8	  and	  Eg5-­‐ispinesib	  complexes	  in	  the	  inhibitor-­‐binding	  regions.	  There	  is	  
a	   significant	   overlap	   of	   BI8	   (blue	   colour)	   with	   ispinesib	   (shaded	   in	   green).	   b)	   Important	  
hydrogen	  bonds	  (represented	  by	  black	  broken	  lines)	  within	  4	  Å	  between	  ispinesib	  (green)	  
and	  Eg5	  residues,	  and	  structural	  water	  molecules	  (represented	  by	  red	  spheres)	  are	  shown.	  
Blue	  broken	  lines	  represents	  the	  salt	  bridge	  between	  Glu116	  and	  Arg221,	  which	  stabilise	  
the	  quinazoline	  ring	  of	  the	  inhibitor.	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3.3.3 Isothermal titration calorimetry 
In	  order	  to	  dissect	  the	  contribution	  made	  to	  the	  measured	  biochemical	   inhibition	  
by	  each	  of	  the	  inhibitor-­‐binding	  pockets,	  we	  investigated	  the	  interaction	  between	  
Eg5	   and	   BI8	   using	   ITC	   competition	   assays.	   By	   blockading	   the	   ispinesib	   site	   using	  
saturating	  concentrations	  of	   ispinesib	  and	  then	  titrating	  in	  BI8,	  the	  binding	  of	  BI8	  
to	  the	  novel	  pocket	  can	  be	  isolated	  and	  characterised	  thermodynamically.	  
Firstly,	   the	   “ispinesib	   blockade”	   method	   was	   validated	   by	   demonstrating	   that	  
ispinesib	   could	  block	   the	  binding	  of	   the	   relatively	  weak	   inhibitor,	  monastrol	   that	  
also	  binds	   at	   the	   ispinesib	   site.	   Ispinesib	  was	   injected	   into	   a	   solution	  of	   Eg5	   and	  
potent	  binding	  observed	  with	  a	  Kd	  value	  of	  >	  0.01	  µM	  and	  a	  heat	  of	  binding	  of	   -­‐
5.82	  ±	  0.19	  kcal/mol.	  Monastrol	  was	  then	  titrated	  into	  the	  ispinesib-­‐bound	  Eg5	  and	  
no	  binding	  was	  observed,	  consistent	  with	  the	  ispinesib	  pocket	  being	  fully	  occupied	  
and	   preventing	   the	   less	   potent	   monastrol	   binding.	   The	   reverse	   experiment	   was	  
then	  carried	  out	  with	  monastrol	  being	   injected	  first.	  Although	  the	  Kd	  (14.3	  ±	  0.65	  
µM)	  was	  higher,	  the	  heat	  of	  binding	  (-­‐15.88	  ±	  0.369	  kcal/mol)	  was	  also	  significantly	  
larger	  than	  that	  of	  ispinesib.	  Ispinesib	  was	  then	  titrated	  into	  monastrol-­‐bound	  Eg5	  
and	  an	  isotherm	  was	  observed,	  indicating	  that	  ispinesib	  was	  displacing	  monastrol.	  
The	   heat	   of	   binding	   to	   the	   monastrol	   complex	   was	   endothermic	   (ΔH	   =	   2.2	  
kcal/mol),	  as	  would	  be	  expected	  given	  the	  individual	  heats	  of	  binding	  (Figure	  3-­‐13). 
All	  the	  inhibitors	  bind	  with	  a	  ligand	  protein	  stoichiometry	  of	  1:1.	  
With	   the	   blockade	  method	   validated,	   BI8 was	   injected	   followed	   by	   ispinesib. In	  
contrast	  to	  the	  previous	  experiment,	  ITC	  data	  measured	  by	  titrating	  in	  BI8	  indicate	  
a	  ratio	  of	  BI8	  to	  Eg5	  of	  2:1 with	  the	  data	  being	  best	  modelled	  with	  the	  sequential	  
binding	  of	   two	  molecules	  of	  BI8	   to	  Eg5	   (Figure	  3-­‐13e).	  This	   two-­‐site	  binding	   is	   in	  
agreement	  with	  our	  novel	  crystal	  structure.	  The	  data	  indicate	  the	  existence	  of	  one	  
strong	  (Kd	  =	  0.65	  ±	  0.002	  µM)	  and	  one	  weaker	  (Kd	  =	  27.518	  ±	  3.936	  µM)	  inhibitor-­‐
binding	  pocket.	  Subsequent	  injection	  of	  ispinesib to	  the	  saturated	  preformed	  Eg5-­‐
BI8	  complex	  showed	  that	  ispinesib	  could	  bind	  to	  Eg5	  with	  a	  ratio	  of	  1:1, indicating	  
that	   it	   can	   replace	  BI8	   from	  one	  binding	   site	   only,	   probably	   the	  overlapping	   site	  
(helix	  α2/loop	  L5/helix	  α3)	  (Figure	  3-­‐13f). 	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The	  reverse	  experiment	  in	  which	  ispinesib	  was	  injected	  before	  BI8	  showed	  that BI8	  
(Figure	   3-­‐13g)	   could	   still	   bind	   to	   the	   preformed	   Eg5-­‐ispinesib	   complex	   with	   a	  
binding	   stoichiometry	   of	   1:1 (Figure	   3-­‐13h). The	   data	   indicate	   that	   the	   second	  
allosteric	  binding	  pocket (helix	  α2/loop	  L5/helix	  α3)	   is	  occupied	  by	   ispinesib, BI8	  
with	  its	  significantly	  higher	  Kd	  value	  cannot	  replace	  ispinesib	  but	  only	  can	  bind	  to	  
the	   novel	   pocket	   that	   is	   still	   unoccupied.	   Since	   the	   Kd	   for	   this	   site	   corresponds	  
moderately	  well	  to	  the	  higher	  affinity	  interactions	  from	  the	  titration	  of	  BI8	  alone,	  
we	   hypothesise	   that	   the	   potent	   binding	   event	   responsible	   for	   the	   observed	  
biochemical	   inhibition	  is	  at	  the	  novel	  pocket.	  The	  stoichiometry	  of	  binding	  (N),	  Kd	  
values,	  entropic	  and	  enthalpic	  values	  are	  represented	  in	  Figure	  3-­‐13i.	  




   




Figure	  3-­‐13:	  ITC	  analyses	  of	  ligand	  binding	  to	  Eg5.	  	  
Raw	   isothermal	   titration	   calorimetric	   data	   (upper	  panels)	   and	  normalised	   ITC	  data	   for	   titrations	  plotted	   versus	   the	  molar	   ratio	  of	   titrant/protein	   (lower	  
panels)	  demonstrating	  saturable	  exothermic	  and	  endothermic	  evolution	  of	  heat	  upon	  sequential	  additions	  of	  a)	  monastrol	  (500	  µM)	  and	  b)	  ispinesib	  (500	  
µM)	  to	  Eg5-­‐monastrol	  complex.	  The	  reverse	  experiment	  was	  performed	  by	  sequential	  additions	  of	  c)	  ispinesib	  (500	  µM)	  and	  d)	  monastrol	  (500	  µM)	  to	  Eg5-­‐
ispinesib	  complex.	  Additions	  of	  e)	  BI8	  (500	  µM)	  followed	  by	  f)	  ispinesib	  (500	  µM)	  to	  Eg5-­‐BI8	  complex.	  The	  reverse	  experiment	  with	  sequential	  additions	  of	  
g)	   ispinesib	  (500	  µM)	  and	  h)	  BI8	  (500	  µM)	  to	  Eg5-­‐ispinesib	  complex.	   i)	  Thermodynamic	  cycle	  for	   ligand	  (ispinesib/monastrol)	  binding	  to	  Eg5,	  showing	  the	  
relationship	  between	  the	  enthalpic	  changes	  of	  binding	  on	  monastrol,	  ispinesib	  and	  ispinesib	  competitively	  replacing	  monastrol	  from	  the	  allosteric	  binding	  
site.	  j)	  Summary	  of	  ITC	  data	  for	  BI8	  in	  combination	  with	  two	  other	  Eg5-­‐specific	  inhibitors,	  ispinesib	  and	  monastrol.	  Data	  analysis	  indicates	  that	  the	  binding	  
data	  fit	  well	  to	  a	  two	  binding	  site	  model	  for	  BI8	  and	  a	  single	  binding	  site	  model	  for	  ispinesib.	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3.3.4 SPR analysis of BI8 binding to Eg5 
While	   the	   ITC	  data	   suggests	   that	   physiologically	   relevant	   binding	  of	   BI8	   is	   at	   the	  
novel	   site,	   it	   is	   not	   conclusive	   and	   further	   confirmation	   was	   required.	   Two	   site	  
binding	  of	  BI8	  was	  further	  investigated	  using	  SPR	  to	  determine	  the	  binding	  affinity	  
for	   the	  novel	   site	   and	   if	   possible	   to	  dissect	   the	   two	   sites.	   This	   technique	   further	  
provided	  evidence	  as	  an	  orthogonal	  method	  for	  the	  results	  already	  obtained	  from	  
the	  ITC	  data.	  	  
3.3.4.1 Study of two site binding of BI8 to Eg5 
SPR	   experiments	   were	   performed	   by	   an	   initial	   BI8	   injection	   (Figure	   3-­‐14a) that	  
allowed	   the	  measurement	  of	   steady	  state	  affinity	   for	   the	   two	  sites	  binding	  using	  
the	   best-­‐fit	   model	   that	   gave	   a	   Kd	   values	   of	   470	   nM	   and	   ~34	   μM,	   respectively	  
(Figure	   3-­‐14g)	   comparable	   to	   the	   affinities	   estimated	   from	   ITC	   measurements	  
(Figure	   3-­‐14j). A	   similar	   “ispinesib	   blockade”	   strategy	   to	   that	   used	   in	   the	   ITC	  
experiments	  was	  then	  used	  to	  distinguish	  the	  binding	  affinity	  at	  each	  site.	  Ispinesib	  
injection	  at	  a	  saturating	  concentration	  of	  10	  μM	  (Figure	  3-­‐14c-­‐black)	  after	  the	  BI8	  
injection	   competitively	   removes	   any	   remaining	  BI8	   and	   from	   the	  mutual	   binding	  
site	  or	  blocks	  BI8	  binding	  to	  this	  site	  in	  the	  subsequent	  BI8	  titration	  (helix	  α2/loop	  
L5/helix	   α3). Following	   ispinesib	   injection	   a	   second	   BI8	   injection	   (Figure	   3-­‐14b)	  
allowed	   BI8	   to	   bind	   to	   the	   new	   α4/α6	   site	   identified	   by	   the	   crystal	   structure.	  
Fitting	   the	   second	   BI8	   injection	   data	   with	   one	   site	   steady	   state	   affinity	   model	  
demonstrates	  a	  Kd	  of	  640	  ±	  9.2	  nM	  (Figure	  3-­‐14g). To	  confirm	  that	  ispinesib	  is	  still	  
bound	   to	   Eg5	   during	   the	   latter	   BI8	   injection	   a	   second	   single	   saturating	   ispinesib	  
injection	   was	   performed	   (Figure	   3-­‐14c-­‐red)	   which	   showed	   no	   response	   towards	  
Eg5	   binding	   proving	   that	   ispinesib	   was	   bound	   to	   Eg5	   for	   the	   duration	   of	   the	  
injections. To	  demonstrate	  the	  validity	  of	  the	  “ispinesib	  blockade”	  method	   in	  the	  
SPR	  system,	  a	  similar	  control	  set-­‐up	  was used	  for	  monastrol	  and	  ispinesib	  (Figure	  
3-­‐14d-­‐f). Monastrol	  binding	  to	  Eg5	  was	  first	  measured	  (Figure	  3-­‐14d)	  with	  a	  Kd	  of	  
1.28	  μM	  (Figure	  3-­‐14j). A	  second	  ispinesib	  injection	  at	  10	  μM	  (Figure	  3-­‐14c-­‐black)	  
competitively	  removed	  monastrol	  due	  to	  its	  significantly	  higher	  affinity	  and	  blocks	  
monastrol	   binding	   during	   subsequent	   titration	   of	   monastrol. A	   final	   ispinesib	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injection	   (Figure	   3-­‐14f-­‐red)	   showed	   that	   ispinesib	   of	   the	   first	   injection	   remained	  
bound	  to	  Eg5	  throughout	  the	  entire	  run	  of	  the	  experiment.	   In	  summary	  both	   ITC	  
and	  SPR	  experiments	  confirm	  the	  two	  site	  binding	  of	  BI8	  as	  well	  as	  that	  BI8	  binds	  
to	  the	  novel	  α4/α6	  site	  with	  nanomlar	  affinity.	  	  
	  
Figure	  3-­‐14:	  Binding	   studies	  of	  BI8,	   ispinesib	  and	  monastrol	   to	  double	  histidine	   tagged	  
Eg5	  immobilised	  on	  NTA	  surface.	  	  
a)	   SPR	   binding	   curves	   for	   various	   concentrations	   of	   BI8	   injection	   from	   0	   to	   528	   μM	  
monitored	   on	   a	   surface	   with	   2000	   RU	   of	   double	   histidine	   tagged	   Eg5.	   b)	   SPR	   binding	  
curves	  for	  various	  concentrations	  of	  second	  BI8	  injection	  from	  0	  to	  528	  μM	  monitored	  on	  
a	   surface	   with	   2000	   RU	   of	   double	   histidine	   tagged	   Eg5	   after	   injection	   of	   saturating	  
concentration	   of	   ispinesib	   indicating	   BI8	   binding	   to	   a	   novel	   second	   site.	   c)	   Ispinesib	  
injection	  at	  10	  μM	  before	   (black)	  and	  after	   (red)	   second	  BI8	   injection.	  The	   first	   ispinesib	  
injection	  competitively	  removes	  BI8	  from	  the	  mutual	  site	  which	  allows	  BI8	  to	  bind	  only	  to	  
the	   second	   novel	   site	   whereas	   the	   second	   ispinesib	   injection	   with	   low	   or	   no	   response	  
confirmed	   that	   ispinesib	   remains	   bound	   to	   Eg5	   through	   second	   BI8	   injection.	   d)	   SPR	  
binding	   curves	   for	   various	   concentrations	   of	   monastrol	   injection	   from	   0	   to	   40	   μM	  
monitored	  on	  a	  surface	  with	  2000	  RU	  of	  double	  histidine	  tagged	  Eg5.	  e)	  SPR	  binding	  curves	  
for	  various	  concentrations	  of	  second	  monastrol	  injection	  from	  0	  to	  40	  μM	  monitored	  on	  a	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surface	   with	   2000	   RU	   of	   double	   histidine	   tagged	   Eg5	   after	   injection	   of	   saturating	  
concentration	   of	   ispinesib	   indicating	   monastrol	   cannot	   bind	   as	   monastrol	   has	   lower	  
affinity	   than	   ispinesib	   for	   the	   same	   binding	   site.	   f)	   Ispinesib	   injection	   at	   10	   μM	   before	  
(black)	   and	   after	   (red)	   second	   BI8	   injection.	   The	   first	   ispinesib	   injection	   competitively	  
removes	   monastrol	   from	   the	   allosteric	   inhibitor-­‐binding	   site	   thus	   monastrol	   shows	   no	  
response	   upon	   second	   injection	   and	   second	   ispinesib	   injection	  with	   low	  or	   no	   response	  
confirmed	   that	   ispinesib	   remains	   bound	   to	   Eg5	   throughout	   second	  monastrol	   injection.	  
The	  data	  were	   globally	   ﬁtted	  using	   a	   steady	   state	   affinity	  model	   for	   g)	   2(BI8):1(Eg5).	  All	  
measurement	   for	   SPR	   binding	   were	   reference	   corrected	   and	   model	   for	   steady	   state	  
binding	  suggested	  good	  fit	  with	  χ2	  around	  ≥	  10.	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3.4 MPP1 
3.4.1 Human MPP1 
3.4.1.1 Physodic acid discovered as an inhibitor of human mitotic 
kinesin MPP1 
3.4.1.1.1 MPP1 expression and purification 
	  
Human	   MPP1	   is	   a	   protein	   with	   1781	   residues.	   It	   contains	   a	   N-­‐terminal	   motor	  
domain	  (aa	  56	  to	  486)	  with	  the	  characteristic	   loop	  L6	  insertion	  (aa	  186	  to	  262),	  a	  
particularly	  long	  discontinuous	  coiled	  coil	  region	  (aa	  568	  to	  1516)	  and	  a	  C-­‐terminal	  
globular	   domain	   (aa	   1517	   to	   1780) (Figure	   3-­‐15a).	   Two	   MPP1	   constructs	   were	  
cloned,	   one	   coding	   for	   residues	   1	   to	   477,	   which	   include	   the	   small	   N-­‐terminal	  
domain	  of	  unknown	  function	  (residues	  1	  to	  56)	  preceding	  the	  motor	  domain.	  The	  
second	   construct	   contained	   residues	   57-­‐491	   that	   encode	   a	   protein	   covering	   the	  
MPP1	  motor	  domain	  (named	  MPP157-­‐491)	  and	  part	  of	  the	  neck	  linker	  (Figure	  3-­‐15a	  
and	  b).	  They	  were	  transformed	  into	  an	  E.	  coli	  expression	  vector for	  expression	  and	  
purification	   and	   the	   proteins	   were	   used	   for	   further	   experiments.	   Mass	  
spectrometry	   fingerprint	   analyses	   with	   sequence	   coverage	   of	   56	   %	   and	   77	   %	  
confirmed	  that	  the	  two	  purified	  proteins	  were	  human	  MPP1.	  Gel	  filtration	  analysis	  
revealed	  that	  MPP11-­‐477	  (51	  kDa)	  and	  MPP157-­‐491	  (43	  kDa)	  were	  both	  monomeric	  in	  
solution	  (Figure	  3-­‐15b	  and	  c).	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Figure	  3-­‐15:	  Bar	  diagram	  of	  full	  length	  MPP1	  and	  two	  expressed	  MPP1	  motor	  domains.	  	  
a)	  Bar	  diagram	  of	  human	  MPP1.	  MPP1	  has	  a	  small	  N-­‐terminal	  domain	  of	  unknown	  function	  
(aa	   1-­‐56)	   preceding	   the	   motor	   domain	   (aa	   57-­‐486).	   The	   motor	   domain	   contains	   an	  
unusually	   long	   insertion	   in	   the	   loop	   L6	   region,	   which	   is	   unique	   for	   kinesin-­‐6	   family	  
members,	  and	  nucleotide	  binding	  as	  well	  as	  MT	  interacting	  regions.	  The	  motor	  domain	  is	  
followed	  by	   a	   stalk	   domain	  predicted	   to	   form	  a	  discontinuous	   coiled	   coil	   (aa	  568-­‐1515).	  
The	  globular	  C-­‐terminal	  domain	  (aa	  1516-­‐1780)	  contains	  a	  phosphorylation	  site	  (Thr1604)	  
and	  the	  Pin1	   interacting	  region.	  Two	  MPP1	  constructs	  were	  used	   in	  this	  study:	  MPP11-­‐477	  
covers	   the	  small	  N-­‐terminal	   region	  and	  the	  motor	  domain,	  whereas	  MPP157-­‐491	   codes	   for	  
the	  motor	  only.	  SDS-­‐PAGE	  of	  motor	  protein	  constructs	  after	  gel	  filtration	  -­‐	  b)	  MPP11-­‐477	  c)	  
MPP157-­‐491.	  Mass	   spectrometry	   confirmed	   both	   the	   proteins	   and	   the	   low	   percentage	   of	  
degraded	  product	  that	  was	  obtained	  after	  purification	  of	  MPP11-­‐477.	  
	  
3.4.1.1.2 Steady state ATPase measurements and determination 
of IC50 values 
	  
To	   optimise	   the	   experimental	   conditions	   for	   inhibitor	   screening	   and	   further	  
inhibition	  assays	  we	  first	  investigated	  the	  basic	  kinetic	  parameters	  of	  MPP11-­‐477	  and	  
MPP157-­‐491 (Table	  3-­‐4	  and	  Figure	  3-­‐16).	   The	   salt-­‐dependence	  of	   the	  basal	  ATPase	  
activity	   by	  measuring	   the	   kcat	   in	   the	   presence	   of	   increasing	   NaCl	   concentrations	  
was	  determined.	   The	  activity	  of	  MPP1	  was	   seen	   to	  decrease	  with	   increasing	   salt	  
concentration	   indicating	   that	   the	  basal	  MPP1	  ATPase	  activity	   for	  both	  proteins	   is	  
best	  measured	   in	   the	  absence	  of	   salt	   (Figure	  3-­‐16a). The	  basal	  ATPase	  activity	   in	  
the	   presence	   of	   increasing	   ATP	   concentrations,	   in	   the	   absence	   of	   salt,	  was	   then	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determined	   to	   analyse	   the	   kinetic	   parameters	   of	   the	   MPP1	   constructs. The	  
maximum	  kcat	  is	  0.016	  ±	  0.001	  s-­‐1	  with	  an	  KM,ATP	  of	  685	  ±	  16	  µM	  for	  MPP11-­‐477	  and	  a	  
kcat	  of	  0.010	  ±	  0.001	  s-­‐1	  with	  a	  KM,ATP	  of	  128	  ±	  2.1	  µM	  for	  MPP157-­‐491.	  Subsequently,	  
the	  MT-­‐stimulated	  ATPase	  measurements	  led	  kcat values	  of	  3.1	  ±	  0.2	  s-­‐1	  and	  4.1	  ±	  
0.1	   s-­‐1	   for MPP11-­‐477	   and	  MPP157-­‐491,	   respectively,	   corresponding	   to	   193-­‐fold	   and	  
410-­‐fold	  stimulations	  compared	  to	  the	  basal	  ATPase	  activities.	  KM,ATP	  values	  of	  44	  ±	  
4	  µM	  and	  82	  ±	  2	  µM	  (Figure	  3-­‐16c) and	  K0.5,MT	  	  values	  of	  102	  ±	  3	  nM	  and	  112	  ±1	  nM	  
were	  determined	  for	  MPP11-­‐477	  and	  MPP157-­‐491,	  respectively	  (Figure	  3-­‐16d).	  
	  
	  
Figure	  3-­‐16:	  Characterisation	  of	  the	  basal	  and	  MT-­‐stimulated	  ATPase	  activity	  of	  MPP1.	  	  
a)	   Effect	   of	   the	   NaCl	   concentration	   on	   the	   basal	   ATPase	   activity	   of	   MPP11-­‐477	   ()	   and	  
MPP157-­‐491	   (ο)	   at	   saturating	  ATP	  concentration	  of	  2	  mM.	  b)	  The	  basal	  ATPase	  activity	   for	  
MPP11-­‐477	   ()	   and	   MPP157-­‐491	   (ο)	   in	   the	   presence	   of	   increasing	   ATP	   concentration,	  
measured	   in	   the	   absence	   of	   salt,	   NaCl.	   c)	   Determination	   of	   the	   MT-­‐stimulated	   ATPase	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activity	  of	  MPP11-­‐477	   ()	  and	  MPP157-­‐491	   (ο)	  d)	  MT-­‐stimulated	  ATPase	  activity	  of	  MPP11-­‐477	  
()	  and	  MPP157-­‐491	  (ο)	  at	  increasing	  MT	  concentrations.	  
Results 
   





Table	  3-­‐4:	  Basal	  and	  MT-­‐stimulated	  steady	  state	  ATPase	  activity	  of	  MPP1	  proteins	  
 
	  
















MPP11-­‐477	   56	   51	   0.016	  ±	  0.001	   68.5	  ±	  16.2	   3.1	  ±	  0.2	   44	  ±	  4.1	   102	  ±	  3.2	  
MPP157-­‐491	   77	   43	   0.0103	  ±	  0.001	   128	  ±	  2.1	   4.1	  ±	  0.1	   82	  ±	  2.3	   112	  ±	  1.0	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3.4.2 Identification of compound inhibiting MPP1 
Screening	   for	  MPP1	   inhibitors	  was	  performed	  by	  measuring	   the	   inhibition	  of	   the	  
basal	  ATPase	  activity	  in	  the	  absence	  of	  salt	  and	  in	  the	  presence	  of	  1	  mM	  ATP	  using	  
the	   protein	   construct	   MPP157-­‐491.	   Several	   small	   molecule	   libraries	   from	   the	  
National	  Cancer	  Institute	  (NCI),	  USA	  were	  screened	  including	  the	  mechanistic,	  the	  
structural	   diversity	   and	   the	  natural	   product	   sets	   and	   full	   details	   are	  described	   in	  
the	   materials	   and	   methods	   section.	   61	   hits	   were	   obtained	   in	   the	   single	   point	  
primary	   screen	   from	   a	   total	   of	   2520	   compounds.	   A	   repetition	   of	   the	   primary	  
screening	  was	  performed	  to	  confirm	  the	  initial	  hits	  and	  15	  compounds	  were	  found	  
to	  still	  inhibit	  MPP1.	  A	  schematic	  representation	  is	  given	  in	  Figure	  3-­‐17.	  
3.4.2.1.1 Cytophos assay  
	  
To	   further	  confirm	  the	  15	  primary	  hits	  as	   inhibitors	  of	  MPP1	  a	  secondary	  screen,	  
the	  Cytophos	  assay,213	  was	  used.	  The	  Cytophos	  assay	  relies	  on	  the	  formation	  of	  a	  
Malachite	   green/phosphate	   complex	   instead	   of	   a	   coupled	   redox	   reaction.	   This	  
provides	  a	  useful	  partially	  orthogonal	  assay	  system	  and	  eliminates	   false	  positives	  
due	  to	  lactate	  dehydrogenase	  and	  pyruvate	  kinase	  inhibition.	  Table	  3-­‐5	  shows	  the	  
inhibition	  profiling	  of	   the	  15	   compounds.	  Compounds	   that	   showed	  50%	  or	  more	  
inhibition	   were	   selected	   for	   the	   subsequent	   analysis.	   13	   compounds	   inhibited	  
MPP1	  while	   the	   remaining	   two	  had	  no	  effect	   on	  MPP1	  activity.	   Several	   of	   these	  
compounds	  have	   issues	  with	  drug-­‐like	  properties	  but	  some	  represent	   reasonable	  
starting	  points.	  Interestingly,	  when	  these	  compounds	  were	  measured	  to	  see	  their	  
effect	   on	   Eg5	   and	   MKLP-­‐2	   activity,	   10	   were	   found	   to	   also	   inhibit	   either	   Eg5	   or	  
MKLP-­‐2.	  Thus,	  3	  compounds	  were	  finally	  found	  to	  specifically	  inhibit	  MPP1.	  Among	  
them	  Norlobaric	  acid	  was	  selected	  for	  further	  SAR	  study	  due	  to	  it	  being	  the	  most	  
potent	  compound,	  having	  reasonable	  drug-­‐like	  properties	  (logP,	  molecular	  weight,	  
solubility,	  net	  charge)	  and	  commercial	  availability	  of	  analogues.	  Table	  3-­‐5	  provides	  
the	   details	   of	   the	   secondary	   screening	   of	   compounds	   targeting	   MPP1.	   It	   also	  
provides	  specificity	  measurements	  identifying	  three	  compounds,	  which	  only	  inhibit	  
MPP1	  activity.	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Table	  3-­‐5:	  Inhibition	  profiling	  of	  13	  compounds	  against	  MPP1	  activity	  using	  Cytophos	  assay.	  
15	  compounds	  obtained	  from	  primary	  screening	  were	  tested	  by	  Cytophos	  assay	  as	  a	  secondary	  screening	  method.	  13	  out	  of	  15	  were	  identified	  to	  inhibit	  
MPP1	  and	  two	  (green)	  did	  not	  inhibit	  MPP1.	  These	  compounds	  were	  also	  measured	  for	  inhibition	  of	  Eg5	  and	  MKLP-­‐2	  ATPase	  activities.	  10	  compounds	  were	  
found	  to	  inhibit	  Eg5	  and/or	  MKLP-­‐2	  whereas	  3	  compounds	  were	  specific	  to	  MPP1.	  Norlobaric	  acid	  (NSC	  31867)	  with	  the	  highest	  potency	  was	  selected	  for	  
further	  SAR	  and	  specificity	  studies.	  The	  other	  consideration	  for	  selecting	  Norlobric	  acid	  was	  the	  availability	  of	  analogues	  for	  further	  biochemical	  studies.	  n.i.	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86.9	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Figure	  3-­‐17:	  Schematic	  representation	  of	  inhibitor	  screening	  against	  MPP1	  activity.	  
The	  figure	  gives	  a	  representation	  of	  the	  inhibitor	  screening	  of	  MPP1	  performed	  on	  2520	  
compounds	   from	   the	   NCI.	   The	   primary	   screening	   with	   ATPase	   activity	   assay	   and	   the	  
secondary	   screening	   (Cytophos	   assay)	   identified	   13	   hits	   of	   MPP1	   that	   were	   further	  
narrowed	  down	  to	  three	  hits	  after	  determining	  the	  specificity	  against	  Eg5	  and	  MKLP-­‐2.	  
Consequently,	  Norlobaric	  acid	  with	  the	  maximum	  inhibition	  against	  MPP1	  was	  selected	  
for	  further	  SAR	  studies.	  
	  
3.4.3 Initial SAR study of inhibitor analogues of Norlobaric 
acid 
Selection	  of	  Norlobaric	  acid	  led	  to	  the	  identification	  of	  a	  series	  of	  11	  structurally	  
related	  depsidones	  and	  depsides	  through	  similarity	  and	  substructure	  searching	  of	  
commercial	  and	  non-­‐commercial	  databases.	  Depsides	  get	  their	  name	  due	  to	  the	  
presence	   of	  polyphenyls	   composed	   of	   two	   or	   more	  monocyclic	  aromatic	  units	  
linked	   by	   an	  ester	  bond.	   Similarly	   depsidones	   have	   a	   similar	   structure	  with	   the	  
presence	  of	  a	  cyclic	  ester.	  Both	  depsides	  and	  depsidones	  are	  naturally	  occurring	  
compounds	   obtained	   from	   lichens.	   Examples	   for	   depsides	   and	   depsidones	   are	  
shown	   in	   Figure	   3-­‐18.	   These	   compounds	  were	   either	   obtained	   commercially	   or	  
from	  the	  NCI.	  Some	  of	  the	  compounds	  have	  also	  been	  synthesised	  by	  Dr.	  Sophie	  
Tomasi	  and	  her	  group,	  CNRS,	  France.	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Figure	  3-­‐18:	  Structure	  of	  depsides	  and	  depsidones.	  
a)	  The	  structure	  of	  the	  depside	  Atranorin	  shows	  the	  monocyclic	  aromatic	  units	  linked	  by	  
an	  ester	  bond.	  b)	  The	  structure	  of	   the	  depsidone	  Lobaric	  acid	  shows	  a	  similar	  structure	  
to	  that	  of	  depsides	  but	  with	  the	  presence	  of	  an	  additional	  seven	  ring	  cyclic	  ester.	  
	  
SAR	   study	  of	   11	   analogues	  was	  performed	  with	   the	  determination	  of	   their	   IC50	  
values	   for	   the	   inhibition	   of	   the	   basal	   and	  MT-­‐stimulated	  ATPase	   activity	   (Table	  
3-­‐6).	  
Among	  the	  11	  compounds,	  Physodic	  acid	  (1)	  was	  the	  most	  active,	   inhibiting	  the	  
basal	  and	  MT-­‐stimulated	  ATPase	  activities	  with	   IC50	  values	  of	  4.6	  ±	  0.8	  µM	  and	  
10.7	  ±	  1.7	  µM,	  respectively.	  The	  depsides	  Atranorin	  (7)	  and	  Diffractaic	  acid	  (8)	  did	  
not	  inhibit	  MPP1	  ATPase	  activity.	  	  
Analysis	  of	  the	  structure	  of	  these	  compounds	  and	  their	  relation	  to	  the	  inhibiton	  
of	  MPP1	  activity	  revealed	  that	  the	  most	  active	  MPP1	  inhibitors	  such	  as	  Norlobaric	  
acid	   (1),	   Physodic	   acid	   (2)	   and	   Lobaric	   acid	   (9)	   contain	   2	   alkyl	   substituents.	  
Physodic	  acid	   shares	  a	  high	  structural	   similarity	   to	   the	   initial	   inhibitor	  of	  MPP1,	  
Norlobaric	  acid.	  The	  differences	  are	  the	  rearrangement	  of	  a	  keto	  group	  on	  one	  of	  
the	  two	  alkyl	  chains	  and	  addition	  of	  a	  carboxyl	  group	  to	  one	  of	  the	  aromatic	  rings.	  
The	   depsidones	   Variolaric	   acid	   (10),	   Salazinic	   acid	   (4),	   Stictic	   acid	   (5)	   and	  
Norstictic	   acid	   (6),	  which	   contain	   an	   additional	   five-­‐membered	   ring	   system	  but	  
lack	  the	  alkyl	  chains	  are	  either	  weak	  inhibitors	  of	  MPP1	  or	  are	  inactive	  which	  may	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be	  due	  to	  the	  loss	  of	  the	  alkyl	  chain.	  The	  depsides	  used	  in	  this	  study	  also	  showed	  
no	  effect	  on	  the	  activity	  of	  MPP1	  suggesting	  the	  important	  role	  of	  the	  alkyl	  chains	  
in	  inhibiting	  MPP1	  (Figure	  3-­‐19).	  	  
To	   test	   the	  specificity	  of	  Physodic	  acid	   for	  MPP1,	   the	   inhibition	   for	  13	  available	  
kinesins	  was	   investigated.	  Table	  3-­‐7	   represents	   the	  specificity	  measurements	  of	  
Physodic	  acid	  against	  the	  13	  human	  kinesins.	  
	  
Figure	  3-­‐19:	  Inhibition	  of	  MPP-­‐154-­‐491	  ATPase	  activity	  by	  depsidones.  
a)	   Inhibition	   of	   basal	   ATPase	   activity	   of	   MPP-­‐1	   by	   Norlobaric	   acid	   (NSC31867,	   ),	  
Physodic	   acid	   (NSC5916,	  )	   and	   Parellic/Psoromic	   acid	   (NSC92186,	   ▪).	   b)	   Inhibition	   of	  
MT-­‐stimulated	  ATPase	  activity	  of	  MPP-­‐1	  by	  Norlobaric	  acid	  (NSC31867,	  ),	  Physodic	  acid	  
(NSC5916,	  )	  and	  Parellic	  acid	  (NSC92186,	  ▪).	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Table	  3-­‐6:	  SAR	  study	  of	  depsidones	  and	  depsides	  from	  lichen	  as	  potential	  inhibitors	  of	  human	  MPP1.	  	  
The	   inhibition	   of	   the	   basal	   and	  MT-­‐stimulated	  MPP1	   ATPase	   activities	   for	   two	   protein	   constructs,	  MPP157-­‐491	   and	  MPP11-­‐477	   are	   shown.	  MIA:	  Maximum	  




Structure	   Inhibition	  of	  

















18.7	  ±	  2.6	  
	  
24.4	  ±	  3.5	   10.8	  ±	  1.7	  
	  






5.4	  ±	  0.5	   5.8	  ±	  0.9	   10.4	  ±	  1.7	  
	  




Stictic	  acid	   	  
n.i.	  
	  
52.1	  ±	  19.3	   n.i.	  
	  







32.8	  ±	  7.8	   50.6	  ±	  5.4	  
	  




Salazinic	  acid	   	  
24.8	  ±	  4.0	   49.8	  ±	  11.2	   31.4	  ±	  3.8	  
	  
74.1	  ±	  15.8	  
	  
Results 
   




Diffractaic	  acid	   	  
n.i.	   n.i.	  
	  




	   	  
n.i.	  
	  





	   	  
n.i.	  
	  
16.6	  ±	  2.8	   n.i.	  
	  






63.6	  ±	  6.6	  
	  
29.2	  ±	  8.8	   77.3	  ±	  12.6	  
	  





23.7	  ±	  3.1	   16.0	  ±	  3.4	   13.0	  ±	  1.9	  
	  














5.4	  ±	  2.3	   17.8	  ±	  2.2	   4.6	  ±	  1.0	  
	  




acid	   	  
n.i.	  
	  
58.8	  ±	  11.4	   13.9	  ±	  2.8	  
	  
36.7	  ±	  9.2	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Table	  3-­‐7:	  Specificity	  of	  Physodic	  acid	   tested	  on	  the	   inhibition	  of	   the	  basal	  and	  MT-­‐
stimulated	   ATPase	   activities	   of	   a	   variety	   of	   human	   kinesins	   involved	   in	   mitosis	   or	  
intracellular	  transport.	  
	  







MPP157-­‐491	   kinesin-­‐6	   90	   90	  
Kif15	   kinesin-­‐12	   n.i.	   n.i.	  
Eg5	   kinesin-­‐5	   n.i.	   n.i.	  
MKLP-­‐1	   kinesin-­‐6	   20	   40	  
MKLP-­‐2	   kinesin-­‐6	   n.i.	   n.i.	  
Kif7	   kinesin-­‐4	   20	   n.i.	  
Kif27	   kinesin-­‐4	   20	   n.i.	  
CENP-­‐E	   kinesin-­‐7	   50	   60	  
Kif5A	   kinesin-­‐1	   n.i.	   n.i.	  
Kif5C	   kinesin-­‐1	   20	   n.i.	  
Kif3b	   kinesin-­‐2	   20	   40	  
Kif9	   kinesin-­‐9	   40	   50	  
Kif4	   kinesin-­‐4	   40	   40	  
Kif24	   kinesin-­‐13	   10	   5	  
	  
3.4.3.1.1 Determination of the type of inhibition of physodic 
acid for MPP1 in the absence and presence of MTs 
	  
The	  screen	   identified	  physodic	  acid	  as	  the	  most	  potent	   inhibitor	  of	  MPP1.	  The	  
assay	  was	  then	  used	  to	  determine	  the	  type	  of	  inhibition.	  In	  the	  absence	  of	  MTs,	  
physodic	  acid	  is	  an	  uncompetitive	  inhibitor	  of	  MPP1	  with	  respect	  to	  ATP	  (Figure	  
3-­‐20a).	  Similarly,	  in	  the	  presence	  of	  MTs,	  physodic	  acid	  is	  also	  an	  uncompetitive	  
inhibitor	   of	  MPP1	   with	   respect	   to	   ATP	   (Figure	   3-­‐20b).	   In	   all	   experiments	   the	  
highest	   concentration	   of	   ATP	   was	   fixed	   well	   above	   the	   Km,ATP	   for	   MPP1.	   In	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Figure	  3-­‐20: Type	  of	  inhibition	  of	  MPP-­‐154-­‐491	  ATPase	  activity	  measured	  with	  Physodic	  
acid.  
a)	   The	   type	   of	   inhibition	   determined	   in	   the	   absence	   of	   MTs	   at	   increasing	   ATP	  
concentrations.	  Physodic	  acid	  is	  uncompetitive	  with	  respect	  to	  ATP	  as	  shown	  by	  (●)	  0;	  
(■)	   1	   μM;	   (♦)	   5	   μM;	   (▲)	   10	   μM;	   (◊)	   20	   μM	   of	   inhibitor	   concentration	   at	   increasing	  
concentrations	   of	   ATP	   up	   to	   2	   mM.	   b)	   The	   type	   of	   inhibition	   determined	   in	   the	  
presence	  of	  MTs	  at	  increasing	  ATP	  concentrations.	  Physodic	  acid	  is	  uncompetitive	  with	  
respect	  to	  ATP	   in	  the	  MT-­‐stimulated	  ATPase	  assay	  as	  shown	  by	  (●)	  0;	   (■)	  1	  μM;	  (♦)	  5	  
μM;	   (▲)	  10	  μM;	   (◊)	  20	  μM	  of	   inhibitor	  concentration	  at	   increasing	  concentrations	  of	  
ATP	   up	   to	   2	   mM.	   c).	   Physodic	   acid	   demonstrates	   mixed	   inhibition	   for	   MPP1	   with	  
respect	   to	   MTs	   as	   shown	   by	   (●)	   0;	   (■)	   1	   μM;	   (♦)	   5	   μM;	   (▲)	   10	   μM;	   (◊)	   20	   μM	   of	  
inhibitor	  concentration	  at	  increasing	  concentrations	  of	  MTs	  up	  to	  20	  µM.	  
	  
The	   molecules	   described	   here	   do	   not	   have	   ideal	   drug-­‐like	   properties.	   They	  
contain	  undesirable	  substructures	  such	  as	  aldehyde	  groups,	  which	  are	  known	  to	  
be	   reactive,	   or	   esters	   that	   are	   prone	   to	   hydrolysis.	   However,	   the	   selectivity	  
exhibited	  suggests	  a	  genuine	   inhibitory	  effect	  and	  further	  characterisation	  will	  
be	  necessary	  to	  demonstrate	  this.	  
3.4.3.2 Crystallisation trials 
The	  crystal	  structure	  of	  the	  MPP1	  motor	  domain	  would	  provide	  insights	  into	  the	  
structure	  and	   conformation	  of	   the	   loop	   L6	   region	   that	  differentiates	   kinesin-­‐6	  
members	  from	  all	  other	  kinesins.	  The	   initial	  trials	  for	  crystallisation	  of	  MPP154-­‐
491	   in	   pET-­‐28a	   (with	   a	   non-­‐cleavable	   C-­‐terminal	   his-­‐tag)	   did	   not	   yield	   any	  
crystals.	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Crystallisation	   trials	   of	   different	   constructs	   of	   purified	   MPP1	   motor	   domains	  
were	   unsuccessful	   so	   a	   second	   approach	   using	   methylation	   of	   the	   solvent-­‐
exposed	  lysine	  residues	  was	  adopted.	  Reductive	  methylation201	  has	  been	  shown	  
to	  be	  an	  effective	  rescue	  strategy	  for	  proteins	  recalcitrant	  to	  crystallisation	  with	  
a	   moderate	   but	   significant	   success	   rate	   in	   generating	   useful	   crystals.	   	   This	  
approach	  generally	  decreases	  the	  solubility	  of	  the	  protein	  and	  it	  is	  thought	  that	  
this	   is	  due	  to	  the	  increase	  in	  hydrophobicity	  resulting	  from	  the	  methyl	  groups.	  
However	   this	   approach	   also	   failed	   to	   yield	   crystals	   of	   MPP1.	   Consequently,	  
orthologues	   of	  MPP1	   were	   investigated	   as	   further	   avenues	   towards	   a	   crystal	  
structure.	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3.4.4 MPP1 orthologues from M. musculus, R. norvegicus 
and X. laevis 
3.4.4.1 Protein expression of different MPP1 motor domain 
orthologues 
MPP1	  from	  R.	  norvegicus,	  M.	  musculus	  and	  X.	   laevis	  share	  85%,	  80%	  and	  60%	  
sequence	   similarity	   in	   the	   motor	   domain,	   respectively,	   with	   human	   MPP1	  
(Figure	  3-­‐21).	  Each	  of	  these	  orthologues	  was	  expressed	  in	  E.	  coli	  as	  described	  in	  
the	   materials	   and	   methods.	   Protein	   preparations	   after	   the	   final	   gel	   filtration	  
chromatography	  were	  obtained	  at	  almost	  75-­‐90%	  purity.	  A	  representative	  SDS-­‐
PAGE	  for	  MPP1	  from	  each	  species	  is	  shown	  in	  Figure	  3-­‐22.	  
Hs              MESNFNQEGVPRPSYVFSADPIARPSEIN-FDGIKLDLSHEFSLVAPN----TEANSFES 55  
Mm              MESHLNPDGVPRPSYVFSADPIARPLEIN-FDGVKLDLSHEFSLVASN----PAANSLGS 55  
Rn              MESHLNQDGVPRPSYVFSADPIARPSEIN-FDGVKLDLSHEFSLVAAN----PGANSLES 55  
Xl              MKPAEVKYPPPRPSYLGVAITYPERDEPQPIDDLRTNLADKFLSLGGSESESTQKDSLGS 60 
                *:.       *****:  * . ..  * : :*.:: :*:.:*  :. .    .  :*: *   
 
Hs              KDYLQVCLRIRPFTQSEKE-LESEGCVHILDSQTVVLKEPQ-CILGRLSEKSSGQMAQKF 113  
Mm              KNYLQVCLRIRPFTQSEKE-HEAEGCVQVLDSQSVLLKDPQ-SILGHLSEKSSGQVAQKF 113  
Rn              KNYLQVCLRIRPFTQSEKG-HEAEGCVQVLDSQTVLLKDPQ-SILGHLSEKSSGQMAQKF 113  
Xl              QDHMQVYLRVRPFTAGETEQKEAQDCISIPDSSSVLVKPPHNSQACRLSEKANGSVAQKF 120                  
                ::::** **:**** .*.   *::.*: : **.:*::* *: .   :****:.*.:****   
 
Hs              SFSKVFGPATTQKEFFQGCIMQPVKDLLKGQSRLIFTYGLTNSGKTYTFQGTEENIGILP 173  
Mm              SFSKVFGPETSQKEFFLGCIMQPVKDLLEGHSRLIFTYGLTNSGKTYTFQGTEENIGILP 173  
Rn              SFSRVFGPETSQKEFFQGCIMQPVKDLLKGHSRLIFTYGLTNSGKTYTFQGTEENIGILP 173  
Xl              TFTHVFGPDTTQAQFFDGTIKQHVIDFIKGQNRLIFTYGVTNAGKTFTFQGTKDNEGILP 180                            
                :*::**** *:* :** * * * * *:::*:.*******:**:***:*****::* ****   
 
Hs              RTLNVLFDSLQERLYTKMNLKPHRSREYLRLSSEQEKEEIASKSALLRQIKEVTVHN--- 230  
Mm              RTLNVLFDSLQERLYTKMSFKPHRCREYLKLSSDQEKEESANKNTLLRQIKEVTIHN--- 230  
Rn              RTLNVLFDSLQERLYTKMSFKPHRCREYLQLSSDQEKEESANKNTLLRQIKEVTIHN--- 230  
Xl              RSMDMLFNSIQGRVYNKMDVKPHRCKDYVRLTKEQVKAEVALKNSVLRQIKEVDCSIRSN 240                   
                *::::**:*:* *:*.**..****.::*::*:.:* * * * *.::*******          
Hs              ------DSDDTLYG-SLTNSLNIS-EFEESIKDYEQANLNMANSIKFSVWVSFFEIYNEY 282  
Mm              ------DSYDVLCG-HLTNSLTIP-EFEESVNSCDQSSLNVDN-IKYSVWVSFFEIYNES 281  
Rn              ------DSYDILCG-RLTNSLTIP-EFEETMNNCEQSSLNVDN-IKYSVWVSFFEIYNES 281  
Xl              NSRNCQDTTDFINDEGLTNSSSILSDMDDHLRHSEESKLALDGSAKFSVWVSFCEIYNEC 300                        
                      *: * : .  **** .*  :::: :.  :::.* : .  *:****** *****    
 
Hs              IYDLFVPVS-SKFQKRKMLRLSQDVKGYSFIKDLQWIQVSDSKEAYRLLKLGIKHQSVAF 341  
Mm              IYDLFVPVS-SKFQKRKMLRLSQDIKGYSFIKDLQWVQVSDSKEAYRLLKLGVKHQSVAF 340  
Rn              IYDLFVPVS-SKLQKRKMLRLSQDVKGYSFIKDLQWIQVSDSKEAYRLLKLGVKHQSVAF 340  
Xl              IYDLLDPISGDKFYKRKTLRLALDLKGYSFVKDLQWIEVSDSTEACKILALGKKFQSIAY 360                  
                ****: *:* .*: *** ***: *:*****:*****::****.** ::* ** *.**:*:   
 
Hs              TKLNNASSRSHSIFTVKILQIEDSEMSRVIRVSELSLCDLAGSERTMKTQNEGERLRETG 401  
Mm              TKLNNASSRSHSIFTIRILQIEDSEIPRVTRVSELSLCDLAGSERSMKTQNEGERLREAG 400  
Rn              TKLNNASSRSHSIFTIRILQIEDSEIPRVTRVSELSLCDLAGSERSMKTQSEGERLREAG 400  
Xl              TKLNSSSSRSHSIFTVRLLKIEDSDIPRVLKVSELALCDLAGSERCTKTQNEGERLKESG 420                  
                ****.:*********:::*:****::.** :****:*********  ***.*****:*:*   
 
Hs              NINTSLLTLGKCINVLKNSEKSKFQQHVPFRESKLTHYFQSFFNGKGKICMIVNISQCYL 461  
Mm              NINTSLLTLGKCINVLKNSEKSKVQ-HVPFRESKLTHYFQSFFTGKGKICMIINISQSCS 459  
Rn              NINTSLLTLGKCISVLKNSDKSKIQQHVPFRESKLTHYFQSFFTGKGKICMIINISQCCS 460  
Xl              NINTSLLILGKCINALKTSQQSKAQQHVPFRESKLTHYLQSFFSGKGKVCMIVNICQSAS 480                  
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Hs              AYDETLNVLKFSAIAQKVCVPDTLNSSQEKLFGPVKSSQDVSLDSN-SNSKILN-VKRAT 519  
Mm              AYDETLNVLKFSTTAQRVYVPDTLSSSQEKSFASNKSLQDVSLDSN-LDNKILN-VKRKT 517  
Rn              AYDETLNVLKFSTVAQKVYVPDTLSSSQEKSFGSTKSLQDVSLGSN-LDNKILN-VKRKT 518  
Xl              SYDETLNVLKFSAVAQKVLILESCQNSEAVPCVQKKSAREVSFIINNADSKHWNSRKRAT 540                  
                :***********: **:* : :: ..*:       ** ::**:  *  :.*  *  ** *  
	  
Figure	  3-­‐21:	  Sequence	  alignment	  of	  MPP1	  motor	  domains	  from	  different	  species.	  	  
Human	  MPP1	   shares	   85%	   similarity	  with	  M.	  musculus	  MPP1,	   80%	  with	  R.	   norvegicus	  
MPP1	  and	  60%	  with	  X.	  laevis	  MPP1.	  
	  
	  
Figure	  3-­‐22:	  Protein	  expression	  of	  MPP1	  orthologues.	  	  
Figure	   shows	   purified	   proteins	   of	   MPP1	   orthologue	   from	   a)	   M.	   musculus,	   b)	   R.	  
norvegicus	  and	  c)	  X.	  laevis.	  
 
3.4.4.2 Study of Physodic acid using steady state ATPase 
assay 
The	  kinetic	  parameters	  in	  the	  form	  of	  kcat	  for	  the	  activity	  of	  the	  proteins,	  Km,ATP	  
for	   the	   affinity	   towards	   ATP	   and	   K0.5,MTs	   for	   their	   affinity	   for	  MTs	   in	   all	   three	  
orthologues	  of	  human	  MPP1	  shows	  similarity	  to	  that	  of	  human	  MPP1	  as	  shown	  
in	  Figure	  3-­‐23(a-­‐d)	  and	  Table	  3-­‐8.	  	  
Physodic	   acid	   was	   then	   tested	   against	   the	   three	   MPP1	   orthologues	   to	   test	  
whether	   it	   is	   effective	   against	   the	   orthologues	   human	   MPP1.	   Under	   MT-­‐
stimulated	  conditions	  MPP1	  of	  M.	  musculus	   is	   inhibited	  by	  physodic	  acid	  with	  
an	  IC50	  value	  of	  10.8	  ±	  0.73	  µM	  whereas	  MPP1	  of	  R.	  norvegicus	  is	  inhibited	  with	  
an	  IC50	  of	  13.6	  ±	  1.20	  µM	  and	  MPP1	  of	  X.	  laevis	  MPP1	  with	  an	  IC50	  of	  12.2	  ±	  1.91	  
µM	  (Figure	  3-­‐23e-­‐f).	  	  
This	   indicates	  that	  physodic	  acid	  not	  only	  inhibits	  human	  MPP1	  but	  also	  MPP1	  
from	   other	   species	   sharing	   a	  moderate	   to	   high	   degree	   of	   sequence	   similarity	  
with	   human	   MPP1	   with	   similar	   potency.	   This	   will	   have	   practical	   benefits	   as	  
purified	   human	   MPP1	   is	   unstable	   and	   these	   alternative	   enzymes	   provide	   a	  
surrogate	  system.	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Figure	  3-­‐23:	  Characterisation	  and	   inhibition	  of	   the	  basal	  and	  MT-­‐stimulated	  ATPase	  
activity	  of	  MPP1	  orthologues	  from	  three	  different	  species.	  	  
a)	  Effect	  of	  the	  NaCl	  concentration	  on	  the	  basal	  ATPase	  activity	  of	  M.	  musculus	  (),	  R.	  
norvegicus	  (Δ )	  and	  X.	  laevis	  (♦)	  MPP1	  at	  saturating	  ATP	  concentration	  of	  1	  mM.	  b)	  The	  
basal	   ATPase	   activity	   for	  M.	  musculus	   (),	  R.	   norvegicus	   (Δ)	   and	  X.	   laevis	   (♦)	   in	   the	  
presence	  of	  increasing	  ATP	  concentration,	  measured	  at	  a	  concentration	  of	  0	  mM	  NaCl.	  
c)	   Determination	   of	   the	   MT-­‐stimulated	   ATPase	   activity	   of	   M.	   musculus	   (),	   R.	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norvegicus	  (Δ)	  and	  X.	  laevis	  (♦)	  MPP1	  d)	  MT-­‐stimulated	  ATPase	  activity	  of	  M.	  musculus	  
(),	   R.	   norvegicus	   (Δ)	   and	   X.	   laevis	   (♦)	   MPP1	   at	   increasing	   MT	   concentrations.	   e)	  
Inhibition	   of	   the	   basal	   ATPase	   activity	   of	  M.	   musculus	   (),	   R.	   norvegicus	   (Δ)	   and	   X.	  
laevis	  (♦)	  MPP1	  by	  Physodic	  acid.	  f)	  Inhibition	  of	  the	  MT-­‐stimulated	  ATPase	  activity	  of	  
M.	  musculus	  (),	  R.	  norvegicus	  (Δ)	  and	  X.	  laevis	  (♦)	  MPP1	  by	  Physodic	  acid	  (5916).	  Mm	  
–	  M.	  musculus,	  Rn	  –	  R.	  norvegicus,	  Xl-­‐	  X.	  laevis.	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Table	  3-­‐8:	  Kinetic	  parameters	  for	  MPP1	  from	  three	  different	  species	  and	  inhibition	  of	  their	  basal	  and	  MT-­‐stimulated	  ATPase	  activity	  by	  Physodic	  acid.	  
The	  kinetic	  parameters:	  kcat,	  K0.5,MTs,	  KM,ATP	  and	  estimated	  IC50	  for	  Physodic	  acid	  for	  the	  MPP1	  orthologues.	  The	  kinetic	  parameters	  are	  similar	  to	  that	  of	  the	  
human	  MPP1.	  Also,	  Physodic	  acid	  is	  potent	  against	  these	  three	  species	  as	  seen	  for	  human	  MPP1.	  All	  values	  reported	  represent	  the	  mean	  ±	  standard	  error	  
from	  three	  experiments.	  	  
 





Inhibition	  of	  basal	  











activity	  of	  MPP1	  
[µM]	  
M.	  musculus	   0.0174	  ±	  0.0005	   25.4	  ±	  3.0	   9.89	  ±	  1.07	   4.809	  ±	  0.142	   40.1	  ±	  1.1	   434	  ±	  4.6	   10.8	  ±	  0.73	  
R.	  norvegicus	   0.0174	  ±	  0.0003	   33.8	  ±	  3.1	   11.9	  ±	  0.78	   5.654	  ±	  0.210	   30.1	  ±	  0.4	   800	  ±	  1.3	   13.6	  ±	  1.20	  
X.	  laevis	   0.0162	  ±	  0.004	   59.3	  ±	  4.1	   18.8	  ±	  2.18	   4.570	  ±	  0.149	   61.1	  ±	  1.2	   395	  ±	  3.9	   12.2	  ±	  1.91	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3.4.4.3 Crystallisation trials 
With	  crystallisation	  trials	  of	  human	  MPP1	  unsuccessful,	  crystallisation	  trials	  of	  MPP1	  from	  
other	  species	  were	  also	  carried	  out	  using	  a	  range	  of	  commercial	  screens	  as	  described	  in	  
Materials	  and	  Methods.	  The	  trials	  were	  unsuccessful.	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3.5 Human MKLP-2 
3.5.1 Expression and purification of protein 
MKLP-­‐2	   shares	   sequence	   homology	   with	   the	   motor	   domain	   of	   other	   kinesins.	   Ample	  
structural	   information	   is	   available	   for	   Eg5	   thus	   it	   is	   used	   as	   a	   subject	   sequence	   for	  
sequence	  alignment	  and	  secondary	  structure	  predictions	  of	  MKLP-­‐2.	  This	  indicates	  similar	  
secondary	  structural	  elements	  in	  the	  MKLP-­‐2	  and	  Eg5	  motor	  domains28	  (Figure	  3-­‐24a).	  It	  
also	  shows	  the	  very	  long	  loop	  L6	  insertion	  in	  MKLP-­‐2	  and	  few	  residues	  (marked	  in	  yellow	  
arrow),	  with	  a	  unique	  insertion	  in	  the	  conserved	  motor	  domain	  that	  is	  observed	  only	  for	  
kinesin-­‐6	  members.	  The	  protein	  expressions	  after	  the	  final	  gel	  filtration	  chromatography	  
were	   obtained	   at	   almost	   90%	   purity.	   A	   representative	   SDS-­‐PAGE	   for	   MKLP-­‐2	   motor	  
domain	  is	  shown	  Figure	  3-­‐24b.	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Figure	  3-­‐24:	  Sequence	  alignment	  and	  SDS-­‐PAGE	  of	  purified	  MKLP-­‐2	  motor	  domain.	  	  
a)	   Sequence	   alignment	   of	   MKLP-­‐2	   and	   Eg5	   motor	   domains	   predicting	   the	   secondary	   structure	  
elements	  based	  on	  sequence	  similarity.	  It	  shows	  the	  loop	  L6	  insertion	  of	  MKLP-­‐2	  that	  might	  form	  
the	   putative	   inhibitor-­‐binding	   site	   and	   a	   few	   residues	   around	   loop	   L6	   that	  might	   contribute	   to	  
inhibitor-­‐binding.	   The	   yellow	   arrow	   represents	   the	   single	   mutations	   of	   MKLP-­‐2	   motor	   domain	  
used	   in	   the	   study	  based	  on	   residues	   in	  Eg5	  motor	  domain	   that	  play	  an	   important	   role	   in	   ligand	  
binding.	  b)	  Protein	  obtained	  after	  final	  purification	  of	  MKLP-­‐256-­‐505.	  The	  protein	  was	  confirmed	  by	  
mass	   spectroscopic	   analysis.	   The	   lower	   molecular	   weight	   bands	   were	   confirmed	   to	   be	   either	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3.5.2 Characterisation of putative inhibitor-binding site 
Paprotrain166	   has	   been	   identified	   as	   the	   first	   inhibitor	   of	  MKLP-­‐2.	   To	   narrow	   down	   the	  
putative	   inhibitor-­‐binding	  site,	  a	  deletion	  mutant	  of	  MKLP-­‐2	  motor	  domain	  was	  created	  
without	   the	   long	   loop	   L6	   region	   (MKLP-­‐256-­‐505ΔL6).	   	   Also,	   three	   further	   mutants	   were	  
generated;	  each	  containing	  a	  single	  alanine	  mutation	  (L187A,	  W356A	  and	  W359A).	  These	  
residues	   were	   selected	   based	   on	   Eg5	   structures	   where	   these	   residues	   were	   shown	   to	  
undergo	  significant	  conformational	  changes	  on	  inhibitor	  binding	  as	  shown	  in	  various	  X-­‐ray	  
crystal	  structures	  of	  Eg5-­‐inhibitor	  complexes.214	  	  
Initial	  kinetic	  characterisation	  and	  salt-­‐dependence	  kinetic	  assays	  were	  carried	  out	   in	  an	  
analogous	  manner	   to	  MPP1.	  MKLP-­‐2	  also	  showed	  the	  highest	  activity	   in	   the	  absence	  of	  
NaCl	   in	   ATPase	   assays	   (Figure	   3-­‐25a).	   The	   kinetic	   parameters	   for	   the	   basal	   and	   MT-­‐
stimulated	  ATPase	   activity	   in	   the	   absence	   and	  presence	   of	   inhibitors	   for	   the	  mutations	  
MKLP-­‐2L187A,	  MKLP-­‐2W356A,	  MKLP-­‐2W359A	  were	  determined	  and	  compared	  to	  those	  of	  wild-­‐
type	  MKLP-­‐2	  (MKLP-­‐2WT).	  The	  kcat	  values	  for	  the	  basal	  and	  MT-­‐stimulated	  ATPase	  assays	  
of	   the	   mutants	   show	   similar	   rates	   of	   ATP	   hydrolysis	   to	   that	   of	   the	   wild-­‐type	   MKLP-­‐2	  
(Figure	  3-­‐25a).	  The	  basal	  and	  MT-­‐stimulated	  KM,ATP	  values	  were	  also	  very	  similar	  to	  wild-­‐
type	  MKLP-­‐2	  with	  a	  maximum	  of	  0.6-­‐fold	  decrease.	  Also,	  K0.5,MT	  are	  also	  very	  similar	   for	  
the	  wild-­‐type	  and	  mutant	  MKLP-­‐2	  (Figure	  3-­‐25b-­‐d).	  Therefore,	  the	  kinetic	  parameters	  for	  
the	  basal	  and	  MT-­‐stimulated	  ATPase	  activity	  of	  the	  wild-­‐type	  and	  MKLP-­‐2	  mutants	  display	  
no	  significant	  differences	  (Table	  3-­‐9). Wild-­‐type	  and	  mutant	  MKLP-­‐2	  were	  then	  assayed	  in	  
the	  presence	  of	  paprotrain	  in	  both	  basal	  and	  MT-­‐stimulated	  ATPase	  assays.	  MKLP-­‐2WT	  is	  
inhibited	  with	   an	   IC50	   of	   2.5	   ±	   0.4	   and	   0.98	   ±	   0.18	  µM	   respectively	   for	   basal	   and	  MT-­‐
stimulated	  ATPase	  assay	  (Figure	  3-­‐25e-­‐f).	  For	  MKLP-­‐2L187A	  and	  MKLP-­‐2W356A	  the	  decrease	  
in	  affinity	  for	  paprotrain	  is	  insignificant	  suggesting	  that	  these	  residues	  have	  no	  role	  to	  play	  
in	   inhibitor	   binding.	   However,	   the	   IC50	   for	   MKLP-­‐2W359A	   increases	   by	   ∼20	   fold	   for	   the	  
inhibition	  of	  MT-­‐stimulated	  ATPase	   activity	   of	  MKLP-­‐2.	   For	   the	  MKLP-­‐256-­‐505ΔL6	  mutant	  
there	  was	  no	  inhibition	  by	  paprotrain	  observed	  indicating	  that	  loop	  L6	  plays	  a	  vital	  role	  in	  





   





Figure	  3-­‐25:	  Characterisation	  of	  the	  basal	  and	  MT-­‐stimulated	  ATPase	  activity	  of	  MKLP-­‐2.	  	  
a)	  Effect	  of	  the	  NaCl	  concentration	  on	  the	  basal	  ATPase	  activity	  of	  MKLP-­‐256-­‐505	  ()	  and	  	  
MKLP-­‐256-­‐505ΔL6	   ()	   at	   saturating	   ATP	   concentration	   of	   1	  mM.	   b)	   The	   basal	   ATPase	   activity	   for	  
MKLP-­‐256-­‐505	   ()	   and	   MKLP-­‐156-­‐505ΔL6	   ()	   in	   the	   presence	   of	   increasing	   ATP	   concentration,	  
measured	   at	   a	   concentration	   of	   0	   mM	   NaCl.	   c)	   Determination	   of	   the	   MT-­‐stimulated	   ATPase	  
activity	  of	  MKLP-­‐256-­‐505	  ()	  and	  MKLP-­‐256-­‐505ΔL6	  ()	  d)	  MT-­‐stimulated	  ATPase	  activity	  of	  MKLP-­‐256-­‐
505	   ()	   and	  MKLP-­‐256-­‐505ΔL6	   ()	   at	   increasing	  MT	   concentrations.	   e)	   Inhibition	   of	   basal	   ATPase	  
activity	   of	  MKLP-­‐2	  wild-­‐type()	   and	   loop	   L6-­‐deletion	  mutant	   ()	   by	   paprotrain.	   f)	   Inhibition	  of	  
MT-­‐stimulated	   ATPase	   activity	   of	   MKLP-­‐2	   wild-­‐type	   ()	   and	   loop	   L6-­‐deletion	   mutant	   ()	   by	  
paprotrain.	  MKLP-­‐256-­‐505	  wilt	  type	  is	  represented	  as	  WT	  and	  MKLP-­‐256-­‐505ΔL6	  is	  represented	  as	  ΔL6.	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Table	  3-­‐9:	  Summary	  of	  kinetic	  parameters	  for	  wild-­‐type	  and	  mutants	  of	  MKLP-­‐2.	  
	  





















MKLP-­‐2WT	   0.045	  ±	  0.0001	   82	  ±	  1.9	   1.5	  ±	  0.4	  
(85)	  
5.89	  ±	  0.27	   74.7	  ±	  1.2	   130	  ±	  0.05	   0.98	  ±	  0.2	  
(95)	  
MKLP-­‐2ΔΔL6	   0.044	  ±	  0.0002	   18	  ±	  0.005	   n.i.	  
(40)	  
5.0	  ±	  0.15	   210	  ±	  20	   61.4	  ±	  0.06	   n.i.	  
(30)	  
MKLP-­‐2L187A	   0.043	  ±	  0.004	   60	  ±	  0.2	   1.07	  ±	  0.16	  
(80)	  
7.59	  ±	  0.05	   232	  ±	  6.2	   54.3	  ±	  0.8	   3.6	  ±	  0.6	  
(70)	  
MKLP-­‐2W356A	   0.044	  ±	  0.003	   39.9	  ±	  1.0	   1.13	  ±	  0.19	  
(60)	  
6.47	  ±	  0.25	   161	  ±	  2.1	   42.1	  ±	  0.1	   1.3	  ±	  0.2	  
(60)	  
MKLP-­‐2W359A	   0.030	  ±	  0.003	   27.1	  ±	  0.1	   7.11	  ±	  1.1	  
(70)	  
5.43	  ±	  0.15	   147	  ±	  1.4	   95.4	  ±	  1.6	   18.6	  ±	  2.8	  
(60)	  
*MIA:	  Maximum	  inhibition	  attained	  
3.5.3 SAR study of MKLP-2 inhibitors using steady state 
ATPase assays 
An	  initial	  SAR	  study	  to	  investigate	  the	  importance	  of	  different	  substituents	  of	  paprotrain	  
was	  carried	  out	  using	  both	  basal	  and	  MT-­‐stimulated	  MKLP-­‐2	  ATPase	  assays.	  The	  chemical	  
structure	  of	  paprotain166	  and	  other	  compounds	  from	  this	  study	  are	  shown	  in	  Table	  3-­‐10.	  
The	  analogues	  were	  initially	  synthesised	  for	  the	  measurement	  of	  inhibition	  of	  MKLP-­‐2	  and	  
an	  SAR	  study	  was	  carried	  out	  in	  collaboration	  with	  Drs.	  Christophe	  Labrière	  and	  Catherine	  
Guillou.	   The	   inhibition	   of	   the	   basal	   and	  MT-­‐stimulated	   ATPase	   activity	   of	   135	   inhibitor	  
analogues	  are	  summarised	  in	  Table	  3-­‐10.	  All	  description	  of	  compounds	  are	  based	  on	  this	  
table.	  Further	  analysis	  of	  the	  compounds	  based	  on	  the	  in	  vitro	  inhibition	  is	  still	  ongoing.	  	  
To	  rationalise	  the	  SAR	  study,	  the	  structure	  of	  paprotrain	  was	  delineated	  into	  five	  regions:	  
(A)	   the	   pyridine	   ring,	   (B)	   the	   indole	   ring,	   (C)	   the	   double	   bond	   bridge,	   (D)	   the	   nitrile	  
function	  and	  (E)	  the	  substituent	  of	  the	  double	  bond	  as	  shown	  in	  Figure	  3-­‐26.	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Figure	  3-­‐26:	  Structure	  of	  paprotrain	  with	  the	  different	  regions	  of	  modification	  for	  SAR	  study.	  
Paprotrain	   analogues	   were	   synthesised	   after	   delineating	   the	   paprotrain	   structure	   into	   five	  
different	   regions	  A-­‐E.	   The	   SAR	   analysis	   is	   based	   on	   each	   individual	   region	   or	   in	   combination	   of	  
different	  regions.	  
	  
Firstly	  substitution	  of	  the	  pyridine	  ring	  (region	  A)	  with	  phenyl	  rings	  and/or	  introduction	  of	  
a	   functional	  group	   in	   the	  same	  meta	  position	  as	   the	  nitrogen	  atom	  of	   the	  pyridine	   ring	  
results	   in	  a	  total	   loss	  of	   inhibition	  (332-­‐1).	   Introduction	  of	   large	  constituents	   in	  the	  para	  
position	   as	   SMe	   (44-­‐3)	   are	   unfavourable	   for	   the	   inhibition	   of	   basal	   and	  MT-­‐stimulated	  
ATPase	  activities	  of	  MKLP-­‐2.	  
Changes	  in	  the	  indole	  ring	  (region	  B)	  such	  as	  introduction	  of	  a	  methoxy	  group	  in	  the	  6	  or	  4	  
positions	   (260-­‐1	   and	  398-­‐1)	   or	   introduction	  of	   a	  nitrogen	  atom	   in	   the	  7-­‐position	  of	   the	  
indole	   (505-­‐1)	   decreases	   the	   inhibitory	   potency.	   When	   the	   7-­‐position	   (399-­‐1)	   is	  
substituted	   by	   a	  methoxy	   group	   total	   loss	   of	   inhibiton	   occurred.	   Substitution	   in	   the	   5-­‐
position	  with	   an	   ethoxy	   group	   (387-­‐1)	   leads	   to	   the	   compound	  being	  more	   potent	   than	  
paprotrain.	   Large	   substituents	   like	   phenyl	   (621-­‐1)	   or	   thiophene	   (622-­‐1)	   present	   in	   2-­‐
position	  resulted	  in	  loss	  of	  inhibition	  as	  well.	  Alkylation	  (418-­‐2)	  or	  acylation	  (419-­‐2)	  of	  the	  
indole	  leads	  to	  inactive	  compounds.	  	  
Modulations	  of	  the	  central	  linker	  (region	  C)	  were	  undertaken.	  Shorter	  (one	  atom,	  296-­‐1)	  
or	  longer	  (three	  atoms,	  i.e.	  170-­‐2	  or	  four	  atoms	  i.e.	  412-­‐2)	  linker	  between	  the	  indole	  and	  
the	  pyridine	  rings	   lead	  to	   inactive	  molecules.	  The	  vinylogous	  derivative	  524-­‐1	   is	   inactive	  
showing	  that	  the	  nitrile	  position	  of	  the	  nitrile	  function	  is	  also	  sensitive.	  	  
Substitution	   of	   the	   nitrile	   function	   (region	   D)	   mostly	   rendered	   the	   compounds	   either	  
inactive	  (133-­‐1)	  or	  the	  potency	  decreased	  considerably	  (93-­‐1	  and	  115-­‐1).	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Modifications	  of	  the	  double	  bond	  bridge	  (region	  C)	  and	  removing	  the	  substituent	  of	  the	  
double	  bond	  (region	  E)	  (163-­‐1)	  leads	  to	  higher	  potency	  than	  paprotrain.	  	  
Overall	   two	   compounds,	  163-­‐1	   and	  387-­‐1	   were	   found	   in	   this	   SAR	   study	   to	   have	   2-­‐fold	  
more	  potency	   than	  paprotrain.	   Further	   cell-­‐based	   analyses	  of	   the	   active	   compounds	   as	  
well	  as	  specificity	  measurements	  are	  still	  underway.	  	  
Table	  3-­‐10:	  Inhibition	  of	  basal	  and	  MT-­‐stimulated	  ATPase	  activities	  by	  paprotrian	  analogues.	  	  
The	   table	   represents	   the	   IC50	   values	   for	   the	   inhibition	   of	   the	   basal	   and	  MT	   -­‐stimulated	   ATPase	  




Structure	   Inhibition	  of	  








1.35	  ±	  0.2	   0.83	  ±	  0.1	  
44-­‐3	  
	  
n.i.	   n.i.	  
93-­‐1	  
	  
n.i.	   82.9	  ±	  54.5	  	  
93-­‐2	  
	  
n.i.	   n.i.	  
97-­‐2	  
	  
10.6	  ±	  4.8	   6.4	  ±	  0.5	  	  
98-­‐3	  
	  
n.i.	   0.6	  ±	  0.2	  
100-­‐2	  
	  































   




n.i.	  	   0.5	  ±	  0.1	  
104-­‐1	  
	  
n.i.	   n.i.	  
105-­‐1	  
	  
n.i.	  	   50.3	  ±	  20.5	  	  
108-­‐1	  
	  
14.8	  ±	  1.2	   5.4	  ±	  2.2	  
112-­‐1	  
	  
2.6	  ±	  0.1	  	   0.8	  ±	  0.1	  
115-­‐2	  
	  
5.91	  ±	  1.1	   4.91	  ±	  2.1	  
120-­‐3	  
	  
12.5	  ±	  5.8	  	   17.4	  ±	  4.4	  
121-­‐1	  
	  
1.9	  ±	  0.3	   0.3	  ±	  0.1	  
128-­‐2	  
	  
4.1	  ±	  1.6	   1.1	  ±	  0.1	  	  
129-­‐1	  
	  
11.9	  ±	  2.1	   5.3	  ±	  2.2	  	  
130-­‐2	  
	  
n.i.	   n.i.	  
130-­‐4	  
	  

































































   




n.i.	   n.i.	  
134-­‐1	  
	  
n.i.	   n.i.	  
138-­‐2	  
	  
n.i.	   n.i.	  
147-­‐1	  
	  
n.i.	   n.i.	  
150-­‐1	  	  
	  
n.i.	   n.i.	  
151-­‐1	  
	  
n.i.	   n.i.	  
154-­‐1	  
	  
n.i.	   n.i.	  
160-­‐1	  
	  
n.i.	   n.i.	  
163-­‐1	  
	  
1.5	  ±	  0.2	   0.6	  ±	  0.1	  
173-­‐1	  
	  
n.i.	   n.i.	  
174-­‐1	  
	  
n.i.	   n.i.	  
174-­‐2	  
	  



























































   




n.i.	   n.i.	  
182-­‐1	  
	  
n.i.	   n.i.	  
182-­‐2	  
	  
n.i.	   n.i.	  
191-­‐2	  
	  
n.i.	   n.i.	  
195-­‐2	  
	  
n.i.	   n.i.	  
206-­‐1	  
	  
n.i.	   n.i.	  
206-­‐2	  
	  
n.i.	   n.i.	  
207-­‐1	  
	  
n.i.	   n.i.	  
209-­‐1	  
	  
n.i.	   n.i.	  
209-­‐2	  
	  
n.i.	   n.i.	  
210-­‐2	  
	  
n.i.	   n.i.	  
215-­‐3	  
	  
























































   




n.i.	   n.i.	  
217-­‐1	  
	  
n.i.	   n.i.	  
226-­‐1	  
	  
n.i.	   n.i.	  
228-­‐2	  
	  
n.i.	   n.i.	  
229-­‐1	  
	  
n.i.	   n.i.	  
239-­‐1	  
	  
n.i.	   n.i.	  
239-­‐2	  
	  
n.i.	   n.i.	  
252-­‐2	  
	  
n.i.	   n.i.	  
260-­‐1	  
	  
5.6	  ±	  0.9	  	   5.4	  ±	  0.7	  	  
261-­‐2	  
	  
n.i.	   n.i.	  
262-­‐1	  
	  
n.i.	   n.i.	  
277-­‐1	  
	  







































































   




n.i.	   n.i.	  
291-­‐1	  
	  
n.i.	   1.1	  ±	  0.2	  	  
294-­‐1	  
	  
n.i.	   n.i.	  
296-­‐1	  	  
	  
n.i.	   n.i.	  
310-­‐1	  
	  
n.i.	   n.i.	  
312-­‐1	  
	  
n.i.	   n.i.	  
320-­‐1	  
	  
5.0	  ±	  2.1	   0.5	  ±	  0.1	  
320-­‐2	  
	  
n.i.	   n.i.	  
332-­‐1	  
	  
n.i.	   n.i.	  
343-­‐3	  
	  
2.7	  ±	  0.5	  	   2.3	  ±	  0.2	  
344-­‐1	  
	  





























































   




1.8	  ±	  0.7	  	   3.4	  ±	  2.3	  	  
365-­‐2	  
	  
3.3	  ±	  0.9	  	   6.8	  ±	  0.8	  	  
375-­‐1	  
	  
2.8	  ±	  0.3	  	   3.6	  ±	  0.4	  
377-­‐3	  
	  
3.0	  ±	  2.2	   3.9	  ±	  0.9	  
387-­‐1	  
	  
1.1	  ±	  0.5	   0.9	  ±	  0.1	  
389-­‐1	  
	  
1.5	  ±	  1.5	   1.6	  ±	  0.3	  
398-­‐1	  
	  
4.2	  ±	  1.5	   3.3	  ±	  0.3	  
399-­‐1	  
	  
n.i.	   n.i.	  
400-­‐2	  
	  
0.5	  ±	  0.6	   2.8	  ±	  0.4	  
401-­‐1	  
	  
1.0	  ±	  0.4	   2.6	  ±	  0.4	  
412-­‐1	  
	  
































































   




n.i.	   n.i.	  
417-­‐2	  
	  
n.i.	   n.i.	  
418-­‐2	  
	   	  
n.i.	   n.i.	  
419-­‐1	  
	  
n.i.	   n.i.	  
429-­‐1	  
	  
n.i.	   n.i.	  
430-­‐1	  
	  
n.i.	   n.i.	  
436-­‐3	  
	  
n.i.	   n.i.	  
457-­‐1	  
	  
9.4	  ±	  2.6	   12.9	  ±	  2.1	  
464-­‐1	  
	  
n.i.	   7.4	  ±	  2.6	  
466-­‐1	  
	  






































































   




n.i.	   n.i.	  
469-­‐1	  
	  
n.i.	   4.3	  ±	  1.4	  
472-­‐1	  
	  
n.i.	   n.i.	  
473-­‐1	  
	  
9.9	  ±	  4.7	   10.9	  ±	  2.5	  
474-­‐1	  
	  
n.i.	   n.i.	  
475-­‐2	  
	  
n.i.	   n.i.	  
481-­‐2	  
	  
n.i.	   n.i.	  
482-­‐1	  
	  
n.i.	   n.i.	  
484-­‐1	  
	  
n.i.	   n.i.	  
485-­‐2	  
	  




























































   




n.i.	   n.i.	  
494-­‐1	  
	  
3.6	  ±	  0.4	   6.1	  ±	  1.0	  	  
496-­‐2	  
	  
6.1	  ±	  1.2	   3.2	  ±	  0.4	  
501-­‐1	  
	  
n.i.	   n.i.	  
504-­‐2	  
	  
n.i.	   n.i.	  
505-­‐1	  
	  
11.0	  ±	  4	  	   10.2	  ±	  1.2	  
506-­‐1	  
	  
4.5	  ±	  1.7	  	   8.2	  ±	  2.3	  
507-­‐2	  
	  
n.i.	   n.i.	  
508-­‐1	  
	  
n.i.	   n.i.	  
512-­‐1	  
	  























































   




n.i.	   n.i.	  
514-­‐1	  
	  
4.7	  ±	  1.3	   1.9	  ±	  0.3	  
515-­‐1	  
	  
n.i.	   n.i.	  
524-­‐1	  
	  
n.i.	   n.i.	  
540-­‐1	  
	  
n.i.	   n.i.	  
541-­‐1	  
	  
n.i.	   n.i.	  
550-­‐3	  
	  
n.i.	   n.i.	  
562-­‐2	  
	  
3.9	  ±	  1.1	   3.1	  ±	  1.2	  
565-­‐1	  
	  
n.i.	   n.i.	  
566-­‐1	  
	  
n.i.	   n.i.	  
567-­‐2	  
	  

























































   




13.3	  ±	  2.7	   3.1	  ±	  1.2	  
577-­‐1	  
	  
n.i.	   n.i.	  
585-­‐2	  
	  
n.i.	   n.i.	  
587-­‐1	  
	  
6.8	  ±	  1.5	   10.2	  ±	  2.1	  
588-­‐1	  
	  
n.i.	   n.i.	  
589-­‐1	  
	  
n.i.	   n.i.	  
591-­‐1	  
	  
11.4	  ±	  4.2	   16.6	  ±	  8.6	  
592-­‐2	  
	  
n.i.	   1.6	  ±	  0.5	  
593-­‐1	  
	  
n.i.	   n.i.	  
596-­‐1	  
	  
n.i.	   n.i.	  
601-­‐1	  
	  




























































   




n.i.	   n.i.	  
609-­‐1	  
	  
n.i.	   n.i.	  
619-­‐1	  
	  
1.4	  ±	  0.3	   0.8	  ±	  0.2	  
620-­‐1	  
	  
n.i.	   n.i.	  
621-­‐1	  
	  
n.i.	   n.i.	  
622-­‐1	  
	  
n.i.	   n.i.	  
624-­‐1	  
	  
3.7	  ±	  1.4	   0.4	  ±	  0.3	  
	  
3.5.4 Crystallisation trials 
Crystallisation	  trials	  of	  the	  purified	  human	  MKLP-­‐2	  motor	  domain	  constructs	  (MKLP-­‐21-­‐591,	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4 Discussion and future perspectives 
4.1 Understanding the mechanism of Eg5 targeting drugs 
and future directions  
4.1.1 A better understanding of ispinesib binding and 
affinity towards the Eg5 motor domain 
Eg5	   shows	   significant	   potential	   as	   a	   drug	   target	   for	   cancer	   chemotherapy,	   and	  
correspondingly	  has	  attracted	  widespread	  attention	  with	  numerous	   inhibitors	   in	  various	  
phases	   of	   drug	   development.8,119,122 All	   Eg5	   inhibitors	   developed	   to	   date	   target	   the	  
globular	  motor	  domain,	  where	  they	  bind	  to	  one	  of	   three	  distinct	  sites:	  ATP	  competitive	  
inhibitors	  bind	  either	  in	  or	  close	  to	  the	  ATP	  binding	  site	  (P-­‐loop)131,215,	  whereas	  allosteric	  
inhibitors	  either	  bind	  to	  the	  loop	  L5	  region	  or	  at	  the	  interface	  between	  helix	  α4	  and	  α6.131 
The	   allosteric	   pocket	   of	   Eg5	   is	   an	   attractive	   target,	   not	   only	   because	   it	   can	   provide	  
specificity	   to	   inhibitors	   over closely	   related	   kinesins,	   which	   generally	   possess	   a	   much	  
shorter	  loop	  L5	  region	  that	  cannot	  furnish	  a	  comparable	  binding	  pocket,	  but	  also	  have	  an	  
edge	  over	  other	  inhibitor	  binding	  in	  competition	  to	  ATP/ADP	  due	  to	  the	  highly	  conserved	  
nucleotide	   site.	   Previous	   work	   has	   shown	   that	   ispinesib	   is	   a	   promising	   allosteric	   Eg5	  
inhibitor	  that	   is	  already	  in	  multiple	  phase	  II	  clinical	  trials	  and	  the	  work	  presented	  in	  this	  
thesis	  towards	  understanding	  its	  interaction	  will	  inform	  the	  design	  of	  novel	  compounds	  in	  
this	   site. It	   is	   therefore	   surprising	   that	   so	   far	  no	   structural	   data	   in	   the	   form	  of	  PDB	   co-­‐
ordinates	   for	   the	   Eg5-­‐ispinesib	   complex	  had	  been	  available. The	   structure	  presented	   in	  
this	  thesis	  of	  the	  ternary	  Eg5-­‐ADP-­‐ispinesib	  complex	  seeks	  to	  remedy	  this. The	  interaction	  
of	  ispinesib	  with	  Eg5	  is	  dominated	  by	  hydrophobic	  interactions	  and	  there	  are	  essentially	  
no	  hydrophilic	   interactions.	   	  Analysis	  of	  the	  binding	  mode,	  as	  well	  as	  a	  comparison	  with	  
other	   allosteric	   Eg5	   inhibitors,	   suggests	   a	   number	   of	   ways	   in	   which	   ispinesib	   could	   be	  
modified	  while	  either	  retaining	  or	  even	  improving	  its	  affinity	  for	  Eg5,	  an	  argument	  further	  
supported	   by	   the	   development	   of	   the	   second	   generation	   ispinesib	   based	   analogue	   SB-­‐
7439218 and	   the	   amount	   of	   additional	   data	   on	   the	   development	   of	   ispinesib-­‐related	  
compounds	   in	   the	   patent	   literature216.	   Interactions	   of	   the	   quinazolinone	   ring	   system	   in	  
ispinesib	  with	  residues	  of	  Eg5	  form	  a	  crucial	  part	  in	  the	  high	  potency	  of	  the	  inhibitor.	  The	  
aromatic	  rings	  of	  Trp127,	  Tyr211	  and	  Phe239	  around	  the	  inhibitor-­‐binding	  pocket	  of	  Eg5	  
interact	  strongly	  with	  this	  ring	  system	  of	  ispinesib	  leading	  to	  tight	  binding	  of	  the	  inhibitor.	  
Recent	  development	  of	  SB743921	  explores	  substitution	  of	  atoms	  in	  the	  aromatic	  portion	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of	   ispinesib	   increasing	  bonding	  energies	   in	  and	  around	  the	   ring	  system.	   In	  addition,	   the	  
chlorine	   substituent	   of	   ispinesib	   does	   not	   harness	   all	   interactions	   with	   Phe239	   and	  
Leu216	  suggesting	  that	  affinity	  can	  be	  further	  improved	  by	  additional	  substitutions	  on	  the	  
benzo-­‐ring.	  Modification	  of	  the	  solvent-­‐exposed	  amino-­‐alkyl	  group	  may	  not	  enable	  better	  
interactions	   but	   instead	   provide	   better	   physiochemical	   properties,	  which	  might	   help	   in	  
better	   modulating	   the	   pharmacokinetic	   properties	   of	   the	   drug	   candidate.	   This	  
information	  should	  prove	  invaluable	  for	  future	  iterations	  of	  this	  inhibitor	  scaffold,	  be	  it	  to	  
improve	   potency,	   to	   alter	   pharmacokinetics	   or	   to	   counter	   the	   ever-­‐present	   threat	   of	  
resistance127.	   
4.1.2 The underlying mechanism of resistance of Eg5 
towards small molecule inhibitors 
The	  major	  challenge	  in	  cancer	  chemotherapy	  is	  the	  emergence	  of	  resistance.	  Tumour	  cells	  
may	   take	  different	   routes	   to	   avoid	   inhibition	  of	   a	   primary	   target,	  which	   include	   a	  wide	  
variety	  of	  mechanisms	  such	  as	  up-­‐regulating	  alternative	  pathways,	  increasing	  expression	  
of	   drug	   efflux	   pumps	   or	   expressing	   drug-­‐resistant	   variants	   of	   the	   targeted	   protein	   for	  
example	   through	   point	   mutations	   in,	   or	   close	   to,	   the	   inhibitor-­‐binding	   pocket.	   These	  
processes	   are	   evolutionary	   adaptations	   to	   the	   natural	   selection	   pressure	   exerted	   by	  
intervention	  with	  a	  chemotherapeutic	  agent.	  Most	  of	  the	  information	  on	  the	  mechanisms	  
that	   lead	   to	   the	   development	   of	   resistance	   is	   gained	   from	   experiments	   conducted	   in	  
tumour	   cell	   lines	   and	  only	   sparse	   information	   is	   available	   for	   resistance	  mechanisms	   in	  
tumours	  since	  this	  requires	  tumour	  biopsies	  after	  relapse.	  In	  some	  cases	  the	  identification	  
of	  the	  underlying	  mechanism	  that	   leads	  to	  resistance	  during	  cancer	  treatment	  may	  lead	  
to	   the	  development	  of	   second	  generation	   treatments,	   as	   observed	   for	   example	   for	   the	  
treatment	  of	  CML217.	  	  
When	   tumour	   cells	   lines	  were	  exposed	   to	  prolonged	   treatment	  with	   ispinesib;	   it	   led	   to	  
the	  development	  of	  resistance	  demonstrating	  mutations	  in	  the	  loop	  L5	  region	  of	  Eg5.	  The	  
integrated	   combination	   of	   methods	   presented	   in	   this	   thesis,	   including	   kinetic	   assays,	  
calorimetry,	   X-­‐ray	   crystallography	   together	   with	   molecular	   simulations	   (Dr.	   Nahoum	  
Anthony	   and	   Prof.	   Simon	   Mackay)	   were	   performed	   to	   understand	   the	   mechanism	   of	  
resistance	   against	   the	   second	   generation	   clinical	   candidate	   SB743921	   at	   the	  molecular	  
level.	  The	  kinetic	  parameters	   in	  the	  form	  of	  kcat,	  Km,ATP	  and	  K0.5,MTs	   for	  the	  catalytic	  basal	  
and	   MT-­‐stimulated	   ATPase	   activity	   are	   essentially	   unchanged	   for	   the	   wild-­‐type	   and	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mutated	  forms	  of	  Eg5.	  The	  single	  mutations	  Eg5A133D	  and	  Eg5D130V	  generate	  considerable	  
resistance	  factors	  of	  3,500	  -­‐	  4,300	  in	  the	  presence	  of	  SB743921.	  Subsequent	  calorimetric	  
analyses	   confirm	   that	   the	   binding	   affinity	   of	   SB743921	   for	   the	  mutated	   Eg5	   proteins	   is	  
markedly	   reduced,	   which	   accounts	   for	   their	   continued	   turnover	   of	   the	   ATP	   hydrolysis	  
cycle	  and	  the	  consequent	  motor	  function	  in	  the	  presence	  of	  the	  inhibitor.	  Again,	  from	  an	  
evolutionary	   perspective	   this	   is	   to	   be	   expected	   –	   natural	   selection	   has	   resulted	   in	   a	  
mutant	  protein	  with	  lower	  affinity	  for	  the	  inhibitor	  while	  retaining	  function	  in	  response	  to	  
the	   selective	   pressure	   of	   chemotherapeutic	   intervention,	   Sheth	   and	   colleagues126,128	  
showed	  that	  inhibition	  by	  another	  Eg5	  inhibitor,	  monastrol,	  could	  also	  be	  greatly	  reduced	  
by	   these	   two	  mutations.	   Inhibitory	  effects	  of	   STLC	  are	  also	  observed	   to	  diminish	   in	   the	  
mutant	   enzymes.	   In	   fact,	   the	   mutations	   not	   only	   diminish	   but	   also	   fully	   abolish	   the	  
inhibitory	   effects	   of	   STLC.	   It	   is	   therefore	   striking	   that	   these	  mutations	   not	   only	   confer	  
resistance	  to	  ispinesib	  and	  to	  its	  structurally	  related	  analogue	  SB743921,	  but	  also	  to	  other	  
Eg5-­‐targeting	   agents	   with	   distinct	   chemical	   scaffolds	   such	   as	  monastrol	   and	   STLC.	   It	   is	  
likely	  that	  other	  ispinesib-­‐related	  agents	  in	  clinical	  development	  would	  also	  be	  inactivated	  
by	  these	  mutations.	  	  
The	  most	   intriguing	   question	   that	   arises	   is	   how	   the	   reduced	   affinity	   has	   emerged.	   The	  
thermodynamics	   of	   the	   binding	   free	   energy	   as	   revealed	   by	   the	   calorimetric	   studies	  
indicate	  that	  the	  mutated	  proteins	  actually	  have	  an	  improved	  enthalpic	   interaction	  with	  
SB743921.	   In	  other	  words,	  when	  a	  complex	  between	  a	  mutated	  protein	  and	   inhibitor	   is	  
formed,	   the	   net	   non-­‐bonded	   interactions	   are	   more	   favourable	   compared	   with	   Eg5WT.	  
Mutations	  invoking	  resistance	  against	  small	  molecule	  inhibitors	  have	  predominantly	  been	  
explained	   through	   reduced	   interactions	   involving	   steric	   or	   electrostatic	   repulsion	  
somewhere	  in	  the	  binding	  site218.	  Calorimetric,	  crystallographic	  and	  molecular	  simulation	  
studies	   suggest	   that	   this	   is	  not	  necessarily	   the	  case,	  and	   that	   there	  are	  other	   factors	   in	  
which	  have	  significant	  implications	  for	  drug	  design	  against	  resistant	  forms	  of	  proteins	  that	  
may	   evolve	   during	   clinical	   exposure.	   The	   crystal	   structures	   of	   Eg5WT	   and	   Eg5A133D	   in	  
complex	   with	   SB743921	   showed	   that	   the	   mutation	   does	   not	   produce	   any	   obvious	  
repulsive	  interactions	  compared	  with	  the	  wild-­‐type,	  and	  indeed,	  that	  the	  two	  complexes	  
are	  very	  similar	  in	  this	  region.	  Additional	  simulation	  studies	  with	  Eg5A133D	  confirm	  that	  in	  
terms	  of	   enthalpy,	   SB743921	  makes	  more	   favourable	   interactions	  with	   the	  binding	   site	  
identify	  that	  specific	  residues	  make	  quantifiably	  better	  interactions	  in	  the	  mutated	  form,	  
which	  overall	  can	  explain	  the	  improved	  enthalpy	  shown	  experimentally.	  Significantly,	  the	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mutated	   residue	   itself	   does	   not	   impact	   on	   the	   non-­‐bonded	   interactions.	   Instead,	   the	  
thermodynamic	  behaviour	  of	   the	  protein	  due	   to	   the	  mutation	  creates	  disorder	   in	  other	  
regions	  of	  the	  protein	  following	  the	  second	  law	  of	  thermodynamics	  and	  this	  plays	  a	  major	  
role	  in	  the	  development	  of	  resistance.	  	  
Crystallographic	   and	   MD	   studies	   confirm	   the	   enthalpic	   gain	   through	   mutation	   but	   its	  
overall	  relation	  to	  the	  reduced	  affinity	  for	  the	  chemotherapeutic	  agent	  and	  its	  ability	  to	  
allow	   normal	   catalytic	   function	   is	   intriguing.	   The	   role	   of	   water	   is	   thought	   to	   be	  
fundamental	  to	  this	  process,	  as	  all	  biological	  processes	  are	  carried	  out	  in	  this	  solvent.	  In	  
this	  case,	  with	  respect	  to	  ligand,	  SB743921	  –	  this	  compound	  is	  the	  same	  in	  all	  studies,	  so	  
the	   hydrophobic	   effect	   of	   promoting	   ligand	   binding	   through	   its	   expulsion	   from	   water	  
cavities	  is	  constant.	  Thermodynamically,	  it	  is	  the	  differences	  between	  the	  complexes	  that	  
are	  the	  key	  in	  this	  process.	  Crystallographic	  studies	  show	  that	  structurally	  the	  mutants	  in	  
the	  absence	  of	  SB743921	  are	  practically	  identical,	  enabling	  them	  to	  function	  normally	  as	  
the	   wild-­‐type	   proteins.	   Thus	   the	   reactants	   are	   virtually	   identical	   but	   the	   products	   are	  
different	   and	   therefore	   changes	   in	   entropy	   are	   associated	   with	   the	   complex	   structure	  
itself.	   To	   gain	   further	   insight	   into	   such	   changes	   in	   disorder	   and	   the	   linkage	   to	   the	  
movement	  of	  the	  mutated	  complex	  along	  with	  its	  propensity	  to	  rigidify	  during	  binding	  for	  
the	   mutants	   compared	   with	   the	   wild-­‐type	   MD	   simulations	   were	   carried	   out.	   Reduced	  
flexibility	  in	  the	  protein-­‐ligand	  complex	  is	  associated	  with	  increased	  order	  and	  structural	  
restraint,	  which	  is	  unfavourable	  in	  entropy	  terms.	  The	  A133D	  mutation	  can	  cause	  a	  chain	  
of	  local	  rearrangement	  of	  hydrogen	  bonding	  and	  salt	  bridging	  (Figure	  4-­‐1)	  that	  transmits	  
structural	   changes	   throughout	   the	   whole	   complex	   and	   causes	   reduced	   flexibility	   in	  
specific	  regions.	  New	  hydrogen	  bonds	  between	  residues	  in	  different	  sub-­‐domains	  (Figure	  
4-­‐2)	   appear	   to	   check	   movement	   and	   rigidify	   the	   overall	   complex.	   The	   enthalpic	   gain	  
through	  tighter	  association	  with	  the	  binding	  site	  is	  therefore	  lost	  through	  the	  transmitted	  
ordering	  of	  the	  complex.	  	  
These	  analyses	  refine	  the	  previously	  held	  notions	  that	  resistance	   is	  a	  result	  of	  a	  protein	  
having	  reduced	  affinity	  for	  a	  ligand	  through	  less	  favourable	  interactions	  with	  the	  binding	  
site.	   Essentially,	   it	   can	   be	   illustrated	   from	   our	   experimental	   results	   that	  mutations	   can	  
induce	  resistance	  by	  using	  the	  randomness	  of	  nature	  in	  its	  evolutionary	  selection	  process	  
that	   has	   found	   a	   way	   to	   confound	   the	   ordered	   attempts	   of	   rational	   drug	   design.	   The	  
resistance	  mechanism	   can	   be	   thought	   of	   as	   an	   extreme	   example	   of	   “entropy/enthalpy	  
compensation”219	  where	  a	  beneficial	   enthalpic	   component	   is	   balanced,	   and	   in	   this	   case	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outweighed,	   by	   an	   opposing	   entropic	   effect.	   	   The	   phenomenon	   typically	   occurs	   when	  
ligands	  are	  designed	  to	  optimise	  interactions	  with	  a	  receptor	  but	  here,	  natural	  selection	  
has	  resulted	  in	  a	  similar	  result.	  	  
	  
Figure	   4-­‐1:	   Structural	   changes	   that	   occur	   around	   the	  A133D	  mutation	  due	   to	   thermodynamic	  
fluctuation	  on	  inhibitor-­‐binding.	  	  
a)	   Interactions	   seen	   in	   the	  minimised	   average	   structure	   of	   the	   SB743921-­‐Eg5WT	   complex	   (gray)	  
taken	  from	  the	  production	  phase	  of	  the	  equilibrated	  structure	  (hydrogen	  bonds	  are	  displayed	  as	  
dotted	   lines).	   Arg138	   guanidine	   forms	   hydrogen	   bonds	  with	   the	   backbone	   carbonyl	   oxygens	   of	  
Ala133	   and	   Asp130.	   Additionally,	   under	   these	   simulated	   conditions,	   a	   salt	   bridge	   is	   formed	  
between	   Glu128	   and	   Lys207.	   b)	   Interactions	   seen	   in	   the	   minimised	   average	   structure	   of	   the	  
SB743921-­‐Eg5A133D	  complex	  (cyan)	  taken	  from	  the	  production	  phase	  of	  the	  equilibrated	  structure.	  
Instead	  of	  the	  Arg138	  guanidine	  hydrogen	  bonding	  with	  the	  backbone	  carbonyl	  oxygens	  of	  Ala133	  
and	   Asp130	   seen	   in	   the	   simulated	   wild-­‐type	   complex,	   the	   Arg	   side-­‐chain	   moves	   by	   4.1	   Å	   and	  
instead	  makes	  a	  salt	  bridge	  with	   the	  new	  Asp133	  carboxylate.	  As	  a	   result	  of	   this	   shift,	   the	  side-­‐
chain	  of	  Glu128	   is	  moved	  away	   from	  Asp133	  by	  3.3	  Å	  and	   the	   salt	  bridge	  between	  Glu128	  and	  
Lys207	   is	   broken.	   There	   are	   a	   number	   of	   consequences	   of	   this	   rearrangement.	   Firstly,	   in	   the	  
mutant	  form	  Lys207	  is	  able	  to	  move	  5.4	  Å	  to	  form	  a	  hydrogen	  bond	  with	  the	  His141	  side-­‐chain,	  
thus	  moving	   helix	   α3	   (207-­‐225)	   closer	   to	   the	   inhibitor-­‐binding	   pocket.	   As	   a	   result,	   Arg221	   and	  
Glu116	  are	  closer	  and	   form	  a	  stronger	  salt	  bridge,	  which	  reduces	   the	   flexibility	  of	   residues	  205-­‐
209	  in	  the	  mutant.	  	  
	  
Discussion and future perspectives  172 
   
  Sandeep K Talapatra 
	  
Figure	   4-­‐2:	   The	   far-­‐reaching	   effects	   of	   the	   A133D	   mutation	   propagated	   throughout	   the	  
SB743921-­‐	   Eg5A133D	   complex	   during	   MD	   simulations	   that	   predicts	   the	   rigidification	   of	   the	  
structure	  when	  compared	  with	  the	  Eg5WT	  complex.	  	  
The	  red	  colour	  and	  its	  depth	  in	  the	  protein	  are	  associated	  with	  higher	  fluctuation.	  Residues	  that	  
form	  new	  interactions	  are	  highlighted.	  The	  backbone	  carbonyl	  oxygen	  of	  Glu200	  is	  able	  to	  make	  a	  
hydrogen	  bond	  with	  the	  side-­‐chain	  hydroxyl	  of	  Ser159,	  reducing	  fluctuation	  of	  residues	  198-­‐202.	  
Two	  salt	  bridges	  form	  with	  the	  side-­‐chain	  of	  Arg53,	  one	  with	  the	  Glu42	  carboxylate	  on	  one	  side	  
and	  with	  Asp59	  on	  the	  other,	  both	  of	  which	  rigidify	  loop	  L2	  (aa	  55-­‐62)	  in	  the	  mutant.	  A	  hydrogen	  
bond	  is	  also	  apparent	  in	  the	  mutant	  between	  the	  backbone	  carbonyl	  of	  Ser233	  and	  the	  backbone	  
NH	   of	   Gly268,	   which	   anchors	   helix	   α3	   (aa	   222-­‐235)	   in	   place,	   whilst	   another	   hydrogen	   bond	  
between	  the	  side-­‐chain	  carboxylate	  of	  Glu351	  in	  helix	  α6	  (aa	  344-­‐355)	  and	  the	  side-­‐chain	  hydroxyl	  
of	  Ser275	  anchors	  loop	  L11	  (aa	  273-­‐282)	  in	  place.	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4.1.3 Dissection of the novel allosteric site of Eg5 and its 
significance in drug discovery of Eg5 targeting drugs 
Development	  of	  resistance	  against	   ispinesib	   in	  the	   loop	  L5	  allosteric	  site	  of	  Eg5	  posed	  a	  
challenge	   to	  devise	  new	  methods	  of	   targeting	  Eg5.	  One	  potential	  method	   is	   to	   target	  a	  
new	  allosteric	  site	  with	  inhibitors,	  which	  is	  unaffected	  by	  mutations	  in	  the	  loop	  L5	  region.	  
Previous	  studies	  based	  on	  the	  BI8	  series	  of	   inhibitors	  have	  suggested	  the	  presence	  of	  a	  
new	   site	   located	   around	   the	   helix	   α6	   –	   neck	   linker	   region128,131	   but	   experimental	  
identification	   of	   this	   site	   has	   been	   elusive.	  We	   solved	   the	   crystal	   structure	   of	   the	   Eg5	  
motor	   domain	   in	   complex	   with	   one	   such	   inhibitor	   BI8	   suggested	   to	   bind	   to	   the	   new	  
allosteric	  site.	  The	  crystal	  structure	  of	  the	  Eg5-­‐ADP-­‐BI8	  complex	  reveals	  a	  novel	  inhibitor-­‐
binding	   site,	   between	   helix	   α4	   and	   α6	   of	   the	   Eg5	   motor	   domain,	   remote	   from	   the	  
extensively	   studied	   ispinesib	   allosteric	   site.	   Unexpectedly,	   inhibitor-­‐binding	   was	   also	  
observed	   close	   to	   the	   ispinesib	   site	   but	   using	   three	   orthogonal	   biophysical	   and	  
biochemical	  techniques,	  we	  have	  shown	  that	  high	  affinity	  binding	  is	  the	  result	  of	  binding	  
to	  the	  novel	  site.	  
The	  binding	  mode	  of	   the	  allosteric	   inhibitor	  BI8	   to	   the	  pocket	   formed	  by	  helix	  α2/loop	  
L5/helix	  α3	  and	   the	  sequence	  of	   structural	   changes	   leading	   to	   the	   final	   inhibitor	  bound	  
state	  have	  been	   revealed	   in	  considerable	  detail	  using	  steady	  state	  and	  pre-­‐steady	  state	  
kinetics	  as	  well	  as	  biophysical	  and	  structural	  methods.108,114 The	  crystal	   structure	  of	   the	  
Eg5-­‐ADP-­‐BI8	  complex	  provides	   the	  structural	  basis	   for	  understanding	   the	  mechanism	  of	  
action	   of	   compounds	   such	   as	   BI8	   that	   target	   the	   novel	   inhibitor-­‐binding	   pocket	   near	  
helices	  α4/α6. An	  obvious	  mechanism	  is	  evident	  from	  the	  analysis	  of	  the	  inhibitor-­‐binding	  
pocket	  where,	  by binding	  between	  helix	  α4	  of	  the	  switch	  II	  cluster	  and	  helix	  α6	  preceding	  
the	  neck	  linker,	  BI8 might	  lock	  the	  conformation	  of	  Eg5.	  Consequently,	  Eg5	  may	  be	  unable	  
to	  undergo	  the	  conformational	  changes	  required	  by	  the	  catalytic	  cycle.	  Small	  changes	  in	  
the	  nucleotide-­‐binding	  pocket	  induced	  by	  ATP	  hydrolysis	  are	  thought	  to	  lead	  to	  amplified	  
structural	   changes	   in	   the	   switch	   II	   cluster	   and	   neck	   linker	   region	   which	   provoke	   the	  
molecular	   motion	   responsible	   for	   shifting	   the	   two	   anti-­‐parallel	   MTs	   apart	   to	   form	   the	  
bipolar	  spindle. As	  observed	  for	  loop	  L5-­‐targeting	  drugs,	  the	  neck	  linker	  conformation	  is	  
in	   an	   ordered	   state	   that	   is	   either	   in	   an	   intermediate	   ‘undocked’	   or	   final	   ‘docked’	   state	  
slowing	  down	  the	  ATP	  release	  leading	  to	  slower	  motor	  movement	  across	  MTs.	  In	  the	  BI8	  
complex	   the	   neck	   linker	   is	   an	   ordered	   ‘undocked’	   state,	   which	   might	   follow	   similar	  
mechanism	  of	   inhibition	   of	   Eg5	  ATPase	   activity.	   BI8	   bound	  between	  helices	  α4	   and	  α6	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(Figure	  4-­‐3)	  might	  hamper	   the	  movement	  of	  both	   the	  switch	   II	   cluster	  and	  the	  α6-­‐neck	  
linker	   regions.	   This	  would	   not	   only	   reduce	   the	  ATP	   turnover	   by	   Eg5	   but	   also	   hinder	   its	  
motility	  along	  MTs,	  which	  are	  pivotal	  for	  proper	  function.	  Thus,	  it	  can	  said	  that	  though	  BI8	  
does	  not	  exactly	  mimic	  the	  mechanism	  as	  for	  loop	  L5	  targeting	  inhibitors	  but	  shares	  major	  
resemblance	  with	  the	  mechanism	  of	  inhibition	  of	  these	  drug	  candidates.	  
	  
Figure	  4-­‐3:	  BI8	  binding	  and	  mechanism	  of	  inhibition.	  	  
BI8	  (green)	  is	  docked	  at	  the	  interface	  of	  helices	  α4	  and	  α6	  about	  13	  Å	  away	  from	  the	  nucleotide-­‐
binding	  site	  demonstrated	  with	  the	  structure	  of	  ADP	  (orange-­‐red).	  During	  the	  ATP	  hydrolysis	  cycle	  
of	   Eg5	   large	   conformational	   changes	   in	   switch	   II	   cluster	   cause	  movements	   around	   the	  α6-­‐neck	  
linker	  region	  causing	  Eg5	  to	  move	  along	  MTs220	  which	  might	  be	  blocked	  due	  to	  loss	  of	  flexibility	  of	  
these	  region	  on	  BI8	  binding.	  
 
This	  discovery	  of	  a	  new	  inhibitor-­‐binding	  site	  in	  Eg5,	  coupled	  with	  the	  identification	  of	  the	  
benzimidazole	  series	  of	   inhibitors,	  creates	  the	  opportunity	  for	  both	  structure-­‐based	  and	  
ligand	   based	   approaches	   to	   develop	   novel	   inhibitor	   series	   in	   Eg5. The	   significant	  
conformational	   changes	   on	   ligand	   binding	   generate	   a	   well-­‐defined	   “druggable”	   pocket	  
and	   the	   crystal	   structure	   now	   enables	   the	   application	   of	   structure-­‐based	   design	   and	  
screening	  approaches.	  Significantly,	   the	  development	  of	  these	   inhibitors	  at	  this	  site	   into	  
cancer	   therapeutics	   has	   the	   potential	   for	   delaying	   the	   onset	   of	   resistance	   to	   drugs	  
targeting	   the	   ispinesib	   site. This	   could	   be	   particularly	   relevant	   since	   mutants	   highly	  
resistant	   to	   ispinesib	   treatment	   have	   been	   observed	   in	   cell	   culture	   and	   combination	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therapy	   is	   a	   well-­‐established	   approach	   to	   slowing	   the	   onset	   of	   resistance.128 With	   the	  
existing	   benizimidazole	   inhibitors	   already	   demonstrating	   inhibition	   in	   the	   nanomolar	  
range	   in	  vitro,	  there	  is	  an	  exciting	  possibility	  that	  these	  drugs	  can	  provide	  a	  new	  avenue	  
towards	  cancer	  chemotherapy	  along	  with	  the	  validated	  MTs	  targeting	  drugs	  and	  Eg5	  loop	  
L5-­‐targeting	  drugs.	  	  
4.1.4 Future perspectives of drugs targeting Eg5 
Based	   on	   the	   mechanistic	   characterisation	   of	   Eg5	   targeting	   drugs	   using	   kinetic,	  
biophysical	  and	  studies,	  several	  new	  approaches	  can	  be	  used	  for	  the	  future	  development	  
of	  Eg5	  inhibitors.	  The	  structure	  of	  ispinesib	  provides	  a	  basis	  to	  understand	  the	  underlying	  
mechanism	  of	  highly	  potent	  drugs	  in	  this	  series.	  New	  structurally	  similar	  compounds	  can	  
thus	   be	   synthesised	   and	  used	   for	   further	   increasing	   the	  potency,	   efficacy	   and	  drug-­‐like	  
properties.	  The	  X-­‐ray	  structure	  of	  the	  complex	  also	  makes	  it	  possible	  to	  comprehend	  the	  
individual	   interactions	   of	   different	   residues	   in	   the	   inhibitor-­‐binding	   pocket	   of	   Eg5	  with	  
ispinesib.	   Thus,	   a	   combined	   approach	   of	   structure-­‐based	   and	   ligand	   based	   drug	   design	  
will	   take	   ispinesib	   and	   ispinesib	   like	   compounds	   a	   step	   kimufurther	  where	   not	   just	   the	  
potency	  but	  also	  the	  drug-­‐like	  properties	  of	  the	  compound	  can	  be	  improved.	  
Identifying	  a	  role	  of	  thermodynamics	  of	  inhibitor-­‐binding	  reveals	  a	  unique	  mechanism	  of	  
resistance.	   Development	   of	   resistance	   is	   an	   inherent	   property,	   which	   is	   inevitable	   for	  
most	   if	   not	   all	   drugs.	   Previously	   identified	   resistance	   mechanisms	   for	   cancer	  
chemotherapeutic	   drugs	   at	   various	   stages	   of	   drug	   development	   are	   mostly	   caused	   by	  
steric	   hindrance	   developed	   against	   the	   inhibitor.221-­‐224	   The	   involvement	   of	  
‘enthalpy/entropy	   compensation’	   in	   the	   development	   of	   resistance	   is	   novel	   for	   cancer	  
targeting	  drugs.	  Hence,	  the	  development	  of	  new	  ispinesib-­‐related	  compounds	  has	  to	  be	  
approached	   in	   a	   way	   which	   does	   not	   only	   aims	   at	   increasing	   the	   efficacy	   of	   the	   drug	  
candidates	   but	   also	   goes	   through	   a	   thorough	   investigation	   of	   the	   thermodynamic	  
property	  of	  binding.	  	  
The	  alternative	  approach	  to	  address	  resistance	  is	  to	  find	  inhibitors	  that	  target	  a	  different	  
allosteric	   site.	   The	   crystal	   structure	   of	   the	   Eg5-­‐ADP-­‐BI8	   complex	   shows	   that	   the	   novel	  
benzimidazole	  compound	  BI8	  can	  bind	  to	  a	  new	  site	  between	  helices	  α4	  and	  α6	  and	  also	  
to	   the	   region	   around	   the	   other	   well	   studied	   inhibitor	   site	   comprising	   of	   loop	   L5	   and	  
helices	  α2	  and	  α3.	  This	   crystal	   structure	   is	   the	   first	  experimental	  demonstration	  of	   this	  
site	  and	  opens	  up	  new	  areas	  towards	  Eg5	  drug	  discovery.	  BI8	  has	  been	  shown	  to	  bind	  to	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the	  novel	  site	  with	  a	  higher	  affinity	   than	  the	  site	  near	   loop	  L5	   thus	  development	  of	  BI8	  
analogues	   with	   higher	   potency	   will	   be	   the	   future	   directions.	   With	   existing	   inhibitors	  
already	   showing	   IC50s	   in	   the	   nanomolar	   range,	   the	   detailed	   characterisation	   of	   the	  
interactions	   generated	   by	   the	   structure	   provides	   a	   strong	   foundation	   for	   these	   future	  
efforts.	  
4.2 Development of MPP1 as a new drug target 
MPP1,	  with	  its	  apparently	  exclusive	  role	  in	  cytokinesis,	  is	  a	  possible	  new	  target	  for	  cancer	  
chemotherapy.	  Up-­‐regulation	  of	  MPP1	  in	  bladder	  cancer	  provides	  evidence	  for	  it	  being	  a	  
potential	  therapeutic	  target.145	  The	  inhibitor	  of	  MPP1	  reported	  in	  this	  thesis	  provides	  the	  
initial	  step	  towards	  MPP1	  drug	  development.	  	  
4.2.1 Analysing the inhibitor of MPP1 
Many	   of	   the	   so	   far	   identified	   secondary	   metabolites	   in	   lichens	   are	   unique.	   Lichen	  
metabolites	   have	   been	   shown	   to	   possess	   interesting	   biological	   properties	   including	  
antioxidant,	  antimicrobial,	  antiherbivore	  and	  insecticidal	  activities.225	  Several	  lichens	  have	  
also	   demonstrated	  weak	   cytotoxic	   activity226	   and	   for	   a	   few	   isolated	   lichen	  metabolites	  
growth	  inhibition	  and	  apoptotic	  cell	  death	  has	  been	  reported.227	  One	  interesting	  class	  of	  
lichen	  compounds	   is	   represented	  by	  the	  depsidones	  containing	  the	  dibenzodioxepinone	  
scaffold	   (Figure	  4-­‐4).	  To	  date	  however	   the	   identity	  of	   the	  protein	   targets	   for	  any	  of	   the	  
active	  compounds	  has	  not	  been	  clear.	   Identification	  of	  MPP1	  as	  one	  possible	   target	   for	  
depsidones	  provides	  an	  interesting	  prospect	  towards	  cancer	  chemotherapy.	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Figure	  4-­‐4:	  Chemical	  structures	  of	  compounds	  tested	  for	  MPP1	  inhibition.	  	  
The	   initial	   tested	   inhibitor	   of	   MPP1;	   Norlobaric	   acid	   is	   with	   a	   dibenzodioxepinone	   scaffold.	  
Thereafter,	   Physodic	   acid	   was	   found	   to	   be	   the	   most	   potent	   compound	   while	   testing	   for	   few	  
analogues	   from	  commercial	   and	  non-­‐commercial	   sources.	  On	   the	  other	  hand	  Protocetraric	   acid	  
showed	  no	   inhibition	  of	  MPP1	  ATPase	  activity.	  This	   shows	   initial	  evidence	  of	   the	   importance	  of	  
the	  alkyl	  chains	  in	  the	  inhibitors.	  	  
	  
The	  MPP1	  inhibitors	  presented	  in	  this	  thesis	  open	  up	  new	  areas	  of	  drug	  discovery	  in	  this	  
field.	  A	  more	  ligand	  based	  approach	  to	  getting	  more	  potent	  compounds	  targeting	  MPP1	  
and	  improving	  its	  drug	  quality	  will	  be	  the	  things	  to	  be	  studied	  and	  analysed	  hereafter.	  The	  
identification	   also	   provides	   a	   tool	   compound	   to	   further	   probe	   the	   cellular	   function	   of	  
MPP1.	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4.2.2 Orthologues of human MPP1 for drug discovery 
Human	  MPP1	  proved	  difficult	  to	  express	  and	  purify	  but	  the	  biochemical	  studies	  presented	  
here	  have	  shown	  that	  the	  human	  MPP1	   inhibitors	  are	  also	  effective	  against	  MPP1	  from	  
M.	  musculus	  and	  R.	  norvegicus	  whose	  MPP1	  motor	  domains	  share	  around	  80	  %	  sequence	  
similarity	   with	   the	   human	   protein.	   These	   proteins	   can	   therefore	   provide	   a	   useful	  
surrogate	  for	  human	  MPP1.	  An	  important	  step	  in	  drug	  discovery	  is	  to	  obtain	  a	  complex	  X-­‐
ray	   crystal	   structure	   of	   the	   protein	   and	   the	   ligand.	   MPP1	   from	   other	   species	   offers	   a	  
surrogate	   system	   that	  will	   in	   future	  provide	  opportunities	   in	   the	  direction	  of	   improving	  
the	  potency	  and	  stability	  of	  MPP1	  targeting	  inhibitors.	  
4.3 Advances and progress in drug discovery of MKLP-2 
4.3.1 Identification of unique structural elements in MKLP-2 
involved in inhibitor-binding 
The	   unique	   feature	   of	   kinesin-­‐6	   family	  members	   is	   the	   large	   approximately	   ~96	   amino	  
acids	  domain-­‐like	   insertion	   in	  the	   loop	  L6	  region	  with	  unknown	  function.	  Other	  kinesins	  
have	   only	   a	   few	   residues	   (about	   6	   amino	   acids)	   at	   this	   location.	   In	   the	   absence	   of	   any	  
structural	   information	   on	   the	   MKLP-­‐2	   -­‐	   paprotrain166	   complex,	   the	   study	   on	   MKLP-­‐2	  
deletion	  and	  substitution	  mutants	  in	  and	  around	  loop	  L6	  provides	  key	  initial	  information	  
towards	  understanding	  the	   ligand	  binding	  determinants	  of	  MKLP-­‐2.	  The	   inhibition	  study	  
has	  provided	  a	  tool,	  which	  points	  to	  loop	  L6	  being	  the	  most	  essential	  structural	  element	  
in	   MKLP-­‐2	   that	   interacts	   with	   paprotrain.	   MKLP-­‐2	   with	   and	   without	   the	   loop	   L6	   have	  
completely	   contrasting	   IC50	   values	  with	   the	   inhibitor	   paprotrain.	  Whereas	   the	  wild-­‐type	  
protein	  gives	  an	   IC50	  of	  around	  1	  µM,	  the	   inhibitor	  does	  not	   inhibit	   the	  mutant	  MKLP-­‐2	  
without	   loop	  L6.	   In	   contrast,	   three	  single	  mutants	  of	  MKLP-­‐2	   in	   the	  helices	  and	  strands	  
around	   loop	  L6	  show	   limited	  decrease	   in	  potency	  of	  paprotrain.	  This	  data	  suggests	   that	  
residues	  around	  the	  loop	  may	  also	  play	  some	  role	  in	  inhibitor-­‐binding	  but	  further	  studies	  
are	  necessary	  to	  understand	  their	  role.	  A	  full	  alanine	  scanning	  mutagenesis	  study	  would	  
be	   a	  more	   rigorous	   approach	   in	   that	   respect.	   An	   alternative	   approach	   is	   to	   obtain	   the	  
crystal	   structure	   of	   MKLP-­‐2	   motor	   domain	   that	   would	   provide	   information	   about	   the	  
structural	   elements	   of	   the	   domain	   especially	   the	   loop	   L6.	   The	   crystallisation	   trials	  
presented	  in	  this	  thesis	  were	  not	  fruitful.	  Further	  pursuing	  the	  trials	  based	  on	  new	  cloning	  
techniques	   and	   using	   a	   wider	   variety	   of	   crystallisation	   approaches	   may	   overcome	   the	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difficulties	   in	   crystallisation	   of	   the	   MKLP-­‐2	   motor	   domain.	   Also,	   using	   alternative	  
macromolecular	   structural	   approaches	   like	  NMR	  or	   SAXS	  might	  provide	  evidence	  about	  
the	  structural	  organisation	  of	  the	  motor	  domain	  and	  the	  loop	  L6	  region.	  	  
4.3.2 Progress of paprotrain based drug design of MKLP-2 
inhibitors 
The	  previously	  described	  inhibitor	  paprotrain	  was	  the	  first	  MKLP-­‐2	  inhibitor	  that	  induces	  
apoptosis	  in	  a	  range	  of	  tumour	  cell	  lines	  (HCT	  116,	  BXPC-­‐3,	  CFPAC-­‐1,	  NCI-­‐H1299,	  ASPC-­‐1,	  
K562)166.	   In	   an	   effort	   to	   improve	   the	   efficiency	   of	   paprotrain	   a	   series	   of	   paprotrain	  
analogues	  were	  synthesised	  by	  Christophe	  Labiere	  from	  Dr.	  Catherine	  Guillou's	  laboratory	  
at	  the	  CNRS	  in	  Gif-­‐sur-­‐Yvette,	  France.	  On	  the	  basis	  of	  the	  in	  vitro	  SAR	  study	  presented	  in	  
this	   thesis	   it	   can	   be	   concluded	   that	   the	   replacement	   of	   the	   pyridine	   ring	   by	   different	  
substituted	  phenyl	  rings	  or	  modification	  of	  the	  central	  double	  bond	  (length,	  reduction	  or	  
substitution	  degree)	  lead	  to	  inactive	  or	  less	  active	  compounds	  which	  can	  be	  related	  to	  no	  
inhibition	   in	   the	   SAR	   study.	   However,	   substitution	   of	   the	   indole	   ring	   enhanced	   the	  
potency	   of	   the	   compounds.	   Taken	   together,	   the	   reported	   results	   show	   analogues	   of	  
paprotrain	  are	  promising	  lead	  compounds	  for	  the	  inhibition	  of	  human	  MKLP-­‐2.	  To	  support	  
this	   there	   are	   compounds	   like	   121-­‐1	   and	   387-­‐1,	   which	   show	   2-­‐fold	   higher	   potency,	  
compared	  to	  paprotrain.	  Further	  analysis	  towards	  improvement	  of	  these	  compounds	  can	  
be	  done	  using	  the	  information	  obtained	  from	  these	  studies.	  
Overall	  the	  SAR	  study	  of	  around	  135	  compounds	  only	  improves	  the	  potenty	  by	  two	  fold.	  
This	   suggests	   the	   need	   of	   a	   structure	   based	   drug	   design	   to	   better	   understand	   the	  
interaction	  between	  MKLP-­‐2	  motor	  domain	  and	  the	  inhibitor.	  Future	  directions	  would	  be	  
towards	  obtaining	  the	  structure	  of	  MKLP-­‐2	  motor	  domain	  and	  find	  the	   inhibitor	  binding	  
site.	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4.4 Conclusion 
The	   central	   theme	   of	   the	   work	   in	   this	   thesis	   is	   the	   structural	   and	   mechanistic	  
characterisation	   of	   inhibitor-­‐binding	   to	   Eg5.	   The	   structure	   of	   the	   Eg5-­‐ispinesib	   complex	  
provides	  insights	  into	  the	  interactions	  of	  a	  potent	  tight	  binding	  inhibitor	  that	  could	  drive	  
future	  drug	  development	  targeting	  Eg5.	  Studies	  on	  Eg5	  mutants	  and	  the	  new	  inhibitor	  BI8	  
have	  both	  explained	  the	  little-­‐understood	  mechanism	  by	  which	  resistance	  to	  ispinesib	  is	  
generated	   in	   mutant	   Eg5	   and	   also	   identified	   experimentally	   for	   the	   first	   time	   a	   novel	  
inhibitor-­‐binding	   site.	   This	   work	   might	   provide	   a	   basis	   for	   overcoming	   or	   slowing	  
resistance	  to	  drugs	  targeting	  Eg5.	  	  	  
In	   addition,	   significant	   progress	   has	   been	   made	   in	   the	   expression,	   purification	   and	  
biochemical	  characterisation	  of	  two	  kinesin-­‐6	  members;	  MPP1	  and	  MKLP-­‐2.	  Identification	  
of	  the	  first	  inhibitor	  of	  MPP1	  and	  progress	  in	  developing	  improved	  inhibitors	  for	  MKLP-­‐2	  
provides	   new	   avenues	   to	   develop	   these	   proteins	   as	   possible	   targets	   for	   therapeutic	  
intervention.	  The	  work	  on	  MPP1	  and	  MKLP-­‐2	  presented	  in	  this	  thesis	  lays	  the	  foundations	  
for	   structural	   biology	   and	   drug	   design	   efforts	   similar	   to	   those	  which	   have	   proved	   very	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